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ABSTRACT 
 
Heart failure is consistently one of the top causes of death each year worldwide. 
Ventricular assist devices (VADs) have become common alternatives for patients with severe, 
end-stage heart failure; VADs take a significant load off of the heart and aid in perfusion of 
downstream organs by pumping blood from either or both ventricles to their corresponding great 
vessel. External VAD controllers track specific pump parameters such as estimated flow rates 
and device power consumption.  
Suspected thrombosis is a common clinical adverse event in VAD therapy. In this 
condition, a VAD controller will indicate periods of low flow or high power; clinicians suspect 
that this indicates that a thrombus is increasing friction between the moving components and/or 
obstructing the inflow or outflow. Suspected thrombosis typically results in device exchange 
surgery. A pathology evaluation of the explanted VAD can reveal if materials inside the pump at 
explant originated within or upstream from the device. 
VADs explanted after years of support often had an actively organizing thrombus along 
the inflow cannula or protruding from the insertion site in the ventricle. We hypothesize that 
these thrombi form over time due to regions of stagnation and recirculation of the blood in the 
ventricle. Moreover, as the VAD continues to take a load off of the heart, we suspect that the 
remodeling of the heart will change the flow dynamics within the ventricle and cause thrombi to 
dislodge and travel into the pump. As thrombi of different age and size pass into the device, we 
hypothesize that each VAD model will demonstrate a particular change in flow rate in response 
to the thrombus. 
Through the research in this dissertation, we have investigated these phenomena by 
creating a computational model of the ventricular insertion site before and after cardiac 
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remodeling occurs, and an in vitro model that displays VAD response to thromboembolic 
particles. These computational and in vitro models show that over time, the presence of the VAD 
inflow cannula within the heart will change the potential for thrombi to form around the device, 
dislodge, and travel into the VAD, and result in changes of pump flow rate.  
This research is beneficial to VAD manufacturers and clinicians in the development of 
devices that will limit opportunity for thromboembolic complications, and provide direction for 
treatment of patients currently undergoing VAD therapy. 
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1. INTRODUCTION  
 
Despite major technological and medical advancements made over the past century, 
heart failure continues to be a significant issue facing our nation. Heart failure (HF) accounts for 
over one million hospitalizations each year in the United States (US), with over three million 
secondary hospitalizations annually [1]. In 2007, HF was the underlying cause of 56,565 deaths 
in the US alone [2]. Although the number of patients who survive after being diagnosed with HF 
is increasing, the death rate remains high, keeping HF as one of the leading causes of death [3]. 
The outcome for patients diagnosed with HF remains grim: approximately 50% of patients 
diagnosed will die within five years [3].  
In the US, the New York Heart Association (NYHA) classification system is clinically 
used to categorize HF based on the patient’s symptoms and objective assessment [4]. The 
categories are labeled Class I-IV, with IV being the most severe. When the heart becomes 
enlarged and weakened, it cannot pump blood as efficiently as the body needs. As this decline in 
effective heart function continues, the downstream organs (i.e., kidney, brain, liver, lungs, etc.) 
will become ischemic. This condition can lead to a pathologic heart disease (cardiomyopathy) 
and eventually multi-organ system failure (NYHA Class IV). When patients are diagnosed with 
a cardiomyopathy, the optimal treatment is a heart transplant [5]. Depending on their HF 
classification and other symptoms, patients who are eligible to receive a heart transplant will be 
put on the heart transplant waiting list. In a large number of cases, patients die as a result of HF 
before a donor heart is found. As the population continues to increase, there is a growing 
disparity between the number of donor hearts and potential transplant recipients [6]; in the US, 
consistently only ~2,500 hearts are available for transplant each year [5, 7]. Furthermore, some 
patients’ conditions are so severe they are ineligible to receive a transplant. 
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To combat these challenges in treating HF, specifically the lack of donor hearts 
available, researchers and clinicians have turned to mechanical circulatory assist devices to take 
the load off of the heart and provide adequate perfusion of body tissues. Ventricular assist 
devices (VADs) are surgically implanted pumps attached to either of the ventricles and 
corresponding great vessels to provide circulatory support. VADs are associated with four 
clinical applications: bridge-to-transplant (BTT), bridge-to-recovery (BTR), destination therapy 
(DT), or bridge-to-decision (BTD). VADs have proven to be successful in prolonging the lives 
of patients with refractory heart failure until a suitable donor heart can be found (BTT) [8-14]; 
there has been an increase in usage of VADs over the past few decades [15], resulting in fewer 
patients dying while on the heart transplant waiting list [7]. Additionally, VADs can provide 
long-term support for patients that are ineligible for a heart transplant (DT) [16]. VADs can also 
treat patients with potentially reversible HF (BTR) [17-20], or in the case of moribund patients, 
can be used to stabilize the patient giving doctors time to further evaluate the patient’s condition 
(BTD) [21].  
Since the 1960s, multiple generations of VADs have been developed and refined. VADs 
can be categorized based on patient-pump interface and flow type [22]. Accessory components 
that accompany each device include controllers, drivelines, grafts, and backup batteries. VAD 
controllers display pump parameters such as rotations per minute (RPM), flow rates, power 
consumption, etc. [23], and often store log files that clinicians can read to determine if the pump 
is functioning properly [24]. 
With each generation of assist devices and corresponding accessories, VAD developers 
and researchers are presented with new challenges to make these devices safer and more 
effective than the last. While each generation of VADs improves and meets higher standards 
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provided by advancements in technology, thrombosis has consistently been a concern hindering 
the effectiveness of VAD therapy [25-38]. 
Implanting a medical device inside the body inherently presents opportunities for 
thrombus formation. Patients most likely to be considered for VAD implantation have weak, 
dilated heart chambers, and are likely at risk for thrombus formation along the ventricle walls 
(mural thrombus). In addition, the atrial appendage is a common site for thrombus formation in 
diseased hearts. A thrombus may also form around the ventricular insertion site due to contact 
with a non-biological surface (i.e., the device), or within the ventricle/device as a result of 
stagnant regions or altered blood flow. Thrombi are dangerous because they may pass in to the 
device and cause mechanical failure, or travel through the device and cause ischemic damage 
downstream (e.g., stroke, renal infarct, etc.). Over time, as the VAD takes a significant workload 
off of the heart, the myocardium will likely remodel [39], which may change the flow dynamics 
within the ventricle and potentially dislodge organizing thrombi and send them into the device.  
The Cardiovascular Pathology (CVP) Laboratory at Texas A&M University has 
performed pathology evaluations on 1,000+ VADs from various companies since 2008. 
Frequently, a pathology evaluation is requested by the manufacturer because the pump log files 
indicated periods of high power consumption or periods of low flow, due to presumed ingestion 
of biological material [24] (i.e., thrombus), or blockage of the outflow [40] or inflow cannulae. 
The increase of pump power consumption or low flow can cause a decrease in pump efficiency 
[24]; consequently, the patient may undergo device exchange surgery. VADs are also removed 
and sent for pathology evaluation (at the request of the device manufacturer) when patients 
receive a transplant, expire, or recover. 
During the pathology evaluation of VADs, all external and internal surfaces are closely 
examined for any evidence of thrombi [22]. A histological analysis of material from explanted 
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VADs can reveal the origin of deposits found within VADs and differentiate ante- and post-
mortem events. The morphology of the material can elucidate if a thrombus originated upstream 
from the device or developed de novo (i.e., within the device). In some cases, a gross and 
histological analysis reveal that upstream material may lodge inside a VAD and become a nidus 
for further thrombus formation along internal VAD components. 
Pathology evaluations alone cannot reveal the full story, and clinical correlation is 
always recommended. Clinical information about the patient as well as pump data (power usage, 
flow rates, etc.) are also important and correlation with pathology findings will deliver the best 
account for the device/patient interaction, and provide the most useful information to improve 
VAD therapy. 
VAD manufacturers often use computational modeling during the design phase to 
analyze flow patterns inside VADs. Computational modeling involving the ventricle (inflow 
insertion site) and aorta (outflow site) can also help with device design challenges, revealing 
more about device/patient interaction before pre-clinical trials [41-45]. Furthermore, VADs are 
typically tested prior to pre-clinical trials with in vitro circulatory loops [46, 47]; however, these 
are designed to specifically test the longevity of the device (i.e., how long the device lasts 
without mechanical failure) and testing VADs under hemodynamic conditions to reveal whether 
the device damages blood cells, produces sufficient flow rates, etc. [47-56].  
Device testing can be expanded to include a computational model for determining how 
ventricular remodeling due to prolonged VAD support will change potential for thrombus 
formation and embolization in the device. In addition, in vitro models could be expanded to 
determine precise VAD response to thromboembolism. The research in this dissertation aims to 
present possible VAD testing protocols that can answer these questions and elucidate useful 
 5 
 
information about the patient/VAD interaction without costly or dangerous pre-clinical and 
clinical trials. 
This research will establish a basis for better understanding thrombus formation and 
embolization within VADs as the heart remodels due to long-term mechanical support. 
Additionally, data resulting from this research will be used to better understand the interaction 
between thrombi and VADs, specifically how to precisely detect and treat thromboembolism. 
This research will also make way for device design improvements for better tolerance of embolic 
particles. With better understanding of how thrombi form in the ventricle and how emboli 
interact with VAD components, future VAD designs will limit opportunity for thromboembolic 
complications, and hospitals can provide better clinical management of VAD patients by 
confidently assessing the risk of thrombus formation throughout duration of support. This will 
ultimately result in fewer high-risk, thrombus-related VAD exchange surgeries (thus reducing 
the cost associated with VADs), and reduce the overall risk of thrombosis in VADs. 
The long-term goal of this research is to establish a need for periodic monitoring of 
pump orientation in the ventricle throughout duration of support for evidence of thrombus 
formation. The geometrical changes of the ventricle with an inflow cannula can potentially cause 
catastrophic thromboembolic damage after several years of successful VAD treatment, and 
periodic imaging of the device could prevent these occurrences. Secondarily, this research aims 
to establish VAD testing of thromboembolism as a recommendation for VAD manufacturers 
prior to beginning pre-clinical trials. This could help companies learn specific correlations for 
each individual VAD model, and add to the therapeutic value of receiving a VAD. Specifically, 
this bench-top test could reveal how clots of different strengths and sizes affect VADs and 
determine if there are correlations between the size/shear compliance of the thrombus and the 
magnitude of the power consumption/pressure changes indicated on the pump’s controller log 
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when a thrombus is present. Physicians would have a better indication if thrombolytic agents 
alone could dissolve the thrombus or if an exchange surgery is necessary.  
Overall, this research will add positively to the value of receiving a VAD as a 
destination therapy, bridge-to-transplant, bridge-to-decision, or bridge-to-recovery treatment 
option. 
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2. HEART FAILURE*  
 
Heart Failure (HF) has been a leading cause of death worldwide for decades [2, 57]. HF 
is generically defined as a condition in which the heart is unable to pump blood at an adequate 
rate or an adequate volume. The mechanism of HF is explained using fundamental building 
block of the heart: the cardiac myocyte. 
Cardiac myocytes stretch when blood enters the heart chambers and contract with a 
force great enough to expel blood to the body via the aorta. This is the Frank-Starling Law of the 
Heart: when there is an increase in venous return (blood returning to the heart), the cardiac 
myocytes respond with a greater force, thereby increasing stroke volume. When the body needs 
more oxygen and requires a greater demand from the heart, the myocytes respond by stretching 
more, generating more force, thus increasing cardiac output. This myocyte hyperfunction can 
lead to developmental hypertrophy (Figure 1). A sustained increase in heart function can lead to 
cardiomegaly: a normal, reversible, physiologic enlargement of the heart, involving myocyte 
adaptation. If the stress on the heart is maintained and pushed beyond what the myocytes can 
withstand, pathologic hypertrophy may develop, which involves the beginning of myocyte 
degeneration. At this point, if the stress on the heart is relieved, the heart can remodel to a state 
suitable for providing adequate perfusion of the body tissues. However, if the stress persists, and 
the myocytes continue to degenerate, the heart will progress to an irreversible state of HF. While 
heart transplantation is the optimal treatment for HF, other therapeutic interventions 
                                                      
*Part of this section is reprinted with permission from “Brief review of ventricular assist devices 
and a recommended protocol for pathology evaluations” by Carpenter BA, et. al., 2013. 
Cardiovasc Pathol 22: 408-415, 2013 by Elsevier. 
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(pharmaceutical treatments, medical devices, etc.) may help the heart remodel to a state suitable 
for adequate perfusion of the tissues. 
The Law of Laplace states that the stress on the wall of the ventricle is directly 
proportional to both the internal pressure within the ventricle and the radius of the chamber, and 
indirectly proportional to the ventricular wall thickness. As the pressure within and the radius of 
the ventricle grows, the stress on the wall increases. Under normal conditions, the heart will 
respond with increased thickness (i.e., hypertrophy) to withstand this increase in wall stress. 
 
 
 
Figure 1. Cardiac myocyte response to stress. Hyperfunction of the heart muscle can lead to 
developmental hypertrophy. Sustained hypertrophy can lead to cardiomegaly, a normal reversible 
morphological enlargement of the heart. Application of stress greater than myocytes can adapt to leads to 
pathologic hypertrophy, which if sustained, will lead to irreversible heart failure. 
 
 
 
The heart responds with different morphological changes according to the initial insult to 
homeostasis, which leads to two main classifications of morphological changes: eccentric 
(dilated) and concentric (hypertrophic). Eccentric or dilated cardiomyopathies (DCM) are 
generally associated with cardiac myocyte hypertrophy/remodeling in length, which leads to an 
increase in ventricle diameter with a thinner wall (i.e., increase in lumen volume). Concentric or 
hypertrophic cardiomyopathies (HCM) are associated with cardiac myocyte 
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hypertrophy/remodeling in width, which leads to an increased wall thickness and a decreased 
ventricle diameter (i.e., reduction in lumen volume). 
While the primary cause of HF is idiopathic (unknown), there are several conditions that 
can lead to HF as a secondary problem. When there is residual blood in the ventricle after peak 
systole (indicating decreased cardiac output), the ventricle stretches over time due to the 
increased volume and remodels to a dilated state. This can arise secondarily from insufficient 
valve performance (regurgitation), or an increase in preload (venous return) without maintaining 
equal cardiac output. Additionally, if there is a stenotic vessel, valve, or increased systemic 
resistance, the ventricles must work harder to pump against an increased resistance. Over time 
the ventricular myocytes’ adaptive response will be hypertrophy (increase in myocyte thickness), 
which can lead to a concentric or hypertrophic cardiomyopathy. 
HF can also be divided in to functional classifications. Systolic disorders (forward HF) 
arise when the heart is not able to adequately eject enough blood, while diastolic disorders 
(backward HF) mean the heart cannot properly relax and is unable to fill completely. Disorders 
can also be classified based on which side of the heart is failing. Right-sided backward failure is 
a diastolic disorder in which the blood pools in the extremities because it cannot fill the right 
side of the heart properly. The venous return (blood returning to the right side of the heart) is 
increased and exceeds the right ventricle’s performance capability; this increases hydrostatic 
pressure on the right side of the body (i.e., venous vasculature), and thus causes right-sided 
backward failure. Right-sided forward failure means that blood is not adequately going to the 
lungs, which is an immediately serious condition and the patient would become systemically  
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ischemic rather quickly and perish before this condition could develop beyond an acute state. 
Left-sided backward failure involves fluid accumulation in the lungs, which could potentially be 
fatal. The body has built-in mechanisms to keep the fluid from entering the lungs: the pulmonary 
vessels vasoconstrict when there is an increase in pulmonary pressure, which leads to an increase 
of fluid in the right ventricle. This is only a temporary solution, however, for pulmonary 
hypertension brings a new set of challenges to the body. Finally, left-sided forward failure can 
lead to decreased oxygenated blood reaching the entire body, which could acutely result in 
syncope (fainting), or chronically lead to increased activation of the renin-angiotensin system 
(RAS) and eventually hypertension. 
HF is classified clinically according to the symptoms and objective assessments outlined 
in the New York Heart Association (NYHA) classification system in Table 1 [58]. Patients with 
Class I HF are asymptomatic, whereas Class IV HF patients are unable to perform everyday 
tasks without becoming out of breath, and for the most part are bedridden [4].  
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Table 1. New York Heart Association classification of heart failure [58] 
Class Patient Symptoms Objective Assessment 
I 
No limitation of physical activity. 
Ordinary physical activity does not 
cause undue fatigue, palpitation, 
shortness of breath. 
A No objective evidence of cardiovascular disease. No symptoms and no limitation in 
ordinary physical activity. 
II 
Slight limitation of physical activity. 
Comfortable at rest. Ordinary physical 
activity results in fatigue, palpitation, 
shortness of breath. 
B Objective evidence of minimal cardiovascular 
disease. Mild symptoms and slight limitation 
during ordinary activity. Comfortable at rest. 
III 
Marked limitation of physical activity. 
Comfortable at rest. Less than ordinary 
activity causes fatigue, palpitation, or 
shortness of breath. 
C 
Objective evidence of moderately severe 
cardiovascular disease. Marked limitation in 
activity due to symptoms, even during less-
than-ordinary activity. Comfortable only at 
rest. 
IV 
Unable to carry on any physical activity 
without discomfort. Symptoms of heart 
failure at rest. If any physical activity is 
undertaken, discomfort increases. 
D Objective evidence of severe cardiovascular 
disease. Severe limitations. Experiences 
symptoms even while at rest. 
 
 
 
Cardiac transplantation is the preferred treatment for end stage HF (Class IV). In the US, 
there are consistently between 2,000 and 2,500 hearts available for transplantation per year 
(Figure 2). Consistently, more hearts are needed, leading to people dying while on the waiting 
list. As a result, researchers started looking for alternative treatment methods to accommodate 
the growing disparity between HF patients and available donor hearts. 
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Figure 2. Data from the Organ Procurement and Transplant Network [7] concerning removal from the 
heart transplant waiting list by reason. The number of patients removed from the waitlist due to 
transplantation has stayed relatively consistent. However, since the use of mechanical circulatory support 
began, the number of patients removed due to expiration has decreased steadily in recent years. 
 
 
 
The initiative to find an alternative to heart transplantation began in 1964 at the National 
Heart, Lung and Blood Institute [29]. A goal of the Institute was to find both long- and short-
term circulatory support and ultimately an artificial heart for patients requiring heart transplants. 
Over the next decade, this goal evolved into a search for smaller implantable devices that would 
increase the quality of life for the users [29]. The Jarvik-7-100 was the first total artificial heart 
(TAH) developed and implanted in the 1980s by DeVries et al. [59]. Initially, this device was 
generally considered a success. However, the occurrence of thrombosis and infection in patients 
put a hold on the TAH device by 1991 [60]. Throughout this time, the medical device companies 
increasingly shifted their focus to developing devices to assist the heart rather than completely 
replace it. This shift in focus introduced ventricular assist devices (VADs) to augment heart 
 13 
 
function. One of the first devices created was Thermo Cardiosystem’s HeartMate, a 
pneumatically driven implantable left ventricular assist device (LVAD), which was first 
implanted in human patients starting in 1990 [61]. Over the past 2.5 decades, this industry has 
expanded vastly to include dozens of companies and device designs. Currently, companies 
worldwide are continuing to develop an array of VADs for various clinical indications that have 
proven to be successful in treating patients with HF, resulting in a steady decline of patients 
dying while on the heart transplant waiting list (Figure 2). 
Several generations of VADs have been developed since the quest for alternate HF 
treatments began in the 1960s. While HF continues to be a widespread problem, VAD therapy 
has certainly brought relief to many and is definitely a growing industry that has peaked the 
interest of scientists, clinicians, and engineers worldwide. 
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3. VENTRICULAR ASSIST DEVICES*
Ventricular assist devices (VADs) are medical devices implanted in either the right or 
left ventricle to improve perfusion of downstream organs and tissues in patients with end-stage 
heart failure. VADs work in parallel with the ventricle to pump blood to the aorta (left VAD, or 
LVAD) or the pulmonary artery (right VAD, or RVAD) (Figure 3).  
Figure 3. Diagram of heart with a bi-VAD (i.e., an LVAD and an RVAD). The LVAD receives 
oxygenated blood (red arrows) from the left ventricle and pumps it into the aorta. The RVAD receives 
unoxygenated blood (blue arrows) and delivers it to the pulmonary artery. 
*Part of this section (including Figures 5-7) is reprinted with permission from “Brief review of 
ventricular assist devices and a recommended protocol for pathology evaluations” by Carpenter 
BA, et. al., 2013. Cardiovasc Pathol 22: 408-415, 2013 by Elsevier. 
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Numerous VAD designs have been developed, and currently FDA has approved three 
devices for use in the US: HeartMate II (Thoratec Corp.) [62], EXCOR (Berlin Heart) [63], and 
HVAS (HeartWare, Inc.) [64]. There are several types of VADs that are classified based on type 
of flow (pulsatile or continuous) and interface with patient (intracorporeal or extracorporeal). 
3.1. Types of VADs 
The two main varieties of VADs are pulsatile pumps and the more recent continuous flow 
pumps (Figure 4). Over the past decades, continuous flow pumps have gained precedence 
worldwide because of their smaller size and better performance. Furthermore, single center 
studies have shown little difference in survival rates of patients with the two types of pumps [65, 
66]. 
3.1.1. Pulsatile flow pumps 
The first generation of implantable VADs included pulsatile devices, which attempts to 
replicate the physiologic cardiac output. Examples of pulsatile devices include the Thermo 
Cardiosystems (TCI) HeartMate [61], Berlin Heart® Excor®, the Novacor® LVAS, the Abiomed® 
BVS 5000®, the Arrow LionHeartTM, and the Syncardia Systems Inc. CardioWestTM [67]. These 
pulsatile devices mimic the pumping activity of the heart using a pressure membrane chamber  
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driven by a pneumatic motorized pump. Artificial valves prevent blood from flowing backward, 
which creates pulsation, replicating normal heart rhythm (Figure 4A). Pulsatile pumps normally 
function between 50 to 120 bpm [68]. 
Unfortunately, pulsatile pumps and associated equipment are typically bulky. Patients 
have to wear the pumps and external equipment with caution, thus their mobility is limited. 
Additionally, pulsatile pumps are subject to frequent exchanges due to a variety of complications 
such as suspected thrombi within the device, periods of high power, and adverse host response to 
the device. Fortunately, with pulsatile extracorporeal pumps, the VAD can be replaced quickly 
and efficiently; no additional major surgical procedures are required. These less-invasive 
exchanges are faster and induce less trauma to the body, thus minimizing post-exchange 
complications for patients. Furthermore, post-exchange recovery in pulsatile models has been 
shown in one study to preserve the physiological phenomenon of ventricular unloading unlike 
continuous flow pumps [67]. 
 17 
 
Figure 4. Diagrams of VADs. Based on flow, there are two main types of VADs: Pulsatile (A), and 
Continuous Flow (B). Continuous flow devices are further divided based on direction of flow: centrifugal 
(left) and axial (right). Direction of blood flow in each device type is indicated by red arrows. 
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3.1.2. Continuous flow pumps 
 
The newer-generation VADs are often a continuous flow system designed around either 
axial or centrifugal flow (Figure 4B). Examples of continuous flow pumps include the Thoratec 
HeartMate II®, the MicroMed Cardiovascular Inc. HeartAssist 5®, the HeartWare Inc. HVADTM, 
and the Terumo Heart Inc. DuraHeart [69]. Continuous flow pumps have many advantages over 
pulsatile pumps, including smaller size, greater durability, higher energy efficiency, and lower 
thrombogenicity. 
Continuous flow VADs are becoming more popular because they contain fewer moving 
parts, thereby increasing mechanical reliability and longevity of performance [70]. Additionally, 
continuous flow pumps consume less power, are powered by an electrical unit rather than 
pneumatic power, and have smaller drive accessories than pulsatile pumps. The design offers 
greater comfort and increased mobility for patients. The continuous flow method provides 
vascular perfusion equivalent to that provided by pulsatile pumps [70]. 
Rotary speeds of continuous flow pumps are typically adjusted by the power input delivered 
from an external controller. Speed varies depending on pump design; however most devices run 
at 8,000-12,000 rpm to provide optimal cardiac assist function [71]. 
 
3.2. Pump-patient interface 
 
Ventricular assist devices are further classified based on the interface between the pump and 
the patient (Figure 5). The two types of interface are intracorporeal and 
extracorporeal/paracorporeal. For intracorporeal VADs, the VAD body is implanted entirely 
within the patient's body and the patient must wear the battery/controller connected to the VAD 
 19 
 
via an indwelling driveline that exits through a small incision in the skin (Figure 5A). For 
extracorporeal/paracorporeal VADs, the VAD body is placed outside of the patient and inflow 
and outflow cannulae are connected to the heart through incisions in the skin (Figure 5B).  
Surgical techniques for VAD implantation vary depending on the location of device 
placement, incision size, and need for cardiopulmonary bypass. The most common implant 
procedure consists of a median sternotomy to expose the patient’s heart. If necessary, the patient 
is placed on cardiopulmonary bypass, and the surgeon excises a core of tissue at the base of the 
ventricle. The surgeon then makes an incision through the patient’s abdominal wall and connects 
the ventricle to the inflow of the pump. The VAD either resides in a pouch worn by the patient or 
is placed within the thoracic cavity depending on the pump design. The pump connects to a 
system controller powering the device. 
 
 
 
Figure 5. Types of VADs based on patient-pump interface: Intracorporeal (A) and Extracorporeal (B). 
 
 
 
Implant procedures have become more standardized because of technological 
advancements and mastery of surgical techniques. Recently, surgical implantation has become 
less invasive, requiring smaller incisions. Surgeons are also becoming more efficient at 
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implanting VADs, thus reducing or eliminating the need for cardiopulmonary bypass. These 
newer techniques ultimately decrease post-operative recovery time and improve patient outcome. 
 
3.2.1. Intracorporeal VADs 
 
Intracorporeal VADs are so named because the pump body is placed within the patient’s 
body. The main benefit of this placement is the presence of minimal transcutaneous hardware. 
Because most of this VAD type is within the body, the patient is safer after leaving the hospital, 
with fewer opportunities for daily activities to damage the pump. Intracorporeal VADs are 
further classified as intraventricular and extra cardiac devices. Intraventricular devices are 
surgically affixed into the patient’s ventricle, whereas extra cardiac devices assist heart 
contraction but remain unattached to the heart wall. 
The most common intracorporeal VADs are intraventricular. Examples of 
intraventricular VADs include the Thoratec HeartMate II®, the Jarvik 2000®, the MicroMed 
Cardiovascular Inc. Heart Assist 5®, and the Heartware Inc. HVADTM [67, 69]. An important 
concern when implanting intraventricular VADs is the amount of time the patient must spend on 
cardiopulmonary bypass during surgery [69]. Prior to implantation, VAD components, including 
grafts, must be “pre-clotted,” meaning the woven topography of the blood contact surfaces must 
be covered with adherent material to produce a smooth, essentially uniform surface [69]. The 
major immediate post-operative risk for any VAD implantation is hemorrhage, which can lead to 
right-sided heart failure and infection [69]. 
An example of an intracorporeal extra cardiac device is the Electro-Hydraulic Artificial 
Myocardium (EHAM) developed at Tohoku University, Japan [72]. This device is placed around 
the apex of the left ventricle on the epicardial surface and assists myocardial contraction by 
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creating a restrictive barrier, thus increasing myocardial tissue perfusion [72]. A benefit of extra 
cardiac VADs is the lack of contact between the device and the patient’s circulatory system, 
which reduces the probability of thrombus formation. With the use of extra cardiac VADs, 
surgeons can avoid using cardiopulmonary bypass during implant surgery and lower the chance 
of post-operative bleeding. Extra cardiac VADs are currently in pre-clinical studies. 
 
3.2.2. Extracorporeal/paracorporeal VADs 
 
Extracorporeal or paracorporeal VADs are located mainly outside of the patient’s body. 
This placement benefits both the patient and healthcare providers if the device must be 
exchanged because of suspected thrombus formation or other complication. However, the 
patient’s overall quality of life may be decreased, because the patient must be careful to keep the 
VAD from catching on objects, particularly at home. Extracorporeal VADs, like some 
intracorporeal intraventricular VADs, require cardiopulmonary bypass during implantation and 
pose risk for cannula infection, thrombus formation, hemorrhage, and device failure [73]. 
Examples of extracorporeal VADs include Berlin Heart’s Excor®, which has been approved by 
the United States Food and Drug Administration (FDA) for bridge-to-transplant use in pediatric 
patients, and Abiomed® BVS 5000® [67, 73]. 
 
3.2.3. Determining which VAD to use 
 
It is up to the surgeon to determine which type of VAD to implant in each patient. 
Patient size can be a determining factor, for there are currently no FDA approved intracorporeal 
devices for pediatric use; therefore, infants and small children are most often implanted with 
 22 
 
extracorporeal VADs. For non-infant patients with a more active lifestyle, an intracorporeal 
VAD is most often desired, because the driveline and connecting controller/battery pack are less 
cumbersome and easier to handle than both the inflow and outflow cannulae of an extracorporeal 
VAD. 
 
3.3. Applications 
 
There are three broad applications of VADs: bridge-to-transplant, destination therapy, 
and bridge-to-recovery. In the case of moribund patients, bridge-to-decision is also a short-term 
application of VADs. In these cases, when the patient has end-stage organ failure or their 
neurologic status is unclear, a doctor may decide to implant a VAD in order to stabilize the 
patient. This gives the physicians more time to further evaluate the patient’s condition and make 
a decision [21]. 
 
3.3.1. Bridge-to-transplant 
 
For younger or otherwise relatively healthy patients with a life-threatening, incurable 
heart condition, a heart transplant is the preferred solution. Patient eligibility criteria for heart 
transplant include age, histocompatibility, likelihood of organ acceptance, and overall health, 
aside from heart failure. If a patient meets the requirements for cardiac transplant surgery, he or 
she is placed on a wait list until a donor match becomes available. The donor heart must be of 
compatible size and tissue type. These requirements, coupled with the fact that fewer than 3,000 
donor hearts are available each year worldwide [16], substantially lengthen the amount of time 
patients are on the wait list. The waiting time is often longer than the period for which the 
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patient’s heart can adequately provide oxygenated blood to the body. VADs provide an option 
for assistance to the diseased heart while the patient awaits transplant. This application of VAD 
technology is known as bridge-to-transplant (BTT). Patients waiting for a transplant have an 
increased chance of surviving VAD implant surgery because non-cardiac organ function is 
maintained despite a failing heart [74].  
Often a VAD can elevate a patient’s eligibility status for a heart transplant. For example, 
pulmonary hypertension is a condition that prevents patients from being eligible for a heart 
transplant. Pulmonary hypertension can develop as heart failure progresses as a defense 
mechanism to decrease the amount of fluid going to the lungs. Acutely, this response will 
prevent pulmonary volume overload, which can cause patients to drown in their own fluids. As 
RVADs perfuse the lungs adequately and LVADs take a significant load off the heart, the 
decrease of blood volume in the heart allows the pulmonary vasculature to remodel, reversing 
instances of pulmonary hypertension and effectively elevating patient status. 
 
3.3.2. Destination therapy 
 
For patients with chronic, severe heart conditions who are not expected to recover and 
who are not eligible for heart transplants, VAD implantation is a viable option to improve quality 
of life and extend lifespan. When a patient receives a VAD for destination therapy (DT), the 
device is expected to support the patient for the rest of his or her life. DT patients are often of 
advanced age and/or have substantial comorbidities that preclude them from receiving heart 
transplants. If a patient survives the VAD implant surgery, he or she is likely to have a longer 
and more comfortable life than would have been possible without a VAD [74]. 
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3.3.3. Bridge-to-recovery 
 
Ventricular assist devices are also used in patients with potentially reversible heart 
conditions, such as women with post-partum cardiomyopathies. This application for VADs is 
commonly referred to as bridge-to-recovery (BTR). If a patient has a relatively good prognosis 
for recovery of myocardial function, temporary mechanical circulatory support is more suitable 
than cardiac transplantation. A VAD can assist an unhealthy heart during recovery. The VAD 
takes stress off the native heart, allowing it to recover while maintaining sufficient blood flow to 
other organs. An increasing number of patients are receiving temporary VAD support before 
transitioning back to natural heart function. 
Some patients who are originally assigned to BTT or DT recover from their heart disease 
while receiving assistance from the VAD. In these patients, the VAD is subsequently removed 
without the patient going to transplant. For patients whose native hearts are able to recover, 
receiving a VAD for BTR is better than receiving a donor transplant or permanent VAD [75]. 
 
3.4. Approval and use of VADs in the United States 
 
3.4.1. Bench-top testing 
 
The development process for VADs begins with an initial design and systems testing. 
This process, much like that for other medical devices, is initiated by determining a need for the 
device and then determining the market size. To streamline the time to market, companies often 
set design goals based on previous VAD models and available performance data. After a 
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prototype is developed, initial testing and data collection begin. The results are compared with 
those obtained with current models. 
Collection of benchmark data using research models allows engineers to fine-tune the 
design specifications until the design meets the desired specifications and the final prototype is 
developed. Once all officials in the company approve the VAD, the device enters a “design 
freeze” phase, in which the latest prototype can no longer undergo changes. This phase ends 
initial bench-top testing, and pre-clinical trials may be initiated. 
 
3.4.2. Pre-clinical trials 
 
Pre-clinical trials include data collection related to medical device performance in 
animal models. In the United States, pre-clinical studies are precursors to human trials. These 
studies are typical for a VAD application in the United States, because VADs are considered 
life-sustaining devices and thus classified as Class III devices by the FDA [76]. Therefore, in 
order for a company to obtain approval for a Class III VAD, a premarket approval (PMA) 
application must be submitted. Pre-clinical trial data collection is required for a PMA application 
to be considered complete. 
Pre-clinical testing of a new VAD design is a critical step in evaluating safety and 
performance. The most common animal models for VADs are bovine, ovine, and caprine. In the 
US, pre-clinical studies can be divided into Good Laboratory Practices (GLP) and non-GLP 
studies. GLP is a federal policy that establishes the scientific benchmark for animal studies 
where standards and procedures are set in place to ensure consistency, reliability, and 
reproducibility of the results before FDA submission [77]. Device manufacturers use GLP 
standards to help transition to clinical trials. 
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3.4.3. Clinical trials 
 
Clinical trials are the culmination of medical device development on the path to approval 
status. Data are collected from human patients in whom the devices have been implanted. The 
company determines the amount of clinical data sent to the FDA with the PMA application. 
However, only the clinical trial data sent to the FDA will be interpreted and used in determining 
whether or not the data constitutes valid scientific evidence for the medical device. 
Gold standards similar to those in pre-clinical trials are also used in clinical trials. Good 
Clinical Practices (GCP) are the clinical trial counterpart to GLP. GCP standards are considered 
consistent and reliable, thus ensuring the accuracy and reproducibility of the data collected. 
 
3.4.4. Control groups 
 
In both pre-clinical and clinical trials, it is important to have a control group or an 
acceptable benchmark for comparing study results. For invasive medical devices with few or no 
predicate devices, as is the case for VADs, a control group is difficult to construct. For 
Thoratec’s HeartMate II®, one of the first VADs reviewed by the FDA for BTT applications in 
adults, the only control group available consisted of patients who received drug therapy for heart 
disease without an assist device. The effectiveness of the device was determined based on the 
percentage of patients who survived long enough to receive a transplant or went 180 days with 
VAD support [62]. 
The Interagency Registry for Mechanically Assisted Circulatory Support 
(INTERMACS) is a registry established in 2005 by the National Heart, Lung and Blood 
Institute, the Centers for Medicare and Medicaid Services, FDA, and the University of Alabama 
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at Birmingham. In recent clinical trials, INTERMACS has been used as a control group. The 
registry was used in the clinical trials for HeartWare Inc. HVADTM, which was reviewed by a 
FDA advisory panel in April 2012 [64]. The effectiveness of INTERMACS as a control group is 
being evaluated. 
 
3.5. Pathology evaluation of VADs 
 
According to the FDA PMA application, pathology evaluation of VADs is not currently 
a specific element required for submission. Although biocompatibility, stress, wear, and shelf 
life are examined during non-clinical laboratory studies and/or clinical investigations, pathology 
evaluation is not mandated [76]. However, establishing that a device is safe and effective without 
pathology analysis is challenging. The Cardiovascular Pathology Laboratory at Texas A&M 
University believes complete pathology workup (as outlined below) should be performed for 
both the pre-clinical and clinical portions of any FDA submission, especially PMA submissions. 
These recommendations arise from many years of experience with pathology of VADs at various 
testing stages including pre-clinical trials, clinical trials, and post-market surveillance. 
Pathology data are most credible when an independent pathologist with experience in 
cardiovascular medical device evaluations performs the post-explant examination of a VAD 
focusing on: 
1. Characterizing components of the VAD: 
a. Blood-contact surfaces 
b. Housings, diaphragms, conduits, grafts, sewing rings, etc. 
2. Determining the type of device complication (if applicable) and the physiologic or 
pathologic basis for any device related complications [78]. 
 28 
 
To achieve these two goals, pathologists should use many diagnostic tools and data 
analysis techniques (outlined below). The pathology data gathered from these analyses can aid 
VAD manufacturers in improving pump designs and ultimately producing safer and more 
effective devices.  
A complete pathology analysis involves two tiers of analyses, depending on the situation 
presented in each case. The first set of analyses (Tier 1) should be conducted on any explanted 
VAD, regardless of the reason for explant (death, transplant, exchange, or recovery). These 
procedures constitute a baseline analysis necessary to evaluate the performance of the device and 
the effects it had on the patient. The second set (Tier 2) includes an array of analyses that 
supplement Tier 1 procedures. Tier 2 contains investigative or confirmatory analyses used at the 
pathologist’s discretion. Tier 2 procedures are more time consuming, more expensive, and more 
specialized. The pathologist must be cognizant of specimen retention for Tier 2 analyses while 
performing Tier 1 procedures in order for the additional investigation to augment the pathology 
analysis. Table 2 summarizes analyses in Tiers 1 and 2 [78]. 
 
3.5.1. Tier 1 analyses 
 
Tier 1 analyses are typically the only procedures performed for a routine VAD 
evaluation. They entail both gross and microscopic analyses. For cardiac devices in general, and 
especially VADs, the pathologist should evaluate both the device and the host response. For a 
post-mortem VAD analysis, performing a(n) necropsy or autopsy yields vital details about the 
performance of the VAD, especially the host response to the device (i.e., biocompatibility). A 
preferred technique during the necropsy/autopsy is perfusion-fixation of the patient’s heart and 
VAD. This technique allows superior sections to be made for histological processing one to 
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fourteen days after fixation of the heart and VAD, depending on the amount of tissue present. 
Small amounts of tissue present on the VAD and associated components are adequately fixed 
after 1-2 days, whereas substantial amounts of tissue require longer fixation periods. During the 
necropsy/autopsy, photographic documentation of the following is performed to ensure quality 
data when generating a post-evaluation report: device in situ, key end organs (heart, brain, 
kidneys, intestines, and lungs), and any host or device abnormalities. Additionally, the key end 
organs and samples of any documented lesions are collected for histological preparation. In 
many cases, the pump is removed and submitted independently for evaluation. However, in cases 
where the heart and pump are received and evaluated en bloc, important landmarks to examine 
are: 1) remodeling with possible change in orientation of the inflow conduit; 2) 
endocardial/pump interface healing; 3) signs of ascending infection (via driveline) or seeding 
secondary from the implant insertion (i.e., sewing ring). In the downstream organs, the major 
lesions to look for are infarcts (which could be indicative of thrombosis) and any infection 
related effects. The pathologist evaluates the VAD after device explant and perfusion 
fixation/post-fixation, if applicable.  
The analysis commences with the pathologist and technicians assisting in the evaluation 
verifying the contents received for evaluation (VAD [serial number], attachment device, graft, 
driveline connections, cannulae, etc.). Serial numbers are documented and photographed. The 
pathologist performs an evaluation of the external surfaces, and the technician documents any 
abnormalities. External surfaces include the electrical unit, inflow and outflow cannulae, 
driveline connections, de-airing ports, etc. Throughout the external evaluation, the pathologist 
removes and evaluates the pump accessories (outflow graft, sewing ring, cannula tubing, 
driveline). All aspects of the graft are photographed. First, the external surfaces of the graft are 
photographed, as well as the proximal and distal openings. Then, the graft is cut open, and the 
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entire lumen is photographed. The pathologist evaluates both the superior and inferior surfaces 
of the attachment device, paying close attention to any attached myocardium and/or connective 
tissue for thrombus or pannus formation. The cannulae are evaluated as another blood-contacting 
surface and are examined for any abnormalities. The driveline is observed for contamination by 
blood components, stretching or heating damage of its external surfaces, and contamination 
within the connector. 
After a thorough examination of the external surfaces and VAD accessories, the 
pathologist disassembles the VAD. The inflow and outflow ostia are assessed during the 
disassembly. The pathologist evaluates the opened unit, focusing on the blood contacting 
surfaces, noting and collecting any unusual materials or deposits for histological examination 
(formalin-fixed, paraffin-embedded tissues; hematoxylin and eosin [H&E] and phosphotungstic 
acid hematoxylin [PTAH] stains). These deposits are characterized in a standardized manner by 
appearance, size, color, and location within the pump. The pump is examined for any non-
biologic abnormalities (surface abrasions or imperfections, insufficient valvular response, wear, 
etc.). These abnormalities are documented both photographically and in the written report. Once 
all internal lesions and abnormalities are documented, the evaluation is complete. Figure 6 and 
Figure 7 represent a selection from a 22-24 photograph montage for a Berlin Heart® Excor® 
(Figure 6) and HeartWare Inc. HVADTM (Figure 7) evaluation. 
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Figure 6. A representative subset of photos to be included in montage accompanying the final pathology report for a Berlin Heart EXCOR. A) Superior 
view of pump. B) Pump inflow. C) Inflow valve leaflet. D) Lateral view. E) Pump outflow. F) Outflow valve leaflet. 
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Figure 7. A representative subset of photos from several pump evaluations to be included in montages accompanying the final pathology report for a 
HeartWare HVAD. A) Superior view of all contents received (status post op (s/p) 17 days). B1) Upper housing outflow (s/p 31 days). B2) Lower 
housing outflow (s/p 31 days). C) Inflow (s/p 46 days). D) Opened unit with impeller in situ (s/p 722 days). E) Impeller post (s/p 592 days).
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Next, the pathologist generates a report of the gross findings from both the 
necropsy/autopsy, if applicable, and the VAD evaluation. The technician selects a subset of the 
photographs taken during the evaluation to create a photographical representation of the findings 
during the gross evaluation, referring to the figures by number in the generated report. The 
pathologist supplements the report with his or her findings from light microscopy, including for 
each deposit the etiology (i.e. “pass through” or de novo), morphology, approximate age, if 
possible, and the effect on device performance. Additionally, the pathologist takes 
photomicrographs to visually support the light microscopic findings. Finally, the pathologist 
draws conclusions from the gross and microscopic findings and comments on the overall device 
performance relative to that of idealized or similar devices. Correlation with the clinical findings 
in the patient is always recommended. Report submission to the VAD company is the 
culmination of Tier 1 analyses as performed for every VAD evaluation. 
Microscopic evaluation of deposits found within VADs elucidates more information 
than can be obtained with gross evaluation alone. In VADs that have not been properly rinsed 
immediately following explant, it can be difficult to assess whether the internal components 
contain thrombi or simply post-explant clotted blood. Microscopic evaluation is necessary to 
confirm material composition. Sometimes blood coagulates and settles to the gravity-dependent 
side of a VAD and forms a clot with the heavier blood components (i.e., cellular) gathering at the 
bottom and the lighter components (i.e., fibrin) rising to the top. This is indicative of a post-
mortem blood clot, and can help the pathologist determine the position the patient was laying in 
at time of death. Microscopic evaluation of these deposits will reveal abundant erythrocytes with 
little to no fibrin and no evidence of organization; there are usually loose, randomly oriented 
eosinophilic strands with scattered enmeshed leukocytes. In VADs with rotating surfaces, ante-
mortem/ante-explant thrombi are characterized by an eosinophilic dense matrix arranged in 
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layers that typically show variations of platelet/fibrin layers, fibrin enmeshed erythrocytes and/or 
leukocyte sheets within fibrin enmeshed erythrocytes. These laminar areas are flow dependent. 
For example, high flow shows more compacted cellular elements and lower flow or turbulence 
shows greater accumulations of cellular elements. 
 
3.5.2. Tier 2 analyses 
 
Tier 2 analyses should supplement Tier 1 analyses in specific cases at the discretion of 
the pathologist. This level of analysis requires a more specialized laboratory with specialized 
capabilities. This includes but is not limited to one or more of the following: radiographs (2-5µm 
resolution), computed tomography (CT) analysis (2-10µm resolution), and scanning and 
transmission electron microscopic analysis. 
Radiographs and CT are used to evaluate entire VADs or individual components. These 
are useful resources to determine stress fractures or points of fatigue on moving parts. These 
imaging modalities are used to determine the extent of mineralization within the VAD, which 
correlates with a foreign body response [78]. CT is used to identify device abnormalities that a 
two-dimensional (2D) image cannot display and is performed before device evaluation to 
prevent the movement of particles. Device irregularities are further evaluated using CT after 
injection of a contrast agent (for example, barium). 
Electron microscopy provides a more detailed analysis of the surface of tissues or 
devices. Scanning electron microscopy (SEM) is used to identify the surface topography of 
devices, including degree of fibrin and platelet deposition, abrasion scoring, degree of pitting on 
a device, neointimal growth, and thrombus formation. Transmission electron microscopy (TEM) 
provides comprehensive images of the ultrastructure of the sampled tissue. This information 
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allows the pathologist to provide a detailed description of the biological response to the VAD. 
Scanning transmission electron microscopy (STEM) allows the ultrastructure of samples to be 
visualized without the use of stains common in TEM, thus STEM is effective at imaging tissues 
that cannot be stained. 
In conjunction with SEM, electron dispersive X-ray spectroscopy (EDX) provides an 
elemental analysis of the surface composition of a device or tissue. This technology is used to 
determine the elemental identity of contaminants in medical devices. EDX also supplements 
light microscopy by determining the identity of unstained areas on a slide through the isolation 
of unstained areas within the paraffin block. 
 
3.5.3. Executive summaries 
 
At the conclusion of the VAD studies, the pathologist creates an executive summary 
report to present the major conclusions. The executive summary is a finely detailed report that 
summarizes the methods used to evaluate the device both grossly and histologically, as well as 
the gross and histologic findings. Review of pathology executive summary reports is an 
important step for regulatory agencies in deciding whether a device is safe and effective or not. 
Executive summaries are also extremely useful for studies with large numbers of pump 
specimens, as they enable the pathologist to draw overall conclusions about pump functionality 
and host response. As with all pre-clinical and clinical studies, QAUs are crucial and should 
audit all reports before submission to a regulatory agency. 
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3.6. Discussion 
 
The risk to benefit assessment represents a delicate balance between introducing life-
saving medical devices to market as soon as possible and preventing unsafe devices from being 
implanted in patients. With VAD technology constantly changing, it is difficult to properly 
assess the safety of such devices in a timely manner. Clinical data alone provide only a small 
portion of information about patient interaction with the device. This narrow view could result in 
the implantation of unsafe devices. 
A thorough device study involves both clinical data and a pathology evaluation. 
Pathology, in conjunction with clinical correlation, lets investigators and regulatory agencies 
evaluate VADs of various designs by the same criteria. For example, finding thrombus formation 
grossly and confirming the diagnosis microscopically may reveal potential problems with the 
device, sometimes before clinical symptoms are apparent. All VADs need a pathology 
evaluation with at least the Tier 1 analyses, which includes a gross evaluation, photographic 
documentation, and, if the gross evaluation reveals abnormal deposits, light microscopy. For 
cases with unique or unusual findings, Tier 2 analyses, such as radiography or electron 
microscopy, can aid in identifying abnormal or foreign material. 
A pathologist familiar with comparative anatomy should perform pathology analyses in 
pre-clinical trials. Many of the host responses observed in humans are similar in animals; thus, if 
a complete pathology analysis is performed in pre-clinical trials, unsafe devices are less likely to 
be implanted in humans. However, comparative anatomy has limitations and must be treated 
cautiously so that data are not misinterpreted or overlooked. 
Whereas clinical data elucidate past problems with medical devices, pathology findings 
show past and future problems through the use of integrative techniques that provide a more 
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thorough understanding of the effect of the device on the patient. To accurately indicate VAD 
safety, comprehensive pathology analyses are essential for all VADs, in both pre-clinical and 
clinical trials, and the findings should be correlated with clinical data. This correlation allows for 
a more complete determination of long-term safety and is more useful to medical device 
reviewers. 
 
3.6.1. Rationale for subsequent sections 
 
A wholesome review of pathology evaluations performed throughout the course of pre-
clinical and clinical trials for multiple types of VADs can be useful for comparing different VAD 
models and determining trends seen in each. For example, a classification system for 
categorizing deposits collected from VADs could be developed to learn more about each VAD 
model and how certain pump parameters (flow type, implant duration, speed, etc.) correlate to 
the type of deposits found post-explant. The Cardiovascular Pathology Laboratory at Texas 
A&M University has developed a classification system after 1,000+ VAD pathology evaluations; 
however clinical correlation and correlation with pump log files is necessary to reveal more 
information specific to each pump. The remaining sections of this dissertation provide a 
comprehensive review of blood coagulation as related to VADs, and a computational and bench-
top model that can reveal information specific to each VAD model before pre-clinical trials 
commence. The ultimate goal of these models is to decrease instances of thrombotic 
complications in VADs.  
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4. HEMOSTASIS, CLOTTING, AND THROMBUS FORMATION 
 
The body has built-in mechanisms to maintain homeostasis within the vasculature to 
continue sufficient oxygen delivery and waste removal necessary for life. Blood, as a body 
tissue, is complex and constantly changing its dynamic to provide for the body’s needs [79]. 
Hemostasis, the cessation of blood flow, is an important defense mechanism against vascular 
injury. The mechanism of hemostasis involves clotting of blood at areas of tissue or vessel 
damage. The goal of hemostasis is two-fold: 1) prevent oxygen carrying erythrocytes from 
leaking out into the tissue after vascular injury, and 2) re-establish vessel wall integrity [80]. 
Implanting a VAD causes a disruption in the normal body mechanisms, and the right balance 
between hemorrhage and VAD thrombosis is a difficult and challenging task for manufacturers 
and clinicians. This section provides a general overview of the hemodynamic process and 
discusses the multitude of ways that implantation of a VAD might alter normal physiologic 
hemodynamics. 
 Clotting and thrombosis are common terms used in the medical community with related  
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but different meanings. Clotting can have a negative connotation; however, it is a normal 
physiologic process that prevents injured tissues from hemorrhaging. Thrombosis is pathological 
in nature and can be defined as intravascular blood clotting in an undesirable area [81, 82]. A 
thrombus can disrupt blood flow or become an embolus (moving thrombus). Emboli, depending 
on their size, can occlude blood flow in a downstream vessel potentially limiting oxygen 
delivery and causing ischemic damage. 
 
4.1 Coagulation in vivo 
 
In general, blood coagulation (clotting) begins after an initial insult to tissue, and 
involves primary hemostasis, the coagulation cascade (intrinsic, extrinsic and common 
pathways), and fibrinolysis (Figure 8). This complex process and can be initiated by multiple 
stimuli and many components often overlap.  
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Figure 8. Overview of physiologic coagulation in vivo and changes associated with VAD implantation. 
Coagulation is initiated by two mechanisms: contact with a foreign object (i.e., exposed basement 
membrane, collagen fibers, etc.), and tissue damage. These mechanisms initiate primary hemostasis 
(platelet activation, adhesion and aggregation), and the coagulation cascade (intrinsic, extrinsic and 
common pathways [clotting factors noted in Roman numerals]), which ultimately results in formation of a 
stabilized, fibrin clot. The clot is maintained in size by various mechanisms, including fibrinolysis, and 
eventually the wound is healed. Inserting a VAD into the body changes the coagulation process indicated 
by the dotted purple lines, and may result in the inappropriate formation of a thrombus. 
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4.1.1 Primary hemostasis 
 
Primary hemostasis is initiated when the basement membrane of vessels are exposed 
during tissue injury (e.g., from surgery, trauma, etc.), and begins with activation of platelets, a 
cellular component crucial in coagulation. Activated platelets adhere to connective tissue fibers 
(i.e., exposed basement membrane), as well as glass and metal, within a few seconds after 
contact [80]. Adhered platelets change shape and recruit platelet aggregates to form an initial 
“platelet plug” that seals off the injury. This “platelet plug” is sufficient to prevent major loss of 
blood, but is not a permanent solution. 
 
4.1.2 Coagulation cascade 
 
The coagulation cascade is an amplifying series of enzymatic conversions that ultimately 
results in the formation of fibrin [81], which will fortify the platelet plug created during primary 
hemostasis and increase the likelihood that the clot will heal the injury. Clotting factors derived 
from plasma are denoted by Roman numerals I-XIII. (Refer to Appendix I for a list of all tissue 
factors and detailed description of the coagulation cascade). The coagulation cascade includes 
intrinsic and extrinsic pathways each initiated by separate mechanisms, which eventually 
combine to form the common pathway. The extrinsic pathway begins when tissue damage 
provides a tissue factor (TF) that acts as a catalyst in the activation of factor X [83]. In the 
intrinsic pathway, surface contact with a foreign (non-endothelial) substance (i.e., exposed 
basement membrane, medical device, etc.) acts as a catalyst for activation of factor XII, which 
ultimately joins the extrinsic pathway with the activation of factor X [80]. The common pathway 
involves the conversion of prothrombin to thrombin, which leads to the formation of fibrin 
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monomers. Fibrin is a major part of coagulation because it fortifies and stabilizes the clot to 
adequately heal the injury. 
 
4.2 Coagulation related to VADs – Virchow’s triad 
 
The main goal of blood coagulation is to heal vascular injury. However, when a medical 
device is implanted and in contact with blood, the normal body response may lead to thrombosis, 
a dangerous condition with potentially fatal results. Figure 8 shows how VAD implantation can 
change the normal hemostatic mechanisms to lead to VAD thrombosis (noted in purple dotted 
lines). 
Virchow’s triad has become a focus in the study of physiologic thrombosis [81], and 
describes three major contributing phenomena: alterations in blood coagulability, alterations in 
blood flow, and introduction of non-endothelial surfaces [84] (Figure 9). VAD implantation is 
linked with all of these phenomena, making thrombosis a serious complication associated with 
VAD therapy [26-34].  
Ventricular assist device implantation disrupts the vascular homeostatic environment 
through multiple mechanisms beginning with surgery, following through to long-term post-
operative management. During implantation procedures, patients’ blood coagulability is altered 
due to anticoagulation therapy (heparin, warfarin sodium, etc.), which decreases the risk of 
clotting during and immediately following the surgical procedure [85]. Additionally, the 
introduction of the device will cause alterations of blood flow, introduce new areas of stasis and 
turbulence, and introduce a non-endothelial surface. The rotating components in these devices 
provide a shear force on the blood components [86], and the device itself provides a surface for 
platelets to adhere and aggregate on [87]. Additional factors such as altered endothelial surfaces, 
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infections, and other patient variables [27] may contribute to thrombosis. Regardless of thrombus 
size or origin, if embolized to the pump, the brain or other down-stream organs, the outcomes 
could include pump failure, disability, or death [27].  
 
 
 
Figure 9. Virchow’s Triad with emphasis on how each branch relates to VADs. Changes in blood 
coagulability includes patient conditions that may lead to an increase in clot formation. Non-endothelial 
surfaces can include exposed basement membrane and subendothelial connective tissue from tissue injury 
that occurs during surgery or the surface of the implanted device. Hemodynamic changes mostly refer to 
the changes in laminar flow due to the implant of the device.  
 
 
 
4.2.1 Alterations in blood coagulability 
 
Alteration of blood constituents is one component of Virchow’s triad that may lead to 
thrombosis. Conditions such as pregnancy, thrombocytopenia, Von Willebrand’s disease, and 
many others can change blood coagulability and increase risk of thrombus formation. In fact, any 
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change of levels in blood constituents (platelets, fibrinogen, etc.) may cause undesired clotting, 
requiring that preventative measures be taken during surgical procedures. 
Anticoagulation protocols during VAD implantation are necessary to keep blood from 
clotting within the device before it can begin operating. Aspirin, warfarin, and heparin are 
common drugs known to inhibit coagulation and are used in anticoagulation protocols during 
surgery (Figure 10). Warfarin (brand name Coumadin) interferes with oxidation of vitamin K, 
which then induces liver production of clotting factors (II [prothrombin], VII, IX and X) with 
reduced clotting function [88]. Heparin indirectly prevents coagulation by accelerating the rate at 
which antithrombin (a protein in the blood) offsets thrombin activity [89]; heparin acts by 
increasing the binding of antithrombin to prothrombin and factor X, ultimately preventing fibrin 
formation. Finally, aspirin is effective at decreasing platelet activity by indirectly reducing the 
production of thromboxane in platelets, which leads to diminished platelet aggregation [90]. 
Although these three drugs are the most common anticoagulants, specific doses of each for 
anticoagulation protocols vary between physicians and hospitals, and are sometimes patient- or 
device-specific.  
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Figure 10. Mechanisms of anticoagulation therapy used during surgery. Aspirin, warfarin, and heparin are 
common drugs administered to prevent clotting during surgery. For the duration of a cardiovascular 
implant, such as a VAD, stent, or pacemaker, a combination of these drugs might be prescribed to prevent 
thrombosis within or around the device.  
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A unique balance of anticoagulants must be administered post-operatively to prevent 
both hemorrhage and excessive thrombus formation. Patients are typically administered warfarin 
or aspirin after VAD implantation to help maintain this balance. Shortly after surgery, protamine 
is often used to counteract the effects of heparin [91]. Long-term anticoagulation protocols must 
be revisited for each patient, however, for conditions such as hemorrhage and thrombocytopenia 
[10] might develop that require alternative treatment options.  
 
4.2.2 Alterations in blood flow patterns 
 
Altering blood flow patterns is another aspect of Virchow’s triad that may lead to 
thrombosis. The presence of the VAD inflow cannula in the ventricle changes the flow patterns 
of blood, introducing areas of stasis and recirculation [92]. Areas of stasis allow accumulation of 
thrombogenic substances such as activated thrombin, platelets, etc. In normal circumstances 
these thrombogenic molecules flow downstream and become deactivated once crossing capillary 
beds [93]. However, in areas of stasis, platelets and other trapped molecules initiate coagulation 
and form a thrombus. Additionally, in areas of low blood flow or stasis, rapid desaturation of 
erythrocytes occurs as a result of the inability to exchange oxygen within tissue. This causes the 
area of stasis to become hypoxic, thereby activating the endothelium [93], which exacerbates the 
inappropriate formation of a thrombus. In patients with dilated cardiomyopathy (patients most 
likely to receive a VAD), this mechanism of blood coagulation is common due to the geometry 
of the ventricle and amount of residual blood in the chamber after each stroke, which leads to 
mural thrombus formation. Mural thrombi, if detached from the wall, may easily enter the pump 
and cause mechanical failure or pass-through the device and cause devastating ischemia. 
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While VAD implantations mostly serve as a temporary solution until a donor heart is 
found, in some cases VADs can become a long-term treatment. Over time, as the VAD implant 
duration increases and a significant load is taken off of the heart, the heart will begin to remodel 
to its previously non-dilated state. As the heart remodels, the flow around the cannula in the 
ventricle may change, which can disrupt mural thrombi or any thrombi formed around the 
device. Consequently, it is possible to see complications from VAD thrombosis after several 
years of successful VAD function.  
 
4.2.3 Non-endothelial surfaces 
 
Finally, introduction of foreign objects, the last branch of Virchow’s triad, may lead to 
thrombus formation. Normally, blood is in contact with endothelium, which is the lining all 
vessels, tissues and organs. Any foreign, non-endothelialized object will cause the blood to clot 
in an effort to shield the body from this object. As shown in Figure 8, contact with a foreign 
substance will initiate the intrinsic pathway and platelet activation. In the case of VAD 
implantation, this could happen in response to the device itself. If the patient is not on 
anticoagulants, a thrombus will form. 
The surface texture of the device can initiate clot formation around and within the 
device. Historically, smooth surfaces have been thought to reduce thromboembolic occurrences 
[94]. However, more recently, in both VADs and grafts, textured surfaces have been shown to 
promote deposition of a pseudointimal layer along the surface of the device to create a biological 
barrier between the device and the blood contact surface [95, 96]. On smooth surfaces, any 
microscopic imperfections can become a nidus for platelet aggregation and/or thrombus 
generation. Additionally, if the pseudointimal layer covering textured surfaces is disrupted, 
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thrombi can readily form at the site of the disruption. The constant movement of the heart can 
cause these fragile thrombi to easily break off and travel downstream to cause infarcts or device 
malfunction. 
 
4.3 Summary 
 
Coagulation is a natural response to maintain adequate blood volume following vascular 
injury. Throughout history, Virchow’s Triad has been used to explain physiologic and 
environmental changes that can cause coagulation without first having vascular injury. 
Implantation of a VAD inherently allows each component of Virchow’s Triad to manifest: 
changes in blood coagulability and flow patterns, as well as introduction of non-endothelial 
surfaces. These environmental and physiological changes can result in VAD thrombosis. The 
Cardiovascular Pathology Laboratory at Texas A&M University has performed a pathology 
evaluation of over 1,000 VADs with and without clinical adverse events, and developed a 
classification system for categorizing deposits and findings within multiple VAD models. This 
system can be correlated with clinical data to learn more about the condition of VAD thrombosis 
and eventually limit the opportunity for thromboembolic complications in future designs. 
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5. THROMBOSIS OF VENTRICULAR ASSIST DEVICES 
 
Thrombosis in ventricular assist devices is a common concern facing VAD 
manufacturers and clinicians. Clinically, a thrombus is suspected to be within the pump when the 
controller log associated with the device indicates high power consumption or periods of low 
flow, at which time the device is typically exchanged. A pathology evaluation of the device can 
aid in determining what caused the irregularities noted on the controller log. A gross and 
histological evaluation of specimens found within the device can determine the etiology of the 
clot/thrombus, and provide a timeline for when the thrombus developed [22]. Over the course of 
several years, the Cardiovascular Pathology Laboratory at Texas A&M University has 
categorized the types of deposits found within VADs (Figure 11 and Table 2), which are outlined 
below. 
 
 
 
Figure 11. Types of blood clots/thrombi in VADs. 
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Table 2. Classification of clots & thrombi within VADs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Classification Name Description 
Low impact/distracting deposits  
1. Post-mortem/explant clots Clots formed after death or after device explant 
2. Peri-mortem/explant fibrin deposits Fibrin deposits formed at the time of death or explant 
 
Ante-mortem, true thrombi  
3. Pass-through thrombi Thrombi formed outside of the device that traveled into the device  
4. In situ/de novo thrombi Thrombi formed within the device 
5. Combination thrombi 
Thrombi that originally formed outside device, traveled 
inside the VAD and became a nidus for further in situ 
thrombus formation 
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5.1 Distracting clots 
 
Post- or peri-explant/mortem clotting of residual blood inside VADs will lead to a low 
impact and distracting blood clot. Clots that form quickly after death or explant are dark red 
“currant jelly” clots (Figure 12A). These clots are regionally homogenous and lack organization. 
Histologically, post-explant clots are characterized by loose, randomly oriented, eosinophilic 
strands with abundant enmeshed erythrocytes (Figure 12B). Other times, when the clot forms 
slowly, the cellular components gravitate toward the bottom of the vessel or device, creating a 
“chicken fat” clot with a gray-yellow plasma layer on top (Figure 12C) [97].  
Mild peri-explant fibrin deposits were formed at the time of explant. These deposits have 
started to develop but do not have the same level of organization as ante-explant thrombi (Figure 
12D,E). Excess post- and peri-mortem deposits often complicate pathology evaluation of VADs, 
making it more difficult to see any possible ante-mortem deposits. These clots can, however, 
give indication of the time of death and/or orientation of the specimen at time of death based on 
the way the erythrocytes settle in the “chicken fat” clot. 
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Figure 12. Post- and peri-explant clots. A,B) Post-explant “red currant jelly” clot found within an outflow 
graft. C) Post-explant chicken fat clot. D,E) Peri-explant fibrin deposit. 
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5.2 Pass-through, ante-mortem thrombi 
 
Prior to patient death or explantation of device, thrombi may form outside the device, 
possibly in the atrial appendage, along the ventricle wall (mural thrombus), around the sewing 
ring (inflow insertion site), or elsewhere in the vasculature. If a thrombus dislodges from its 
origin and embolizes into the VAD, it may lodge between pump components and hinder device 
performance, or create micro-emboli to send out the pump outflow. This type of thrombus is 
referred to a “pass-through” thrombus, because it originated outside the pump and traveled into 
or through the pump. The gross and histologic appearances of these thrombi are largely 
dependent on their origin. If a thrombus developed next to high velocity blood flow, there are 
distinct layers alternating between fibrin and erythrocytes, usually with a fragile tip pointing 
downstream (Figure 13A). If a thrombus forms in regions of stagnation, perhaps near the sewing 
ring/apex after incomplete clearing of blood with each contraction, the thrombus will be 
irregularly shaped with pockets of trapped erythrocytes (Figure 13B,C). 
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Figure 13. Pass-through thrombi. A) Organized thrombus formed along sewing ring with a fragile tip and 
distinct laminations from the high flow of blood passed the device. B,C) Organized thrombus found in the 
inflow of an explanted VAD. 
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5.3 In situ/de novo, ante-mortem thrombi 
 
Thrombi may also develop inside the device prior to device explant/patient death. These 
thrombi may form due to stasis/recirculation of blood within the device, shear forces acting on 
the blood, or in reaction to device surfaces. These thrombi are grossly and histologically 
different from post-explant clots: rather than appearing as a dark red “currant jelly” clot or a 
“chicken fat” clot, de novo thrombi are smaller, usually brittle specimens with clear organization 
(Figure 14). The color varies from transparent and white to alternating layers of dark and bright 
red. When thrombi form on flat surfaces (e.g., vane of a centrifugal flow impeller), they are 
usually transparent, and often firmly adhered to the device surface. Histologically, these thrombi 
are characterized by a homogeneous to slightly stranded pale eosinophilic material with 
occasionally enmeshed platelets and erythrocytes. Ante-mortem thrombi formed within the VAD 
are mostly influenced by the high velocity of blood flow. As the blood continues to flow past the 
thrombus, layers form, altering the thrombus morphology. If a thrombus developing on the 
impeller increases in size, it will impede device function, especially if proper device function 
requires a precisely balanced, axially symmetric impeller, or if the geometry provides small 
tolerances (i.e., <1mm) between rotating and stationary components. This may lead to increased 
friction within the device, which would be indicated on the VAD controller log as an increase in 
power. Thrombi formed where two components meet, such as a stator/impeller interface in an 
axial flow device, are typically composed of cellular components with alternating layers of dark 
and light brown regions. The origin of these thrombi is not fully known. Shear forces from the 
rotation of the impeller has shown to activate platelets, and the heat at the component interfaces 
may or may not contribute to the formation of thrombi de novo.   
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Figure 14. De novo style thrombi. A,B) Thrombus collected from the internal flat surface of a centrifugal 
flow device. C,D) Cross section of thrombus collected from a mechanical joint inside an axial flow device. 
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5.4 Combination of pass-through and de novo 
 
Finally, thrombi may form as a combination of the pass-through and de novo style 
thrombi. Some thrombi of origin proximal to VAD inflow that travel into the device become a 
nidus for further thrombus development within the VAD. These deposits grow onto the internal 
pump components, thus hindering performance of the device. Combination-style deposits are 
grossly characterized by two distinct regions: the first (of upstream origin) is grossly similar to 
pass-through thrombi described before. The second is an area of irregular, fragile, semi-
transparent material similar to de novo thrombi (Figure 15).  
 
 
 
Figure 15. Combination of pass-through and de novo style thrombus. This specimen was recovered from 
an explanted VAD. A) Grossly, this specimen has two distinct regions: a light to dark brown area of 
upstream origin (yellow arrow), with a thin, semi-transparent vegetative segments extending from the base 
(red arrow). B) H&E stained section of region of upstream origin. This section is composed of alternating 
layers of fibrin/platelets and fibrin/erythrocytes with scattered leukocytes. C) H&E stained section of 
vegetative region developed de novo on the internal surface of the VAD. This section is composed of a 
dense acellular substrate made up of a fibrin base with alternating layer of fibrin and fibrin enmeshed 
platelets and wispy basophilic material. 
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5.5 Ventricular insertion site – potential source of pass-through thrombi 
 
After numerous VAD evaluations with increasingly lengthened implant durations, the 
inflow cannula insertion site has become a potential source for pass-through thromboemboli that 
needs further investigation. Inflow cannula position and orientation within the ventricle can play 
an important role in VAD thrombosis, for the presence of the inflow cannula can change the 
flow dynamics inside the ventricle, causing areas of stasis or recirculation that can lead to 
thrombus formation. To further understand VAD thrombosis, it is important to also look at 
potential sources of thromboemboli, learn how and where they are forming, and determine if 
there is a way to prevent them from forming at all. 
Patients with dilated cardiomyopathy inherently have increased chances of mural 
thrombi formation (with or without VAD implantation) due to large regions of stagnant flow 
caused by decreased contraction strength and increased ventricular volume. In patients with 
VADs, a thrombus may develop initially due to platelet activation upon contact with the VAD 
surface or because of geometry-induced blood stasis (i.e., around the inflow cannula). As time 
goes on and the thrombus continues to develop, cellular components will collect within the 
thrombus. Normally, inflammatory cells will replace the thrombus with collagen during the 
tissue repair process. However, in the case of VAD implants, the constant high flow of blood 
passing by the thrombus prevents any inflammatory cells from “healing” the thrombus. Thus the 
thrombus continues to develop in alternating layers of fibrin and erythrocytes (Figure 16) 
extending off of the sewing ring or along the inflow cannula. The thrombi in Figure 16 are from 
VADs used in a clinical setting that were removed after 900 days of implantation. 
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Figure 16. Gross and histologic views of organizing thrombi retrieved from explanted VADs. Dark brown 
material extending from the sewing ring and attached myocardium removed from the VAD at time of 
explant (A) was histological composed of layers of fibrin and fibrin-enmeshed erythrocytes indicating that 
this material is an organizing thrombus. Material removed from the exterior of an explanted inflow 
cannula (C) was histologically determined (D) to be an organizing thrombus arranged in laminations 
similar to the thrombus in B. Each of these devices had been implanted for over 990 days. 
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During pre-clinical studies, VADs are implanted into healthy specimens, as pre-clinical 
trials are often used to determine the safety of a device. The tissue response to an implanted 
VAD (Figure 17A,B) after 8 days showed a light brown tissue protruding into the ventricle in 
two areas. This tissue is mostly tan with circular areas of dark brown and lighter brown edges. 
Histologically, the tip of the tissue extending into the lumen of the ventricle is arranged into 
distinct layers with incomplete endothelialization at the tip (Figure 17C). Grossly and 
histologically, this is an area of active thromboegenesis. 
 
 
 
Figure 17. Pre-clinical heart specimen (calf) after VAD removal. A) Cross-section of transected ventricle 
with inflow cannula removed. B) Lateral view of ventricle with inflow cannula removed. C) H&E stained 
sections of thrombus collected from inflow region. 
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5.6 Discussion 
 
5.6.1 Clinical significance 
 
Post-explant blood clots have no clinical significance and often inhibit the pathology 
evaluation of VADs, making it difficult for the pathologist to distinguish between what happened 
before and after the pump was explanted. Post-mortem clots, however, may be useful in 
autopsies for indicating orientation of the device at time of death. The greatest concerns to the 
pathologist and device manufacturer are ante-mortem thrombi. Thrombi have the potential to 
disrupt device function, or send emboli downstream that cause life-threatening or debilitating 
areas of ischemia. 
Thrombi inside the pump can lead to increased areas of friction, which causes an 
increase in power consumption indicated on the VAD controller log [24, 40]. Occlusion of the 
inflow/outflow cannula will cause low flow. Most VAD companies have algorithms to sound 
alarms when logs show either increase in power or a decrease in flow rate, which alerts medical 
professionals to either administer thrombolytics, or in extreme cases, perform a VAD exchange 
surgery. VAD exchange surgeries can be risky depending on the stability of the patient, and may 
provide new physical (and monetary) burdens on the patient. 
The rigidity and elasticity of the thrombus may change the clinical significance [98] of 
VAD thrombosis. Different concentrations of viscoelastic components cause the thrombus to 
react differently to stresses and strains present in the body [99]. Thrombus rigidity and elasticity 
can also depend on age; older thrombi have had more time for the fibrin strands to cross-link, 
thus are more compact but are often brittle and prone to fragmenting [98]. The rigidity and 
elasticity of thrombi will impact how the device or organs sustain thromboembolism; softer 
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thrombi may be broken up small enough to not cause noticeable clinical changes, but more 
brittle thrombi will fragment and provide a higher risk of infarct. In the case of axial flow 
pumps, the upstream thromboemboli can undergo shear and create microemboli to send 
downstream [98]. 
 
5.6.2 Thrombus age 
 
The precise age of a thrombus is difficult to ascertain histologically. As explained 
previously, a thrombus may develop initially due to platelet activation upon contact with the 
VAD surface or from shear forces, or may be initiated because of geometry-related blood stasis. 
As time goes on and the thrombus continues to develop, cellular components (mostly 
erythrocytes) will collect within the thrombus. In the case of vascular injury, leukocytes will 
infiltrate the area, eventually replace the clot with new collagen, and effectively heal the injury. 
However in the case of VAD thrombosis, the constant high flow of blood passing by the 
thrombus prevents any leukocyte activity from clearing out the thrombus. Consequently, the age 
of the thrombus is difficult to determine histologically, for active growth (thrombogenesis) at the 
tip of the thrombus indicates a newly developed (or developing) thrombus, but in fact this 
thrombus may have been initiated at any time after implant. 
 
5.6.3 Inflow cannula surface 
 
In recent generations of VADs, a textured surface has been added to the inflow surface 
to decrease the risk of thrombus formation. The textured surface promotes development of a 
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“pseudointima” along the surface of the device, thus removing the direct connection between the 
device and the blood [85]. However, this smooth “pseudointima” is not always a perfect solution 
for eliminating thrombogenesis, and sometimes a thrombus will extend across the sintered 
surface and on to the smooth surface of the device. 
Due to the constant movement of the heart and the circulating blood, active, organizing 
thrombi around the inflow cannula that protrude into the ventricle present a significant risk for 
the patient. At the right time they could break off, travel through the pump, and cause damage to 
the device or become lodged in a downstream organ, causing an ischemic stroke or infarct.  
5.6.4 Remodeling of the heart 
VADs can be long-term or short-term treatments for HF. With all VADs, the 
perioperative period presents a significant challenge for clinical management of the patient. 
Initial interactions between the native heart/cardiovascular system and device can have an effect 
on device performance [100]; therefore, the patient is carefully monitored for suspected 
thrombus and other adverse events. After an inclusive review of the VADs evaluated in the 
Cardiovascular Pathology Laboratory, some long-term implants have organizing thrombi in the 
ventricle that could easily cause device malfunction or ischemic damage if dislodged. In 
addition, it is worth re-mentioning that the intended recipients for VADs are patients with dilated 
cardiomyopathies, patients with enlarged ventricles. In long-term implants, as the VAD takes a 
significant load off of the heart, the ventricle may remodel [101] which will change the lumen 
size of the ventricle and alter the flow dynamics within the chamber. The healthy pre-clinical 
specimen in Figure 17 produced similar changes as those seen from patients with long implant 
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duration. The re-shaping of the ventricle may be a source for thrombus development putting 
otherwise long-term successful implants at risk for failure. 
 
5.6.5 Reducing instances of VAD thrombosis 
 
Pathology evaluations alone cannot elucidate more information about the formation of 
thrombi, for all examinations are post-explant; clinical information about the patient is usually 
missing and pump data (power usage, flow rates, etc.) are typically unknown to the pathologist at 
time of evaluation. Understanding VAD thrombosis fully has become a focus in VAD research, 
and will continue to be a crucial component in expanding the impact of VADs worldwide.  
The ventricular insertion site offers a unique opportunity for thrombus formation and 
potential origin of thromboemboli that requires further research. Depending on the length of 
implant duration in human cases, the tissue response varies from mild deposition of fibrin along 
the inflow cannula, to areas of active thrombogenesis. 
Therefore, it is important to study the angle and depth of the inflow cannula into dilated 
and normal sized ventricles to determine if this change can produce thrombus formation. This 
research could also determine an optimal inflow cannula orientation for decreasing recirculation 
and stasis of blood, thereby decreasing thrombus formation both during the perioperative period 
and after the heart remodels. Most computational models of VADs are used during development 
stages, and show the operation of the device separate from the vasculature. A computational 
model of VADs in vivo (in a ventricle) could help improve pump design and provide physicians 
with more information about how thrombi form in the ventricle as the implant duration increases 
[102]. 
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6. EFFECT OF MYOCARDIAL REMODELING ON VENTRICULAR THROMBOSIS
DURING LONG-TERM MECHANICAL SUPPORT 
Ventricular assist device implantation procedures begin by determining the insertion site 
of the device. A sewing ring is sewn into either the right ventricle (for a right-VAD [RVAD]) or 
the left ventricle (for a left-VAD [LVAD]) around the desired position. The myocardium within 
the center of the sewing ring is removed, and the VAD is then mechanically fastened to the 
sewing ring. LVAD inflow cannulae are placed within the left ventricle most commonly in either 
of two positions: on the anterior surface lateral to the apex [103, 104] or on the posterior 
diaphragmatic surface [105] (Figure 18). The specific insertion site for each VAD model is 
chosen depending on the surgeon’s preference. Despite the varied implantation techniques, a 
main goal of VAD implantation is to have an unobstructed inflow cannula. If the inflow cannula 
opening is too close to the septum or the free wall, the inflow may be occluded which will result 
in device malfunction [91]. Some surgeons recommend orienting the cannula toward the aortic 
valve [91], while others recommend that the cannula be parallel to the axis of the ventricle 
chamber (i.e., septal wall) [106]. Inflow cannula placement and orientation are monitored during 
surgery via transesophageal echocardiography while simultaneously observing pump function 
(i.e., flow rate) [91]. Before the patient leaves the operating room, if VAD flow rate is not 
optimal, the inflow cannula may be adjusted by rotating the device [106] or re-entering the 
pericardial pocket and adjusting the device. 
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Figure 18. Anterior apical (A) and posterior diaphragmatic (B) options for surgical placement of the VAD 
inflow cannula within the thoracic cavity. 
Inflow cannula position and orientation can also play an important role in thrombosis, a 
condition with potentially fatal consequences. VAD thrombosis has historically been a concern 
in VAD therapy, but the incidence of thrombosis has unexpectedly increased since 2011 [36, 
107]. VAD thrombosis can significantly increase patient morbidity and mortality unless the 
pump is replaced or the patient receives a transplant [36]. Thrombi can either pass into the 
device and cause malfunction, or travel through the pump and cause ischemia-related problems 
downstream. The presence of the inflow cannula changes the flow dynamics inside the ventricle, 
and creates new areas of stasis or recirculation of blood around the inflow cannula, which can 
lead to thrombus formation. In a recent retroactive study performed by Taghavi et al., surgical 
placement of the HeartMate II (Thoratec Corporation, Pleasanton, CA) inflow cannula less than 
55° relative to the center of the device rotor was associated with higher incidence of post-
operative pump thrombosis [108]. In this study, the inflow cannula orientation remained constant 
throughout duration of support. Another study by Truong et al. showed that although a shift in 
inflow cannula orientation in long-term implants is possible, most patients do not experience a 
significant shift that would impact VAD function (i.e., obstruct the inflow and cause low flow 
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rate) [109]. However, instances of cannula misalignment despite correct initial pump placement 
have been documented for several pump models [101, 110-112]. 
As discussed in Section 5, patients with dilated cardiomyopathy inherently have 
increased chances of mural thrombi formation (with or without VAD implantation). After a 
VAD is implanted, a thrombus may develop initially due to the presence of the device initiating 
primary hemostasis. Over time, a thrombus may develop in alternating layers of fibrin and 
erythrocytes extending off of the sewing ring or along the inflow cannula (recall Figure 16). The 
remodeling of the ventricle throughout sustained VAD support [39] may change the blood flow 
patterns in the ventricle, which may cause these organizing thrombi to break off, travel into the 
device, and put otherwise successful long-term implants at a greater risk for failure.  
Computational modeling is a beneficial technique for analyzing the effect on flow 
patterns of inflow and outflow cannulae orientation relative to the shape of the ventricle and 
aorta [41, 42, 45], as well as analyzing potential designs of new inflow cannula geometries [43, 
44]. Computational modeling can also be used to study the areas of stagnation and recirculation 
inside the ventricle lumen with an attached cannula as the heart remodels from a dilated to a 
healthy size. This could be used to determine how remodeling of the heart after long-term VAD 
support will affect thrombus formation and embolization within the ventricle.  
In this section, a computational model is described and utilized for determining how a 
tubular inflow cannula at varied depths and angles in the ventricle affects areas of stasis and 
recirculation in healthy and dilated sized human hearts. If the VAD implant duration is sustained 
for several years, cardiac remodeling from a dilated to a smaller shape will change the blood 
flow patterns within the ventricle and change the potential for organized ventricular thrombi to 
dislodge and pass into the device. Overall, the goal of this study is to provide information that 
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will help VAD developers and physicians decrease the amount of blood clotting in and around 
the inflow cannula to decrease clinical adverse events related to thrombosis. 
6.1 Materials and methods 
To analyze the effects of cardiac remodeling on blood flow patterns inside the ventricle, 
healthy and dilated heart geometries were created in a 3D CAD software based off of 
measurements from human CT data obtained from The Visible Heart Laboratory (University of 
Minnesota, Twin Cities, MN) and measurements from the literature [113-115]. A simple, tubular 
inflow cannula similar in size to the HVAD (HeartWare, Inc.) and the HeartMate II (Thoratec 
Corporation, Pleasanton, CA) was added to the heart geometry in the anterior apical and 
posterior diaphragmatic positions at three different depths into the ventricle (Figure 19). 
Commercially available computational fluid dynamics (CFD) software (StarCCM+, CD-adapco) 
was used to predict the flow patterns present within each geometry. 
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Figure 19. Geometries used for Computational Fluid Dynamics Study. 
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6.1.1 Geometry 
 
DICOM (digital imaging and communication in medicine) files of a healthy human heart 
and a heart with dilated cardiomyopathy were imported into a free CT analysis software (OsiriX 
Imaging Software, Geneva, Switzerland). The following measurements were taken of each left 
ventricle: longest ventricle depth parallel to the septum measured from the bottom of the mitral 
valve, length of the septum when the ventricle was the longest, widest internal diameter, and 
mitral valve width (Table 3). These patient-specific measurements were used to generate 
idealized geometries of both an average and a dilated adult male left ventricle in a 3D CAD 
software (SOLIDWORKS, Dassault Systèmes SolidWorks Corporation, Waltham, MA) with the 
inflow cannula at different depths in anterior apical and posterior diaphragmatic orientations. A 
2D slice was taken across the midline of the inflow cannula in each model (Figure 19) for CFD 
modeling. 
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Table 3. Measurements of healthy and dilated heart 
End Diastole End Systole 
Measurements from Literature/CT Data “Healthy” Heart Dilated Cardiomyopathy “Healthy” Heart 
Dilated 
Cardiomyopathy 
Longest ventricle depth (parallel to the septum) 6.88cm 7.75cm N/A N/A 
Length of septum N/A 8.3 +/- 1.2cm** N/A 8.3 +/- 1.2cm** 
Widest internal diameter 6.83 7.1 +/- 1.1cm** 3.37 +/- 3.7cm*** 6.4 +/- 1.2cm** 
Mitral valve width 3.0-3.5cm+ 3.37cm 3.0-3.5cm+ N/A 
Generalized Measurements for Model Geometry 
Maximum diameter 6.7cm 7.7cm 4.7cm 7.2cm 
Maximum length 6.6cm 9.6cm 6.0cm* 9.4cm* 
Mitral valve width 3.3cm 3.3cm 3.3cm 3.3cm 
Inflow cannula inner diameter 2cm 2cm 2cm 2cm 
*These measurements are for geometries involving the posterior diaphragmatic cannula placement only. For the anterior apical
placement, the length of the ventricle did not change. 
**Measurements from Douglas et al., Table 1. [113] 
***Measurements from Semelka et al., Table 3. [114] 
+Measurements taken from e-Echochardiography, An Echocardiography and Ultrasound Learning Resource  [115] 
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6.1.2 CFD modeling 
CFD was used to determine the regions of stasis and recirculation for each 2D geometry. 
The 2D mesh for each geometry had a base cell size of 0.375mm, and a 6-cell deep prism layer 
at each boundary. Each simulation incorporated laminar flow of a Newtonian fluid with a 
constant density of 1060 kg/m3 [116] and constant viscosity of 3.5E-3 Pa-S (common value for 
blood analogs when assuming a Newtonian fluid at high shear rates, such as those present in the 
heart [117]). The inlet condition was uniform across the mitral valve boundary and set at a 
constant rate of 0.11489 m/s, which corresponds to a flow rate of 6 LPM (typical cardiac output) 
through a tube with diameter of 3.3cm. The motion of the ventricle walls was prescribed with 
mesh morphing. The initial geometry represented end diastole; then the walls contracted toward 
the center (end systole) and expanded back to the original geometry in a periodic fashion 
according to a sinusoidal waveform (time step of 0.01s, period of 1s). The motion of each wall 
was defined by equations in Appendix II. For the dilated hearts, the ejection fraction ranged from 
approximately 9-17%, while the ejection fraction for remodeled hearts ranged from 
approximately 40-56%. Each simulation ran for 17s (i.e., 17 contractions). 
6.1.3 Data analysis 
Each simulation ran for five complete ventricular contractions before data collection 
began to allow the solution to stabilize. Areas of stagnation were analyzed by collecting 
residence time values: at each time step, each cell within the mesh was given a value for length 
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of time the fluid had been in that cell. The residence time values were exported into a 
spreadsheet and then processed in MATLAB. 
The ability of the ventricle to clear the blood from the chamber was measured by 
virtually injecting a dye uniformly across the mitral valve opening for 2 complete cycles. The 
dye highlighted areas of recirculation and stagnation inside the ventricle. Additionally, vorticity 
values within the chamber were analyzed to further identify recirculation zones. 
6.2 Results 
6.2.1 Stagnation – residence times 
Overall, the ventricles with inflow cannula flush with the apex and in-line with the 
mitral valve had the least areas with residence times greater than 10 seconds (i.e., smaller areas 
of stagnation) after 12 seconds of simulation (Figure 20, indicated by areas of orange-red). Only 
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a thin layer of blood remained along the wall of the dilated ventricle throughout the simulation 
(Figure 20A.1); in the remodeled, smaller sized ventricle (Figure 20A.2) the stagnant areas were 
smaller and limited to the wall region on either side of the mitral valve. The inflow cannulae 
implanted at greater depths into the ventricle yielded increasing areas of stagnation around the 
inflow cannula (Figure 20B.1-C.2).  
Overall, the dilated ventricle with inflow cannula flush with the wall and at an angle to 
the mitral valve showed the greatest areas of stagnation (after 12 seconds) (Figure 21). In this 
geometry, the area of stagnation was opposite the VAD inflow cannula, next to the mitral valve 
(Figure 21A.1). Deeper cannula depths resulted in a reduced area of stagnation near the mitral 
valve, but also resulted in areas of stagnation surrounding the cannula (Figure 21C.1). When 
comparing the remodeled to the dilated ventricles, the areas of stagnation decreased when the 
cannula was flush with the lumen and was at a depth of 10mm (Figure 21A.2, B.2), but the 
overall area of stationary blood increased slightly in the remodeled ventricle when the cannula 
was inserted 20mm into the lumen (Figure 21C.2).  
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Figure 20. Residence times values (at end diastole) after 12 contractions for dilated and remodeled 
ventricles with inflow cannula in-line with the mitral valve. The inflow is uniform across the mitral valve 
(MV) boundary and outflow passively flowing out of the VAD inflow cannula (IC). Dilated (1) and 
remodeled ventricles (2) with IC in the anterior apical placement flush with the wall (A), protruding 10mm 
into the lumen (B), and protruding 20mm (C). 
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Figure 21. Residence times values (at end diastole) after 12 contractions for dilated and remodeled 
ventricles with inflow cannula at an angle to the mitral valve. The inflow is uniform across the mitral 
valve (MV) boundary and outflow passively flowing out of the VAD inflow cannula (IC). Dilated (1) and 
remodeled ventricles (2) with IC in the posterior diaphragmatic placement flush with the wall (A), 
protruding 10mm into the lumen (B), and protruding 20mm (C). 
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To quantify and compare the residence time for each of the geometries, the total area 
within the chamber with residence times exceeding a certain threshold at each time step was 
analyzed. This area-sum was normalized by the total area across the entire domain. These values, 
when plotted against time (in seconds), remained zero until the threshold was reached, then 
increased to a certain area value, where it remained asymptotic around a certain area. This 
asymptotic area value was obtained for each threshold and displayed in Figure 22. A threshold of 
3 to 7s was chosen to make sure that each data point contained at least 5 cardiac cycles worth of 
data.  
The anterior apical (straight) cannula placement (Figure 22A) showed a large difference 
between the dilated and remodeled geometries at a threshold of 3-5s. The average residence time 
values for both the dilated and remodeled ventricles did not change much between the flush and 
10mm depth, but significantly increased when the cannula depth changed from 10mm to 20mm. 
After the 5s threshold, the cannula in-line with the mitral valve at a depth of 20mm into the 
lumen has the greatest residence time values regardless of dilated or remodeled geometry. 
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Figure 22. Average normalized volume with residence times that exceeded thresholds ranging from 3-7 seconds. The horizontal axis shows the 
residence times (in seconds) and the vertical axis shows the normalized volume. 
  
79 
For the posterior diaphragmatic cannula placement (Figure 22B), the dilated geometries 
consistently showed greater areas with longest residence time values. Within the same lumen 
size, there was not a significant difference in residence time values when the depth of the 
cannula increased. The dilated ventricle with cannula flush with the wall had the greatest areas 
with increased residence times when compared to the other cannula depths in dilated ventricles. 
6.2.2 Ventricular washout 
When the inflow cannula was in-line with the mitral valve, as the ventricle contracted 
toward the center, the majority of the fluid moved in a straight line directly from the mitral valve 
to the cannula (Figure 23A). As the walls relaxed, the dye that remained circled around in the 
pockets along the upper and lower boundary walls (Figure 23A). When the inflow cannula was 
at an angle to the mitral valve, the dye entering the chamber that did not directly go out of the  
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Figure 23. Snapshots of dye washing through dilated (left) and remodeled (right) ventricles throughout one 
cardiac cycle. 
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cannula swirled around in a large pocket near the upper boundary and a smaller pocket near the 
lower boundary (Figure 23B). 
After each contraction there was less remnant dye until most had been cleared out after 
12 contractions (Figure 24-Figure 25). In the ventricles with inflow cannula in-line with the 
mitral valve, the dye cleared the remodeled chamber (Figure 24B) faster than the dilated 
ventricle  (Figure 24A). The dilated heart with inflow cannula at an angle to the mitral valve 
(Figure 25A) had the most residual dye remaining in the ventricle after 12 contraction. The 
remodeled geometry with cannula at an angle to the mitral valve (Figure 25B) also showed 
increased residual dye after each contraction when compared to the simulations with cannula in 
line with the mitral valve, but not as much as the dilated geometry. 
Figure 26 shows the extent to which the dye had washed out of each ventricle after 12 
contractions. The remodeled heart with the straight cannula was the only geometry where the 
dye had completely washed out within this time frame. The dilated heart with angled cannula 
had the greatest amount of residual dye in the ventricle within this time frame. 
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Figure 24. Snapshots of dye washing through dilated (left) and remodeled (right) ventricles with inflow 
cannula placed in the anterior apical placement. 
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Figure 25. Snapshots of dye washing through dilated (left) and remodeled (right) ventricles with inflow 
cannula placed in the posterior diaphragmatic placement. 
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Figure 26. Residual dye in the ventricle after 12 contractions. 
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6.2.3 Recirculation zones – vorticity 
Ventricles with a cannula implanted in the anterior apical placement had vorticity values 
mostly symmetric across the midline (Figure 27A). When the cannula was implanted in the 
remodeled ventricle at a depth of 20mm, the recirculation zone in the mitral valve pocket was 
pushed through the cannula with each contraction, whereas when the cannula was either flush 
with the wall or at a depth of 10mm, this pocket of recirculation did not leave the ventricle until 
after two contractions. When the cannula protrudes into the ventricle, a small recirculation zone 
appears at the cannula/apex interface. The dilated hearts had larger pockets of recirculation 
toward the periphery of the chamber. These pockets moved across the lumen slower than in the 
remodeled hearts, throughout the duration of three or four contractions. Deeper cannula insertion 
in the lumen created larger recirculation zones at the apex/cannula interface than appeared in the 
remodeled ventricles. 
The ventricles with cannula at an angle to the mitral valve had three main regions that 
developed recirculation zones: along the top wall near the mitral valve, along the apex near the 
cannula, and along the bottom wall between the mitral valve and the cannula (Figure 27B). 
When the ventricle was relaxing, a small recirculation zone was created next to the wall of the 
cannula (arrow); this zone was circulating in the opposite direction as the zones along the top 
wall created from the mitral valve inlet. In the dilated hearts, the zones of recirculation were 
larger and took three or four cycles to leave the chamber, whereas the remodeled hearts had 
smaller recirculation zones that moved through the cannula after two contractions. 
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Figure 27. The z-component of vorticity values for dilated ventricle with inflow cannula in line with the 
mitral valve inflow (A) and at an angle to the mitral valve (B). The black squares indicate areas of interest 
within the chamber: 1) Upper boundary near the mitral valve inlet; 2) Apex/cannula interface; arrow 
indicates the recirculation zone created as the ventricle relaxes; 3) Lower boundary between mitral valve 
and cannula. 
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6.3 Discussion 
Because VADs are mostly implanted in patients with dilated cardiomyopathy, the 
purpose of this study was to first determine an optimal VAD inflow cannula orientation and 
depth that will reduce areas of stagnation and recirculation inside dilated ventricles. Secondarily, 
as sustained mechanical support is likely to lead to myocardial remodeling, a second focus of 
this study was to highlight the change in flow patterns of ventricles after remodeling occurs. A 
complete review of the study results has revealed a possible clinical application and design 
recommendation that could reduce risk of thromboembolic complications in future VAD 
patients. 
6.3.1 Inflow cannula placement in DCM patients 
In a heart with dilated cardiomyopathy, the ventricular wall is thin, and the lumen has 
expanded in volume due to prolonged stretching of cardiomyocytes. These morphological 
changes arise over time after an initial insult to the myocardium renders it weak, preventing the 
ventricular contraction from generating the ejection fraction necessary for adequate downstream 
organ perfusion, leading to blood pooling in the heart. Over time, this buildup of blood causes 
the myocardium to dilate further and become weaker. The main goal of VAD implantation is to 
take the load off of the heart and to bring the heart back to the proper ejection fraction the body 
needs.  
In dilated hearts, when the inflow cannula is flush with the lumen and in-line with the 
mitral valve inflow, there are fewer places for the blood to pool in the ventricle. Out of all the 
geometries studied, this orientation (anterior apical placement) had the smallest regions of 
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stagnation throughout the chamber after 12 heart contractions. As the inflow cannula depth 
increases further into the lumen of the ventricle, the areas of “trapped” blood at the apex/cannula 
interface increases in size (see areas of orange-red in Figure 20B.1, Figure 20C.1). In contrast, 
when a dilated heart has a VAD implanted at an angle to the mitral valve (posterior 
diaphragmatic placement), a depth of 10mm into the lumen is more optimal than flush alignment 
with the ventricle wall. When there is some protrusion into the lumen (10mm), as the wall 
contracts it pushes blood against the cannula and provides a greater force to flush the blood out 
of the crevice between the apex and the cannula (Figure 21B.1). When the cannula is too deep 
into the lumen (20mm), it is easier for the fluid to get trapped into recirculation zones near the 
apex/cannula crevice (Figure 21C.1). When the cannula is flush with the wall and at an angle to 
the mitral valve (Figure 21A.1), the blood entering the ventricle is more likely to get trapped in 
the pocket along the upper boundary near the mitral valve because the contraction is not strong 
enough to push the blood toward the cannula inlet, which is now further away. In this 
configuration, the area of stagnation near the mitral valve is larger in size than the stagnant 
region created by inserting the inflow cannula into the ventricle at either depth.  
All of the dilated ventricles tested in this study had pockets next to the mitral valve and 
around the inflow cannula with higher levels of recirculation, vorticity, and greater residence 
times, furthering the hypothesis that dilated hearts are more susceptible to the formation of mural 
thrombi, as well as thrombus formation along the base of the inflow cannula. Over time, the 
thrombus will continue to organize and, if it dislodges, will increase the chances of causing 
greater mechanical failure. 
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6.3.2 Ventricular remodeling with VADs 
 
As myocardial offloading persists, the volume of blood inside the ventricle decreases, 
and the myocytes will remodel to their shorter length, effectively decreasing the lumen size. 
Throughout ventricular remodeling, it is possible that the inflow cannula will change its 
orientation; however, as mentioned previously, most patients do not experience a significant shift 
in inflow cannula orientation over time [109]. According to the results of the current study, if 
there is not a significant shift in inflow cannula orientation but the heart itself remodels to a 
smaller shape, the flow patterns will be different in the remodeled heart than those present 
immediately post-implant. 
As expected, for each geometry tested, the smaller, healthy-sized ventricles had 
improved washout compared to their dilated counterparts after fewer contractions. If a thrombus 
began organizing while the heart was in a dilated state, as the heart remodels, the increased 
washout combined with the greater force of contraction will increase the risk of dislodging the 
thrombus and sending it into the pump. 
 
6.3.3 Clinical application 
 
Myocardial remodeling in long-term VAD implants is not currently monitored or 
tracked for each patient while undergoing VAD therapy. VAD function is closely monitored 
during and immediately after implantation; throughout the duration of support, controllers 
accompanying the device monitor parameters such as flow rate, impeller RPM, and wattage, and 
will sound alarms if these parameters exceed an acceptable range. VAD position and orientation 
are investigated only if the controller indicates low flow or high power consumption, which may 
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mean a material is obstructing the inflow/outflow, or a thrombus may be inside the pump. Based 
on the results of this study, for long-term implants it could prove beneficial to periodically 
determine the degree to which the heart has remodeled and thus how much the change in lumen 
size and strength of contraction is likely to displace existing thrombi. Administering 
thrombolytics could be beneficial at certain times of the implant duration to decrease risk of 
thromboembolic related complications. 
 
6.3.4 VAD design 
 
The results of this study show that inserting the inflow cannula into the ventricle lumen 
creates areas for stagnation immediately surrounding the cannula. In the simplified motion 
modeled in this study, these regions are never fully washed out with each heartbeat, providing 
opportunity for thrombus formation. It may be possible that decreasing the cannula length can 
decrease the regions of stagnation in the chamber and increase the washout after each ventricular 
contraction. Further research is needed to determine if decreasing the length of the inflow 
cannula is a probable design change to proactively prevent inflow cannula thrombus formation.  
 
6.3.5 Study limitations and future applications 
 
This study only incorporated a 2D representation of a left ventricle with mitral valve 
inlet and a VAD cannula, where the flow out of the cannula was passive and did not have the 
suction effect as it would in vivo. This model did not include the aortic valve outflow. Although 
flow through the aortic valve is limited during VAD support [118], aortic valve output should to 
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be added in a 3D model. Additionally, the movement of the ventricle was simplified and did not 
represent the physiologic wringing motion of the heart. The flow into the mitral valve opening 
was constant across the length of the wall, and not pulsatile as it is in vivo. The inflow cannula 
remained stationary throughout the simulation, whereas in reality there should be minor 
movements with each heartbeat. Finally, the clotting factors and platelet activity were not 
factored into the simulation; however, this may not be an issue because patients are typically put 
on anticoagulants to decrease the function of these clotting components. Although this study has 
physiologic limitations, this model can be used to draw comparisons between the inflow cannula 
orientations and depths in dilated and remodeled sizes as the same limitations are applied to all 
models. This model will serve as a preliminary study to build upon in order to expand its clinical 
accuracy and significance. This model can be expanded to incorporate more complex geometries 
and motions of a 3D representation. Ideally, this computational model can be personalized for 
each patient to determine which orientation of the inflow cannula is best for his or her specific 
heart geometry. This personalized treatment option could incorporate a 3D model derived from 
patient CT data. 
 
6.4 Conclusion 
 
As VADs transition from a temporary to long-term treatment option for heart failure, 
new questions are arising surrounding how cardiac remodeling affects VAD function. The study 
described in this section serves as a preliminary platform for investigating the risk of thrombus 
formation inside a dilated left ventricle after VAD implantation, and possible thrombus 
dislodgement after the myocardium undergoes remodeling. The study showed that there might 
be an optimal cannula depth that minimizes the risk of thromboembolism. This study involving a 
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simplified geometry and simplified motion revealed that placing the VAD inflow cannula in-line 
with the mitral valve inlet (anterior apical placement) and flush with the ventricle wall will result 
in the shortest residence times and greatest washout of dilated ventricles. Placing the cannula at 
an angle to the mitral valve (posterior diaphragmatic placement) results in greater areas of 
stagnation; however, if patient anatomy prevents flexibility in choosing VAD cannula insertion 
site and only allows for posterior diaphragmatic placement, a cannula depth between flush and 
20mm may be optimal for providing the best washout and shortest residence times within the 
ventricle.  
The remodeled ventricles in this study showed improved washout and smaller 
recirculation zones compared to their dilated versions. The increased washout may change the 
possibility of thrombi that formed and developed when the heart was in its dilated state to 
dislodge and travel into the pump. In clinical management of patients with VADs, the orientation 
of the inflow cannula and ventricular lumen size are only monitored if a period of low flow or 
high power consumption is noted on the VAD controller; the results of this study suggest that 
monitoring myocardial remodeling periodically as the patient receives mechanical support could 
improve the value of VAD therapy by decreasing the risk of thromboembolic complications. 
Additional investigation as to how the length of the cannula can affect thrombus formation inside 
the ventricle may also prove beneficial to VAD therapy. Overall, these considerations in VAD 
development and clinical application may decrease the amount of clinical adverse events related 
to thrombus formation and embolization. 
While these considerations may reduce thromboembolic events, thromboembolism is 
still possible any time a VAD is implanted, and VADs should be tested during bench-top design 
concept testing for toleration of embolic particles.  Current in vitro testing of VADs includes 
durability and hemocompatibility testing; these tests answer questions such as: how long will the 
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device last under normal working conditions? Will this device lyse red blood cells? Does this 
device produce sufficient flow rates to keep up with required cardiac output? These tests are 
crucial and should not missed in the development process. However, in vitro testing could be 
taken a step further to answer questions about VAD thrombosis. How does the VAD controller 
log respond to pass-through thrombi? How does the size of the thrombus change the VAD 
response? The remaining sections introduce a method for creating artificial thrombi and a 
controlled environment for testing VAD thrombosis. We believe this research, together with the 
computational model in this section, will translate to clinical VADs used worldwide and will 
overall add to the therapeutic value of receiving a VAD for heart failure treatment. 
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7. CREATING ARTIFICIAL THROMBI*
Clot and thrombus formation have been studied in vitro with both continuous and 
pulsatile flow conditions [51, 52, 119]. These studies characterize the thrombus formation 
morphology in specific locations and geometries based on length, speed, and type of flow and 
material surface. Taylor et al. demonstrated areas of high wall shear stresses leads to larger 
thrombus formation, and multiple studies have shown areas of low flow are more likely to cause 
platelet activation leading to formation of loosely adhered thrombi [52, 86, 87, 120]. Loosely 
adhered thrombi in vivo have a greater potential to dislodge and introduce thromboembolism. 
Introducing a textured surface in the blood has been shown to reduce platelet adhesion and thus 
reduce thrombus formation, however thrombus formation is not completely diminished [52, 87]. 
VADs are typically tested prior to pre-clinical trials with in vitro circulatory loops [46, 
47]; however, these are designed to specifically test the hemodynamic conditions of the device. 
Precise VAD response to thromboembolism needs to be studied in a controlled in vitro setting 
where specific pump parameters (i.e., power consumption, flow rates, impeller RPM) can be 
monitored while various types of thrombi are introduced. This section describes a novel method 
for creating standardized fibrin thrombi that could be introduced into a mock circulatory loop for 
testing VAD response to pass-through thromboembolism. Complete results from experiments 
pertaining to this section are detailed in Appendix III. 
*This section’s text and figures are reprinted with permission from “A method for creating 
artificial thrombi in vitro using a rotating mechanical surface” by Jessen SL, et. al., 2016. ASAIO 
J, Publish-ahead-of-print (DOI: 10.1097/MAT.0000000000000332) by Wolters Kluwer Health 
Lippincott Williams & Wilkins©. 
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7.1 Materials and methods 
 
Normal equine blood was originally collected for transfusion in commercial 450mL 
blood storage bags containing sodium citrate and stored at 5°C. Blood stored beyond its usable 
date for transfusions was made available to this experiment. The blood in all experiments 
mentioned in this paper was collected from the same donor approximately three months prior to 
use. 
Approximately half of the citrated whole blood was collected into 5mL aliquots. The 
remaining blood was transferred from the blood bag to a plastic container with a screw-top lid 
and stored at 5°C. Due to the high sedimentation rate of equine blood [121, 122], the cells 
collected at the bottom of the container and the cell-free plasma top layer was collected using 
pipettes and stored in 5mL aliquots. For superior red blood cell sedimentation, it is best to let the 
blood sit undisturbed for approximately 24 hours before removing the plasma layer [123]. To 
preserve the blood components and ensure success of creating consistent thrombi, 5mL volumes 
of whole blood and plasma were put into separate vials and stored in a 5°C refrigerator and -
20°C freezer, respectively. Approximately 24 hours before plasma clot creation, the plasma was 
transferred to the 5°C refrigerator and allowed to thaw. 
 
7.1.1 Titration of CaCl2 
 
To initiate clotting by counteracting the sodium citrate effect, calcium chloride (CaCl2) 
was added to the blood. Approximately 5mL each of either equine whole blood or plasma were 
collected into separate test tubes. Granular, dihydrate CaCl2 (Macron Fine ChemicalsTM) was 
dissolved in distilled water at a concentration of 12mg/mL [124]. Approximately 50µL of the 
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CaCl2 solution was added to each test tube, once per minute starting at time t = 0. After each 
drop was added, the test tube was tilted to test the coagulation of the blood and plasma. Once the 
test tube could be tilted at a 45° angle without disruption of the liquid, the titration was complete 
and the time and total volume of CaCl2 added were recorded and used for the following 
experiments. 
 
7.1.2 Adding the rotational component 
 
To mimic the forces and conditions inside a VAD in vivo, small plastic petri dishes 
(Corning, Inc., 38mm diameter) were affixed to the shafts of electric and gear motors (four total) 
with 3MTM Dual Lock Reclosable Fastener. This apparatus was arranged so the petri dish rotated 
inside a larger stationary petri dish (Corning, Inc., 50mm diameter) with an adjustable gap 
between the dishes (Figure 28). Each motor was powered by a variable power supply ranging 
from 0–12V and produced speeds ranging from 75–300 RPM. 
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Figure 28. Diagram (A) and photograph (B) of the device used to create thrombi. 
7.1.3 Creation of thrombi 
Multiple clots were created with the setup shown in Figure 28 testing the following 
parameters: 1) CaCl2 concentration, 2) gap size between rotating disk and stationary reservoir, 3) 
RPM, and 4) duration of rotation. For all experiments, both the rotating and stationary petri 
dishes were lined with disposable aluminum foil. After each experiment, clots remained 
stationary for approximately 18 hours to maximize clot condensation. Clots were then carefully 
removed from the aluminum foil and placed in formalin for at least 24 hours. Formalin-fixed 
clots were then sectioned to fit in a 2.5x2.5cm cassette and processed for traditional paraffin 
histology and scanning electron microscopy (SEM) to characterize the microstructure [125]. 
Histology sections were stained with Hematoxylin and Eosin (H&E). Clots examined by SEM 
were dehydrated in progressively increasing concentrations of alcohol (following 24 hour 
formalin fixation), coated with gold using a Ted Pella 108 Manual Sputter Coater, and finally 
imaged using a Tabletop Hitachi TM3000 Scanning Electron Microscope. 
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7.1.3.1 Adjusting the concentration of CaCl2 
 
In order to determine the optimal volume and concentration of CaCl2 necessary for 
clotting of citrated whole blood and plasma, thrombi were created using two concentrations of 
CaCl2: 12 and 24mg CaCl2/mL distilled water. This will also reveal if different concentrations of 
CaCl2 introduce artifactual histologic differences in the morphology of the clots. Approximately 
5mL of whole blood and plasma were collected in stationary test tubes; 0.15mL of CaCl2 was 
added every 3 minutes until clotting was observed. The clotting blood and plasma remained 
stationary for approximately 18 hours to maximize clot condensation before collection and 
formalin fixation. 
 
7.1.3.2 Adjusting the gap height 
 
The distance between the rotating disk and stationary reservoir was set at approximately 
6mm (+/- 1mm) and 4mm (+/- 0.2mm). The distance was set by raising the rotating component 
and measured with calipers. The motors ran for approximately 6 hours then the resulting thrombi 
were collected and fixed in formalin.  
 
7.1.3.3 Adjusting the speed and duration of rotation 
 
In this set of experiments, the motor speed and total time rotating were varied. For this 
set, all four motors were attached to power sources with similar distances between the rotating 
disk and stationary reservoir (4mm +/- 0.2mm). Motors were set to 75, 225, 240 and 300 RPM 
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and ran for approximately 6-48 hours. After the allotted time period, the clots were left 
undisturbed for approximately 4-6 hours before collection and formalin fixation. 
 
7.1.3.4 Clot image analysis 
 
H&E stained sections of clot were photographed using a microscope camera and images 
were read by a program in MATLAB (MathWorks, Inc., Natick, MA) to analyze the clot density 
by determining the percentage of the pixels in the picture that contained clot. Each image 
analyzed contained a consistent square area of clot. Additionally, area and length measurements 
were collected using open-source imaging software (ImageJ, National Institute of Health). 
 
7.2 Results 
 
7.2.1 CaCl2 concentration 
 
The volumes and concentrations of CaCl2 needed to initiate clotting in whole blood and 
plasma are represented in Table 4. 
 
 
 
Table 4. Volumes and concentrations of CaCl2 necessary for clotting 
 12 mg CaCl2/mL 24 mg CaCl2/mL 
5 mL whole blood 1.2mL 0.6mL 
5 mL plasma 2.2mL 1.1mL 
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Using a relatively dilute CaCl2 solution required the addition of a greater volume of 
solution to the blood and plasma to facilitate clotting. The liquid completely clotted in the test 
tube after addition of CaCl2. Grossly, the clots were cylindrically shaped gelatinous, either 
yellow (plasma) or dark red (whole blood) material. Figure 29 shows the H&E stained sections 
of each clot (whole blood and plasma) at different concentrations of CaCl2. Figure 29A and 
Figure 29B (whole blood) show a dominance of red blood cells, while Figure 29C and Figure 
29D (plasma) show primarily a uniform network of fibrin. Histologically, there are no apparent 
differences between the clots created from different CaCl2 concentrations. Computational image 
analysis in MATLAB also reveals no significant differences between the two clotting methods; 
images of randomly select areas of each clot had a density (measured as the percentage of 
colored pixels) that only varied by less than 3.10% for both plasma and whole blood clots. Thus, 
a higher concentration of CaCl2 was used for the remaining experiments because the smaller 
stationary reservoirs limited the amount of liquid that could be added. 
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Figure 29. H&E stained histological samples of thrombi created from whole blood and plasma at different 
concentrations of calcium chloride. Whole blood titrated with 12mg CaCl2/mL distilled water (A) and 
24mg CaCl2/mL distilled water (B); Plasma titrated with 12mg CaCl2/mL distilled water (C) and 24mg 
CaCl2/mL distilled water (D). Scale bar in each image is 100um. 
 
 
 
7.2.2 Gap height 
 
When using whole blood in the setup shown in Figure 28, the blood tended to clot in 
separate sections loose within the stationary reservoir. The largest clot section created in each 
trial ranged in size from 6-7mm x 10-14mm regardless of height of the rotating component. 
Figure 30 shows the resulting histology of whole blood clots created with varied distances 
between the rotating and stationary components. Figure 30A (6mm gap) and Figure 30B (4mm 
gap) show two distinct areas, one consisting of abundant erythrocytes, and the other of fibrin 
enmeshed erythrocytes and leukocytes. These clots, formed at low shear stresses (75 RPM), are 
relatively isotropic, and there are no apparent differences between the two gap widths. Figure 
30C (6mm gap) shows a more uniform section of a fibrin mesh with embedded erythrocytes, 
while Figure 30D (4mm gap) shows fibrin strands arranged into compact layers of common 
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directionality with scattered erythrocytes. These clots, formed at higher shear stresses (225 
RPM), indicates a smaller clearance between the rotating surfaces will create greater 
morphological changes that more closely resemble ante-explant thrombi found in clinically used 
VADs. 
Figure 30. H&E stained histological samples of thrombi created from whole blood with different gap 
heights between the rotation and stationary dish. Thrombus created from whole blood at 75 RPM with a 
6mm gap (A) and a 4mm gap (B) between the rotating disk and stationary reservoir; Thrombus created 
from whole blood at 225 RPM with a 6mm gap (C) and 4mm gap (D) between the rotating disk and 
stationary reservoir. Scale bar in each image is 100um. 
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7.2.3 Speed and duration of rotation 
When using plasma in the setup shown in Figure 28, the blood tended to clot as two 
pieces: one circular gelatinous yellow clot loose within the stationary reservoir and one or more 
sections adhered to the rim of the stationary reservoir. In rare cases the clot adhered to the 
rotating component. As the speed of the rotating component increased, the size of the clot 
created decreased from approximately 40mm to 20mm in largest dimension. As the time of 
rotation increased, the gross appearance of the clot changed from a gelatinous, glistening 
material of larger size to a dry, brittle, dull material smaller in size.  
Figure 31 shows H&E stained histology sections of plasma clots created with varied 
speeds of the rotating component and increasing lengths of duration. As the motors’ run-time 
and speed increased, the resulting thrombi became more layered and compact. When the motor 
ran less than 10 hours, the shear forces from the motor at low RPMs did not have a great effect 
on the thrombi, which resulted in layers spread further apart (maximum width of 33 microns) 
(Figure 31A, D, G). However, as the device rotated for extended periods of time, the layers of 
the thrombi were compacted. This resulted in a tight, more uniform and acellular appearance as 
seen in the 24 hour (Figure 31B, E, H) and 48 hour runs (Figure 31C, F, I). By increasing the 
time of rotation from 24 to 48 hours at 225 RPM, the clot density increased by 3.45% (measured 
by percentage of colored pixels). The gaps between the layers of fibrin strands decreased from an 
average length of 11 microns (Figure 31B) to 5-8 microns (Figure 31H, C) until they were 
essentially nonexistent (Figure 31F, I). 
Figure 32 shows SEM images of plasma clots created from slow speeds with short 
duration (Figure 32A, B) and faster speeds with longer duration (Figure 32C, D). In thrombi 
created at lower speeds and in shorter lengths of time (Figure 32A, B), fibrin strands begin to 
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align into layers. As the motor speed and length of time increased (Figure 32C, D), these layers 
became more compact. 
Figure 31. H&E stained histological samples of thrombi created from plasma with varying motor speeds 
and lengths of time. 75 RPM at 6 hours (A); 75 RPM at 24 hours (B); 75 RPM at 48 hours (C); 225 RPM 
at 6 hours (D); 225 RPM at 24 hours (E); 225 RPM at 48 hours (F); 300 RPM at 6 hours (G); 300 RPM at 
24 hours (H); 300 RPM at 48 hours (I). Scale bar in each image is 100um. 
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Figure 32. SEM images of thrombi created from plasma with varying motor speeds and lengths of time. 75 
RPM at 6 hours (A,B); 300 RPM at 48 hours (C,D). Scale bar in image (A) and (C) is 30um. Scale bar in 
image (B) and (D) is 10um. 
7.3 Discussion 
7.3.1 In vivo thrombi versus in vitro clots 
The implantation of a VAD inherently poses a risk for thrombus formation. Because 
thrombi can damage the pump and/or cause infarction, when a VAD controller log indicates a 
suspected thrombus [24, 28, 38], the physician must pursue either anti-coagulation therapy or 
VAD exchange surgery.  
Thrombi may form inside the VAD due to a combination of shear forces from the 
moving components, areas of stasis within the device, or the blood-device interaction. 
Additionally, thrombi may form outside the VAD, such as around the sewing ring, along the 
ventricular wall, in the atrial appendage, etc. In some cases, thrombi developed outside the 
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device may travel into the VAD and become a nidus for further thrombus formation inside the 
VAD. Regardless of origin, if a thrombus adheres to some part of the VAD, it will cause an 
increase in friction, which leads to the increase in power consumption denoted on the controller 
log. A histological analysis of the material within the device can distinguish post-explant from 
ante- and peri-explant materials and, based on the morphology, determine the potential origin of 
the material [22]. Typically in post-explant VAD evaluations, the thrombi discovered are clots 
that either originated upstream from and traveled through the device, or formed inside the device 
(or some combination of the two). The creation of artificial thrombi with similar features and 
morphologies of in vivo thrombi as discussed in this section will help elucidate the interaction of 
VADs and “pass-through” thromboemboli, which will potentially help VAD manufacturers and 
physicians create and implement devices that can reduce the risks associated with VAD therapy.  
Many histological similarities are observed when comparing the clots produced using 
the technique discussed in this paper to the thrombi seen in vivo. The two most influential factors 
for recreating thrombi with abundant layers were time and speed of rotation. No rotation applied 
to the blood while it was clotting resulted in a post-explant blood clot (Figure 33A-B). The 
greatest difference between these two clots is the amount of erythrocytes per 243mm2 area, 
which differs by less than 10%; this variation is expected because of the innate differences 
between equine and human blood. A small duration of rotation resulted in a clot that resembled 
the peri-explant fibrin thrombus with similar fibrinous layers (Figure 33C-D) that varied in 
density by less than 7%. A faster rotational speed resulted in a clot with dense layers, which 
resembled the organized thrombus seen in vivo (Figure 33E-F). These specimens are 
histologically similar; the only noticeable difference is that the eosinophilic material in the in 
vitro clot (Figure 33E) stained more vividly than the in vivo thrombus (Figure 33F). 
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Figure 33. H&E stained histological comparison of specimens collected from explanted VADs to artificial 
clots created in vitro. Post explant clot in vitro (A) and in vivo (B). Peri-explant fibrin thrombus in vitro 
(C) and in vivo (D). Organized thrombus in vitro (E) and in vivo (F). Scale bar in each image is 100um. 
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7.3.2 Plasma versus whole blood 
In this section, we described a method to create both plasma and whole blood derived 
clots. Although it would be ideal to use whole blood exclusively, plasma has benefits that might 
make in vitro experiments more attainable. Plasma, as opposed to whole blood, created clots that 
showed greater histological uniformity and were more consistently reproducible. Plasma also 
allowed for better visualization of the fibrin strands in comparison to whole blood (i.e., lacked 
enmeshed erythrocytes). Additionally, due to plasma’s ability to be frozen without losing its 
utility, it is much easier to preserve long-term, which readily allows for future experiments 
without acquiring and titrating new blood samples. However, for in vitro experiments that study 
biochemical reactions between the device and the blood, whole blood clots would be necessary 
to ascertain the reaction of blood components (i.e., platelets, leukocytes, and erythrocytes). 
Platelets play an important role in coagulation, particularly inside a VAD. The shear 
stress from device-induced flow activates platelets, which leads to aggregation of platelets, and 
eventually a thrombus. The plasma used in these experiments contained little to no platelets, 
meaning the coagulation came from the plasma proteins. The lack of platelets caused the clot 
that formed to be mostly gelatinous in a flat circular shape mostly formed between the two 
plates. However in the whole blood samples, the platelets were activated and the resulting clot 
was irregular in shape and formed in clumps rather than flat disks.  
7.3.3 This method versus others 
The Chandler Loop is a historic method for creating thrombi in vitro [119]. This method 
uses an inclined rotating closed loop that circulates blood until it coagulates, thus producing a 
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thrombus. These thrombi are grossly and histologically comparable to vascular thrombi [119], 
whereas the method described in this paper focuses on creating clots similar to what would be 
seen within a medical device that has a rotating component. The rotating mechanism within the 
device applies different forces to the blood components not seen in the body naturally.  
Other previous studies that created clots in vitro studied the adhesion characteristics of 
certain materials used in medical devices [52], the potential for thrombi to form on these 
surfaces, how the shear rates applied by the rotating component affected the thrombus formation 
[52, 87], and how certain geometries created a potential for thrombus formation [86]. In the 
method described in this paper, the end goal is to have an artificial clot that can be introduced 
into a mock circulatory loop for the purposes of studying thromboembolism in medical devices, 
specifically VADs. 
 
7.3.4 Study limitations 
 
Only equine blood was made available for this experiment, while bovine, porcine, and 
ovine blood is typically used for VAD development.  Equine blood has a higher sedimentation 
rate23-24 compared to that of humans, however a high sedimentation rate in humans can be 
indicative of an inflammatory reaction in the body, which might be possible in VAD patients. 
Porcine blood is most similar to human blood in adhesive forces [126] while bovine, ovine and 
porcine specimens are most often used for VAD testing due to of size and other physiologic 
similarities. Although equine blood has differences to human blood, the authors believe same 
experiments using blood from different species would yield similar results, with potential 
differences in the titration curve.  
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The parallel plates used in these experiments had a limited clearance of 4-6mm (+/- 
1mm), whereas distances between the impeller and adjacent VAD housing can be much smaller 
(<1mm). Additionally, the parallel plate setup described in this manuscript most closely 
resembles a centrifugal-flow device (as opposed to an axial-flow VAD orientation). The goal of 
this experiment was to add a rotational force to the blood while it was clotting to show the 
morphological changes compared to a clot formed under static conditions. Future testing could 
be performed with real VAD-like conditions (closer gap sizes, and multiple orientations of the 
rotating component) to further describe thrombus formation in an environment with rotational 
forces. 
7.3.5 Future applications 
Future applications of this method include testing “pass-through” thromboembolism in 
VADs. Such a study would include a mock circulatory system incorporating a VAD, pressure 
transducers and a flow meter. Previously citrated blood specimens would be titrated with CaCl2 
as described here, and then clots created in a static environment would then be introduced to the 
system proximal to the VAD. The resulting clots would then be compared histologically to the 
clots created with a rotating component as described in this paper, as well as those seen in vivo. 
This test would determine the pressure changes and changes in flow rate as a clot travels into the 
VAD and potentially correlate the size/age of the clot to magnitude of the power-spike seen on a 
VAD controller log. This flow loop would require a clear liquid, such as water or a 
water/glycerin mixture, in order to be able to visualize the clot as it travels into the device. See 
Section 8 for more information about a bench-top model for testing VAD response to 
thromboembolism. 
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Furthermore, future studies could also be performed to learn more about thrombus 
formation inside of VADs as well. In this case the flow loop would need to be filled with 
previously citrated whole blood (or an appropriate blood analog), and varying amounts of CaCl2 
could be added to the system (as blood is flowing) to allow blood to clot as it would in vivo 
according to shear forces inside the VAD and geometrical constraints. Furthermore, in vivo 
studies could be performed where real-time VAD parameters are monitored while inducing 
instances of thromboembolism by inserting previously formed clots into the ventricle. 
7.4 Conclusions 
Based on the numerous variables tested, we were able to optimize a method to create 
artificial thrombi similar to those seen in blood-contacting devices with rotating surfaces. In all 
experiments, the rotating disk and the stationary reservoir were similar in size, with the rotating 
disk slightly smaller. We believe this caused the thrombi to form almost completely under the 
rotating disk where they experienced the most shear force and allowed minimal stagnation. A 
smaller distance between the rotating dish and stationary reservoir (approximately 4mm) allowed 
formation of a clot large enough to withstand processing and handling with histologic evidence 
of lamination. Due to sample size constraints, 24mg CaCl2/mL distilled water was used because 
less volume could be added to achieve the same amount of clotting for whole blood and plasma.  
This standardized method for creating in vitro whole blood and plasma clots will be used 
for additional studies involving physiologic flow loops to further elucidate the interaction of 
VADs with fibrin thromboemboli (further explained in Section 8). These experiments will 
establish a basis for better understanding of blood flow, thrombus formation and embolization 
within VADs, which will help future VAD designs in limiting thromboembolic complications. 
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8. MODELING VAD RESPONSE TO THROMBOEMBOLISM
Understanding and limiting thromboembolic events is critical to expanding the clinical 
indication for existing devices to other patient populations, as well as introducing new life-
saving devices to the market. Current in vitro testing of VADs includes testing longevity of the 
device (i.e., how long the device lasts without mechanical failure) and testing VADs under 
hemodynamic conditions to reveal whether the device damages blood cells, produces sufficient 
flow rates, etc. [46, 47, 49-56, 127]. In vitro testing could be expanded to reveal the specific 
VAD response to “pass-through” thromboembolism, resulting when thrombi formed outside the 
VAD are transported into the device. If physiologic flow loops used for testing VADs 
incorporated a port for introducing thrombi upstream from the device, VAD researchers could 
ascertain specific patterns for individual VAD models, such as correlations between clot size or 
structure and flow pattern response to “pass-through” thromboembolism. This type of flow loop 
could improve the diagnostic capabilities of thrombosis by retroactively comparing VAD 
controller response in the in vitro model to recorded clinical events. Overall, such a model would 
add to the therapeutic value of receiving a VAD by providing valuable insight to VAD 
manufacturers about how specific VAD models respond to thromboembolic events. Complete 
results from experiments pertaining to this section are detailed in Appendix IV. 
8.1 Materials and methods 
In an effort to model VAD response to “pass-through” thromboembolism, a mock 
circulation environment was created that included mock-VADs with a proximal port for inserting 
artificial thrombi. Two mock intracorporeal, intraventricular VADs were created to simulate 
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centrifugal and axial flow pumps. Fibrin clots of various ages ranging from 14 to 70 days were 
introduced into each device to determine how structural changes brought about with age (i.e., 
stiffness) elicited different responses inside the VAD. The VAD response was characterized by 
monitoring flow rate and pressure drop across the pump before and after the clot entered the 
VAD. Clots were then collected from the device or flow loop for histological comparison to 
thrombi collected from explanted clinical VADs. 
8.1.1 Artificial thrombi 
Artificial thrombi were created using the method outlined in Section 7. Briefly, equine 
and bovine blood collected with sodium citrate for transfusion was stored beyond its clinically 
usable date and made available for this experiment. Plasma was collected after erythrocytes were 
precipitated by standing in refrigerator or by gentle centrifugation. Bovine and equine blood 
have similar clotting factors in the plasma, and the artificial clots created from both had similar 
gross and histologic appearances. To counteract the calcium-chelating effect of citrate, calcium 
chloride was added to each specimen to activate clotting. Resulting clots were stored at 5°C for 
different lengths of time to produce clots of varied stiffness. Clots were created using 5mL 
aliquots of plasma in individual glass test tubes. Next, clots were divided into multiple pieces for 
introduction into the test system. One section from each clot was not introduced into the flow 
loop but retained for analysis as a control. 
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8.1.2 Flow loop setup 
The flow loop was designed to replicate the physiologic environment of an implanted 
left ventricular assist device (Figure 34). Reservoirs were created to simulate systemic resistance 
and venous return, and were connected with ½" plastic tubing. To maintain bovine and equine 
physiologic temperature (38-43°C), the reservoirs were placed in heated water baths. The 
systemic reservoir was placed on a shelf approximately 60cm above the venous return reservoir, 
and the mock-VAD was placed approximately 30cm below the venous return reservoir. The 
heights of the reservoirs added pressure differences in the system; the mock-VAD pumping 
against gravity to the elevated reservoir simulated systemic resistance. Fluid from the lower 
reservoir passively flowed into the mock-VAD to simulate flow into the heart from venous 
return. Because VADs are implanted in functioning ventricles, a peristaltic pump (Masterflex 
I/P, Cole-Parmer, Vernon Hills, IL) was placed in parallel with the mock-VAD to simulate a 
beating ventricle. A one-way valve was placed immediately distal to the mock-VAD to prevent 
retrograde flow into the VAD from the peristaltic pump, and a port for inserting clots was placed 
immediately proximal to the mock-VAD inflow. Pressure transducers (Model A-10, WIKA 
Instrument, LP, Lawrenceville, GA) were placed at the inflow and outflow of the mock-
VAD/peristaltic pump system to determine the pressure drop across the ventricle, and an 
electromagnetic flow meter (IFM SM6000, IFM Efector, Inc., Malvern, PA) measured 
ventricular output. 
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Figure 34. Diagram (left) and rationale (right) of mock-circulatory system. Systemic resistance and venous return were modeled with reservoirs placed 
at different heights. A peristaltic pump was placed in parallel with a mock-VAD to simulate a beating left ventricle with implanted device. Pressure 
across the pumps was measured, and flow was measured distal to the mock-VAD. A port proximal to the mock-VAD inflow allowed for clot insertion 
into the system. 
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8.1.3 Mock VADs 
The centrifugal and axial flow mock-VADs were designed for testing the system’s 
ability to characterize VAD response to “pass-through” thromboembolism (Figure 35). These 
generic, non-specific pump designs replicate the centrifugal and axial flow configurations of 
intracorporeal devices on the market. The casing for the axial pump and lid of the centrifugal 
pump were machined from a 2.5" diameter polycarbonate rod, and the lower housing for the 
centrifugal pump was machined from an acrylic block. These materials were chosen for the 
pump casing for their workability and transparency. The centrifugal flow impeller was machined 
from aluminum, and the axial flow impeller and stator were printed in Acrylonitrile Butadiene 
Styrene (ABS) plastic with a Flashforge Creator 3D Printer (Zhejiang Flashforge 3D 
Technology, Co. Ltd., Jinhua, China). The axial flow impeller design had a low-carbon steel 
sphere (1/8" diameter) glued to the tip to create a ball-bearing interface with the 3D-printed 
stator (Figure 35E). The shaft connected to the impeller of both designs was affixed to a 12V DC 
motor capable of rotating at 2900 RPM. Table 5 lists the specifications for each mock-VAD 
design, including maximum diameter of impeller, inner diameter of pump casing, and clearance 
between impeller and pump housing. 
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Figure 35. Mock-VADs designed in SOLIDWORKS. The impeller in each design was connected to an 
external motor through a rotating seal. A) Centrifugal flow pump design diagram. B) Front view of 
centrifugal flow device. C) Top view of centrifugal flow device with inflow removed. D) Axial flow 
design. E) Impeller/stator interface of axial flow device with outer casing removed. F) Lateral view of 
axial flow device with stator removed (inflow view). G) Top view of axial flow device with inflow on left. 
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Table 5. Specifications for mock-VAD designs 
 Centrifugal Flow Design Axial Flow Design 
Maximum diameter of impeller 33.92mm 32.68mm 
Inner diameter of pump housing 44.33mm 34.82mm 
Clearance between impeller and pump 
housing 5.21mm 1.07mm 
Pitch / revolutions of impeller vanes N/A 1.717 / 1.115 
 
 
 
8.1.4 Data acquisition 
 
VAD response to thromboembolism was characterized by monitoring the flow and 
pressure across the VAD/ventricle system. The pressure transducers and flow meter were 
connected to a data acquisition system (NI ELVIS II, National Instruments Corp., Austin, TX). 
Voltage measurements from the pressure transducers and flow meter were collected and 
exported in spreadsheet form using a custom LabVIEW (National Instruments Corp., Austin, 
TX) program. 
Fibrin clots were introduced into the mock-VAD while the peristaltic pump produced 
pulsatile flow. Pulsatile flow rate was set at a different value for each clot. Higher flow rates 
(1.5-2 LPM) simulated a normal heart; lower flow rates (1.0-1.5 LPM) were used to simulate 
heart failure conditions. The flow rates were scaled down from physiologic values (6 LPM for a 
healthy heart) because the mock-VAD motor allowed for ~2000 RPM (<0.5 LPM), whereas 
clinical VADs operate around 3000-12000 RPM [128, 129] (~6 LPM). During each experiment, 
the loop was filled with approximately 3.2L of either water or a glycerin/water mixture (40/60 
mix) to simulate blood viscosity [130]. Experiments were run at room temperature (21°C), and 
elevated (43°C) and normal (38°C) values for bovine/equine specimens. 
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Baseline flow rate and pressure data were collected separately for each experiment 
before introducing each clot to the system. The peristaltic pump first ran alone and then in 
parallel with the mock-VAD. A stopwatch was started when pressure and flow rate data 
collection began; the clot was introduced to the system via the proximal port, and the time at 
which the clot first entered the VAD was recorded in order to divide data into pre-clot and post-
clot segments. Each clot was observed in the pump for times ranging from 30s to 2min, after 
which the pumps were disconnected from power and clot fragments were collected from within 
the system. 
8.1.5 Data analysis 
Clots were analyzed histologically for microscopic comparison to thrombi collected 
during pathology evaluation of post-explanted clinical VADs [22]. Clots were processed for 
conventional paraffin-embedded histology, stained with Hematoxylin and Eosin (H&E), and 
scanned with an Olympus VS120 Virtual Microscopy Slide Scanning System (Olympus, Corp., 
Center Valley, PA). Pressure and flow rate data were processed in Microsoft Excel and 
MATLAB (MathWorks, Inc., Natick, MA). High frequency noise was removed from pressure 
and flow data using a digital low-pass filter. The pressure drop across the pump was calculated, 
and the mean of the baseline (i.e., flow and pressure data from the peristaltic pump and VAD 
before a clot was inserted) was subtracted from each data set to display variance from the 
normal. 
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8.2 Results 
 
8.2.1 Centrifugal flow mock-VAD 
 
Fibrin clots stored for approximately 30 days were a transparent, white to yellow, 
gelatinous substance less than 2.5cm in diameter with a slightly firm outer layer (Figure 36A). 
Before being subjected to the mock-VAD, sections of clot (approximately 3mm thick) were 
circular and retained their structural integrity during dissection (Figure 36B). During separate 
experiments that simulated normal heart function and heart failure (i.e., higher vs. lower flow 
rates), clots divided into multiple irregularly shaped pieces when interacting with the centrifugal 
flow impeller. The more gelatinous clot sections went into flow loop circulation (Figure 36C), 
while the firmer pieces remained within the device housing loosely adhered to the impeller or the 
housing wall (Figure 36D-G). 
Fibrin clots stored for >30 days (Figure 36H-I) had a gross appearance and interaction 
with the device similar to those of the clots stored for 30 days for both normal and heart failure 
conditions. The gelatinous material broke into fragments that were collected via filtration for 
histological evaluation (Figure 36J). Larger pieces remained in the device housing or the one-
way valve distal to the mock-VAD after the loop was drained (Figure 36K). 
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Figure 36. Plasma clots pre- and post- mock-VAD ingestion. A-G) Plasma clots <30 days old. A,B) Clots created in test tubes. C) Gelatinous sections of 
clots filtered out of flow loop after clot was subjected to rotational forces inside VAD. D-G) Fibrinous parts of clots loosely adhered to the impeller 
(D,E) and device casing (F,G) after the clot was subjected to the VAD. H-K) Older plasma clots (>30 days old). H,I) Clots created in test tubes. J) 
Smaller pieces of clot after contact with the impeller. K) Larger pieces in device casing after VAD was turned off. 
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The fibrin clots altered the flow rate as shown in Figure 37 (experiments simulating 
normal heart function). At room temperature, smaller gelatinous pieces of clot that entered the 
flow loop circulation after breaking off of the initial clot caused negative spikes in flow rate as 
they traveled through the flow meter (artifact; Figure 37A, red arrows). Inserting the clot caused 
an initial 0.5-1 LPM increase in the flow rate (Figure 37, blue arrows). Figure 37C shows an 
adjusted flow rate, in which the average of the baseline measurements (peristaltic pump and 
VAD flow rate before the clot was introduced) was subtracted from the experimental flow rate. 
In Figure 37C, normal heart flow was simulated (~1.5-1.6 LPM, 38°C); flow was relatively 
similar to the baseline (+/- 0.5 LPM) until approximately 6.5s after a large circular clot (15mm 
diameter, 5mm thick) entered the VAD (indicated by the vertical black line at 6.55s), after which 
the flow increased (blue arrow) and then decreased by ~0.5 LPM. Experiments simulating heart 
failure conditions (~1.0-1.5 LPM) produced similar responses in flow rate adjustments: after 
approximately 6-8s, there was a large increase in flow rate followed by a decrease in flow rate 
(similar profile as in Figure 37C). After the pumps were disconnected from power, loose clot 
particles were noted in the tubing and reservoirs. Additionally, clot fragments were observed in 
the pump housing, which had become loosely adhered to the pump components. These 
fragments were gently removed and placed in formalin for histological evaluation. 
Histologically, the artificial clots were composed of an acellular eosinophilic matrix 
similar to the control specimen (Figure 37). The control clot (Figure 37A.1) had a uniform, 
amorphous, sponge-like appearance with small circular gaps scattered throughout. The clot that 
was subjected to the VAD (Figure 37A.2) exhibited a more compact eosinophilic matrix with  
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minimal gaps. In the experiment outlined in Figure 37B (normal heart flow and room 
temperature solution), the deposit collected from the inferior surface of the impeller (Figure 
37B.2) had scattered black punctate material along the specimen, presumed to be grease from the 
rod connecting the impeller to the motor. Compared to the control (Figure 37B.1), the clot 
subjected to the VAD had visible layers of more dense material (i.e., dark vs. light-pink areas). 
The clot shown in Figure 37C traveled through the mock-VAD rather quickly and was exposed 
to the rotating component for less time than previous samples. Thus, these samples (Figure 
37C.2) were histologically similar to the controls (Figure 37C.1). Clots in experiments 
simulating heart failure conditions had histology results similar to those from normal heart flow 
experiments. 
When a larger, firmer section of the clot (Figure 38) entered the mock-VAD, the clot 
remained in the grooves of the impeller (Figure 38A) and initially decreased the flow rate 
(Figure 38B); however, over time, the flow rate gradually increased (Figure 38B). Histologically, 
this clot had more compact layers (Figure 38C) than the control (the clot section not subjected to 
the device, Figure 38D). 
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Figure 37. Results for centrifugal flow experiments. A,B) Flow rates monitored from an electromagnetic flow meter distal to the peristaltic pump and 
centrifugal flow mock-VAD. C) Adjusted flow rate of flow loop (flow rate observed throughout duration of experiment minus the average flow rate 
prior to insertion of clot). Vertical black line indicates time that the clot entered the mock-VAD. Horizontal axis indicates time in seconds, and vertical 
axis indicates flow rate in liters per minute (LPM). Blue arrows indicate initial spike in flow rate; red arrows indicate artifact due to clot pieces passing 
through the flow meter. A.1-C.2) H&E stained histology sections of control clots (1) and clots subjected to the devices (2). Scale bar in each histology 
image is 100 microns (um). 
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Figure 38. Plasma clot with fibrinous gross morphology (17 days old). A) Clot was introduced into device 
and remained in impeller grooves throughout duration of rotation. B) Flow rate data collected and 
displayed in LabVIEW program. The red vertical line indicates the time the clot entered the pump. C) 
H&E stained histology section of clot ingested by mock-VAD. D) H&E stained histology section of 
control. 
 
 
 
8.2.2 Axial flow mock-VAD 
 
Clots used for the axial flow mock-VAD experiments were grossly similar to those used 
for the centrifugal flow. This specific pump design allowed clots to stay intact and remain mostly 
in the pump housing throughout each experiment. The stator provided an added barrier for clots 
upon entering the pump. In most cases, the clot adhered to the impeller vanes (Figure 39A), 
stator struts (Figure 39C,G), or casing wall (Figure 39E). 
When the peristaltic pump was set to higher flow rates to simulate normal heart function, 
the adjusted flow rate after the clot entered was shifted above the horizontal axis (Figure 39B,D), 
with occasional spikes in flow (red arrows in Figure 39D). For heart failure conditions (i.e., 
lower flow rates), the flow rates remained relatively similar to the baseline flow (Figure 39F,H),  
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with an occasional spike in flow (red arrows in Figure 39H). The temperature of the solution had 
no appreciable effect on adjusted flow rate or clot behavior, and the pressure drop across the 
peristaltic pump and mock-VAD remained relatively constant throughout the duration of each 
experiment for both axial and centrifugal flow devices (Figure 40). 
Histologically, clots from axial flow VAD experiments had minimal changes from 
control clots (Figure 41). Control clots were microscopically uniform in all directions and 
composed of a loose eosinophilic matrix (Figure 41A,D). The test clots, approximately 2 months 
old, had similar histologic changes after being exposed to higher and lower flow rates (Figure 
41B,C, higher flow rates; Figure 41E-G, lower flow rates). Each clot was histologically 
composed of two distinct regions. Near the center, the eosinophilic matrix is similar to the 
controls, but toward the edges, the matrix was much denser and had distinct laminations. In one 
experiment with pulsatile flow set to a lower flow rate, a piece of the clot broke off of the stator 
and was collected via filtration (Figure 41G); this clot was histologically composed of faint 
regions of eosinophilic material with various larger gaps in the tissue.  
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Figure 39. Results for axial flow experiments. A,B) 3D printed impeller with clot loosely adhered to the impeller vane and corresponding adjusted flow 
rate data. Clot entered the VAD at t = 76s. C,D) Clot loosely adhered to 3D printed stator and corresponding adjusted flow rate data. Clot entered the 
VAD at t = 19s. E,F) Clot loosely adhered to the wall of the pump housing and corresponding adjusted flow rate data. Clot entered the VAD at t = 84s. 
G,H) Two clot pieces loosely adhered to the stator and corresponding adjusted flow rate data. Clot entered the VAD at t = 32s. 
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Figure 40. Adjusted pressure readings across the peristaltic pump and mock-VAD. The mean baseline 
pressure was subtracted from the pressure drop across the axial flow (A) and centrifugal flow (B) mock-
VADs. Vertical black line indicates time that the clot entered the mock-VAD. Horizontal axis indicates 
time in seconds, and vertical axis indicates pressure in millimeters of Mercury (mmHg). 
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Figure 41. H&E stained sections of clots from axial flow experiments. Top Row: Clots from normal flow simulations (i.e., higher flow rates; See Figure 
39A-D). Bottom Row: Clots from heart failure flow simulations (i.e., lower flow rates; See Figure 39E-H).  
Top Row: A) Control clot B) Clot subjected to the mock-VAD at higher flow rates that was recovered from the vanes of the impeller (Figure 39A). C) 
Clot subjected to the mock-VAD at higher flow rates that was recovered from the stator (Figure 39C).  
Bottom Row: D) Control clot. E) Clot subjected to the mock-VAD at lower flow rates that was recovered from the wall of the pump housing (Figure 
39E). F) Clot subjected to the mock-VAD at lower flow rates that was recovered from the stator (Figure 39G). G) Clot subjected to the mock-VAD at 
lower flow rates that was recovered from the flow loop via filtration. 
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8.3 Discussion 
 
The purpose of this study was to model VAD response to thromboembolism by 
monitoring pressure drop and flow rate across mock-VADs as artificial thrombi were introduced 
proximally to the device. Overall, this flow loop revealed specific flow patterns for both the 
centrifugal flow and the axial mock-VAD models. Softer, more gelatinous clots that fragmented 
when ingested by the centrifugal flow device caused an initial increase in flow rate followed by a 
flow rate decrease, while firmer clots that remained in the impeller caused an initial decrease in 
flow rate. After the clot was inserted in the axial flow device, the average flow rate was 
increased from the baseline when the flow loop ran under normal heart conditions (higher flow 
rates). When the flow loop ran under heart failure conditions (lower flow rates), the average flow 
rate did not vary much from the baseline except for sporadic spikes. Histologically, for both 
mock-VAD designs, differences in clot morphology before and after exposure to the VAD are 
observed, indicating that the VAD does have an impact on clot morphology. Changing the 
temperature of the solution did not affect the flow rate or pressure patterns in either of the mock-
VAD models studied. This indicates that elevation in temperature from an infection (often seen 
in VAD patients at the driveline insertion site) or other sickness may not change the reaction of 
VADs to thromboembolism. 
 
8.3.1 What does this study tell us about VAD/controller design? 
 
The results of this study show that pump design markedly affects consequences of a 
VAD’s ingestion of a thrombus. The stator of the axial flow mock-VAD served as an initial 
barrier for clots, and in many cases the clots remained on the stator regardless of the flow and 
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temperature settings. The centrifugal flow mock-VAD had fewer components and a much 
greater clearance between the impeller and the casing wall. This allowed the “pass-through” clot 
to move beyond the VAD more easily than it did in the axial flow model. Additionally, the 
conical shape and soft material composition of the axial flow impeller allowed the clot to stay 
mostly intact, whereas the metal impeller of the centrifugal flow device disrupted clot integrity 
more and caused most clots to divide into multiple pieces and enter flow loop circulation. 
The range of changes noted over time as clots were introduced to the mock-VADs 
suggests that it may be difficult to know that a thrombus is in the device based solely on flow 
and pressure data; in some of the axial flow experiments the flow remained steady (except for a 
few small spikes in flow rate) while the clot remained inside the VAD chamber. However, 
subtracting the average baseline data from experimental values may aid in determining when the 
flow rate is deviating from normal. This information could be translated into the clinical use of 
VADs, where baseline information for each VAD model could be incorporated into algorithms 
(based on VAD RPM, heart rate, body size, etc.) used to generate data captured in controller logs 
and sound alarms when there is a deviation from normal. The loop discussed here could be used 
to test this algorithm for each VAD model and determine the magnitude of flow irregularity at 
which surgical intervention is necessary. 
8.3.2 How does this study relate to clinical VADs? 
The clots created for these experiments were made from platelet poor-plasma. These 
clots are comprised principally fibrin and lack platelets, which are normally present in clinical 
thrombi. However, the histological results in these experiments strongly resemble those from 
thrombi from clinical VADs (see Section 7). Often, thrombi that develop in vivo in the high-
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velocity regions within the ventricle have a distinct appearance; the flow causes the thrombus to 
form in layers alternating between fibrin and entrapped erythrocytes, usually with a fragile tip 
pointing downstream. The artificial clots had similar velocity-induced laminations of fibrin, 
although they lacked enmeshed erythrocytes.  
These mock-VADs were designed as nonspecific devices using generic components for 
centrifugal and axial flow devices. Therefore, results seen with these two mock-VADs are not 
necessarily expected for any particular centrifugal or axial flow VAD models currently on the 
market or undergoing investigation. Additionally, the flow rates produced by the mock-VADs 
and peristaltic pump were not at human physiologic or clinical values. However, this in vitro 
system was designed to easily incorporate actual VADs and accessory components (e.g., 
controllers) from various sources to examine specific correlations for each model. In particular, 
this bench-top test could reveal how clots of different sizes and firmness affect VADs. It could 
also determine whether the size or consistency of the thrombus correlates with the magnitude 
and duration of power consumption or pressure changes indicated on the pump’s controller log. 
Results could be retroactively compared to clinical experiences with those specific devices and 
correlated with resulting pathology evaluations. Additionally, this flow loop setup could 
potentially allow for testing of thrombolytic treatments in vitro before clinical testing. Thus, 
physicians could better determine whether thrombolytic agents alone could dissolve a thrombus 
or if an exchange surgery is necessary. 
 
8.3.3 Future applications 
 
The system developed in this paper solely measured the pressure drop across and the 
flow rate distal to the mock-VAD/peristaltic pump system. For future studies, the data 
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acquisition system will be expanded to incorporate VAD power consumption data and measure 
VAD RPM throughout thrombus ingestion. This study modeled the interaction of VADs with 
thrombi that formed outside the VAD (around the sewing ring, in the atrium, atrial appendage, 
etc.). This in vitro model could be adapted to study thrombus formation within VADs (de novo 
thrombi). Whole blood could be used as opposed to the glycerin/water mixture to simulate blood 
viscosity, or various blood components (thrombin, fibrinogen, factor XIII, platelets, etc.) could 
be added to the existing system to induce thrombus formation [131]. This type of in vitro testing 
could be useful throughout the development of VADs as well, because there are many device-
blood interactions that should be considered in thrombus formation. All iterations of the VAD 
design could be tested to see which geometries most limit opportunities for thromboembolic 
showers and resulting downstream ischemia. This system could prove to be beneficial for VAD 
manufacturers by providing insight into pump design and flow rates at a lower cost than 
performing pre-clinical in vivo studies. 
 
8.3.4 Thromboembolism in pulsatile VADs 
 
This section focused on pass-through thromboembolism in continuous flow, 
intracorporeal VADs; however, a pulsatile VAD design, such as the Berlin Heart EXCOR, is 
also currently on the market for use in the US. One major benefit to using the Berlin Heart 
EXCOR VAD is that it is easily exchangeable [132]. The instructions for use manual requires 
that the pump be visually inspected every four hours for evidence of thrombi inside the device 
with the aid of a flashlight [133]. If a thrombus is discovered anywhere in the device chamber, 
the device may be replaced [133]. The in vitro model discussed in this paper would be useful for 
testing new device designs and the potential for thromboemboli to develop, but in vivo testing of 
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extracorporeal VADs is significantly less cumbersome than intracorporeal devices, due to the 
external placement of the device and ease of exchange. 
8.4 Conclusion 
In the development of VADs, in vitro testing is crucial for determining the lifetime of 
the device and assessing whether the device inherently damages the tissues and blood (e.g., 
hemolysis). However, there is currently not an in vitro testing protocol for determining the 
device response to thromboembolism, which is a significant and common clinical concern in 
VAD therapy. The in vitro system developed in this study has proven successful at 
demonstrating VAD response to “pass-through” thromboembolism by characterizing the flow 
rate and pressure drop across mock-VADs as artificial clots were introduced. This system has the 
potential to be an effective tool for testing VAD controller log response to and indication of 
thromboembolism. The authors recommend that all existing and new VAD designs use an in 
vitro testing system similar to that described here to analyze the interaction of the device and 
various types of thromboemboli. The correlations between clot size or structure and flow profile, 
power consumption or impeller RPM could be retroactively compared with controller log data 
from previously implanted devices to increase understanding of clinical events and help limit 
chances of thromboembolic complications in future designs. Understanding the relationship 
between the thrombus and the device response is one of the keys to creating, improving, and 
implementing devices that will help more patients living with heart failure. 
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9. SUMMARY 
 
Ventricular assist devices have been widely documented as successful alternatives to 
heart transplantation for treating patients with end-stage heart failure. Thrombosis in VADs is a 
major complication associated with VAD therapy that can put otherwise successful implants at 
risk for mechanical failure or cause patient death. 
As more VADs become approved for use in the United States, the overall usage of 
VADs has increased. With increased use, more frequently VADs are providing cardiac 
assistance for increasing lengths of time. As such, the idea of studying ventricular remodeling 
due to sustained mechanical circulatory support is still relatively new and thus not much data 
relating late-stage VAD thrombosis with myocardial remodeling has been presented in the 
literature. 
In an effort to investigate this phenomenon, a computational model was made to 
simulate the VAD inflow cannula insertion site in dilated, diseased ventricles with weak 
movements, and remodeled, smaller-sized ventricles with a decreased lumen volume and 
increased contraction strength.  
The computational model was used to compare anterior apical placement of the inflow 
cannula (in-line with the mitral valve) to the posterior diaphragmatic insertion site (at an angle to 
the mitral valve). Additionally, each insertion site was examined with the cannula placed at 
various depths into the lumen. At all depths, the anterior apical placement of the cannula was 
superior in terms of decreased regions of recirculation and stagnation. For this orientation, 
inserting the cannula deeper into the lumen increased the areas of trapped blood around the 
inflow cannula.  
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When the cannula is at an angle to the mitral valve, a depth in between the extremes of 
flush with the wall and deep into the lumen provided the best ventricle performance (for dilated 
hearts) in terms of recirculation and stagnation. This depth decreased the overall distance blood 
entering the chamber must travel to reach the cannula inflow, without creating large pockets of 
recirculation between the inflow cannula and the apex of the heart. 
In the computational model described, the ventricles consistent with dilated 
cardiomyopathy (DCM) had greater stagnant regions along the ventricular walls, as well as 
around the inflow cannula. This corroborates the hypothesis that patients with DCM are more 
susceptible to mural thrombus formation. The ventricles consistent with a remodeled geometry 
had increased washout and decreased regions of stagnation. This supports the hypothesis that 
ventricular insertion site is a potential source for thrombus formation and sustained VAD support 
may increase chances of dislodging thrombi thus sending them into VADs that had clinically 
been adverse-event free for multiple years. 
In a clinical setting, when a thrombus travels into the pump, it is suspected that the 
presence of the thrombus increases the friction within the device, and causes periods of high 
power consumption. Depending on the thrombus size, the inflow or outflow may be obstructed, 
resulting in low flow through the device. Either way, a thrombus may decrease pump efficiency, 
damage the device, or create micro-emboli that cause areas of ischemia downstream (e.g., stroke, 
renal infarct, etc.). When a thrombus is suspected, thrombolytic drugs may be administered to 
break up the clot; if thrombolytics are unsuccessful, a VAD exchange procedure is required. 
In an effort to understand what is seen clinically, an in vitro model was created that can 
be used for testing specific VAD models’ response to thromboembolism. This model involved 
creating artificial thrombi and introducing them into a flow loop that incorporated a VAD 
working in parallel with a pulsatile pump, thus simulating a VAD operating in parallel with the 
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ventricle in vivo. Although this model was only used to test mock-VADs, this model did reveal 
that it is possible to determine specific VAD response to thromboembolism. A model such as the 
one described here could be used to define correlations between size or age of a thrombus and 
the magnitude of changes experienced within the pump as displayed on the unit’s controller. 
This model revealed that the pump design and materials used for each component 
markedly affects consequences of a VAD’s ingestion of a thrombus. Additionally, this model 
revealed the importance of establishing a baseline of normal activities within the pump, so it is 
easier to determine when the VAD operation is deviating from normal. 
9.1 Conclusions and final remarks 
The research in this dissertation set out to investigate the phenomenon of thrombosis in 
ventricular assist devices. The motivation for this research began after performing pathology 
evaluations on hundreds of explanted VADs revealed similar thrombi in pumps that had been 
operating in the body for several years. These thrombi were organizing and extending from the 
ventricular insertion site, along the inflow cannula. This phenomenon was investigated by 
creating a computational model of a ventricle with an implanted inflow cannula before and after 
sustained mechanical support. 
Secondarily, hundreds of pathology evaluations of explanted VADs revealed that many 
deposits found within the device originated outside the device, possibly in the atrial appendage, 
along the ventricle wall (mural thrombus), or around the inflow cannula insertion site. This type 
of thrombus (termed “pass-through” thrombus) was investigated further by creating an in vitro 
mock-circulatory loop used to reveal specific VAD response to thromboembolism. 
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Based on this research, several changes can be recommended that will overall reduce 
instances of VAD thromboembolism and thus increase the value of VAD therapy. First, 
evaluating the geometry of patients’ hearts as duration of mechanical support increases will 
provide physicians with a better indication of how the heart is remodeling, and if there is a 
chance for thrombus formation or dislodgment that would put the patient at risk for mechanical 
failure or thrombus-related ischemic damage. Second, prior to pre-clinical studies, testing the 
VAD response to thromboembolism in a bench-top setting (i.e., in vitro) will give a better idea 
of what is going on inside the device when certain parameters are displayed on the controller, 
which will ultimately provide better indication of how to treat the patient (i.e., device exchange 
versus thrombolytics). 
Overall, this research has helped in understanding the relationship between thrombi and 
VADs, which will aid in creating and improving devices for treating patients with heart failure 
worldwide. 
139 
REFERENCES 
[1] Blecker S, Paul M, Taksler G, Ogedegbe G, Katz S: Heart failure-associated hospitalizations 
in the United States. J Am Coll Cardiol 61: 1259-1267, 2013. 
[2] Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, et al.: Heart disease and stroke 
statistics-2011 update: a report from the American Heart Association. Circulation 123: e18-
e209, 2011. 
[3] Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, et al.: Long-term trends in the 
incidence of and survival with heart failure. New Engl J Med 347: 1397-1402, 2002. 
[4] Mosterd A, Hoes AW: Clinical epidemiology of heart failure. Heart 93: 1137-1146, 2007. 
[5] Baran GR, Kiani MF, Pravee S: Cardiovascular devices: getting to the heart of the matter. In: 
Healthcare and biomedical technology in the 21st century: an introduction for non-science 
majors. Springer Science+Business Media, New York, NY, 2014. DOI 10.1007/978-1-4614-
8541-4_9. 
[6] Orians CE, Evans RW, Ascher NL: Estimates of organ-specific donor availability for the 
United States. Transpl P 25: 1541-1542, 1993. 
[7] Department of Health and Human Services, Health Resources and Services Administration, 
Healthcare Systems Bureau, Division of Transplantation, Rockville, MD; United Network for 
Organ Sharing, Richmond, VA; University Renal Research and Education Association, Ann 
Arbor, MI: 2015 annual report of the U.S. Organ Procurement and Transplantation Network and 
the scientific registry of transplant recipients: transplant data 1995-2014. Available at: 
http://optn.transplant.hrsa.gov. Accessed 5 Jan 2015. 
[8] Sun BC, Catanese KA, Spanier TB, Flannery MR, Gardocki MT, et al.: 100 long-term 
implantable left ventricular assist devices: the Columbia Presbyterian interim experience. Ann 
Thorac Surg 68: 688-694, 1999. 
[9] Gandhi SK, Huddelston CB, Balzer DT, Epstein DJ, Boschert TA, Canter CE: Biventricular 
assist devices as a bridge to heart transplantation in small children. Circulation 118: S89-S93, 
2008. 
[10] John R, Kamdar F, Liao K, Colvin-Adams M, Boyle A, Joyce L: Improved survival and 
decreasing incidence of adverse events with the HeartMate II left ventricular assist device as 
bridge-to-transplant-therapy. Ann Thorac Surg 86: 1227-1235, 2008. 
[11] Sharma MS, Webber SA, Morell VO, Gandhi SK, Wearden PD, et al.: Ventricular assist 
device support in children and adolescents as a bridge to heart transplantation. Ann Thorac Surg 
82: 926-933, 2006. 
[12] Almond CS, Morales DL, Blackstone EH, Turrentine M, Imamura M, et al.: The Berlin 
Heart EXCOR pediatric ventricular assist device for bridge to heart transplantation in US 
children. Circulation 127: 1702-1711, 2013. 
 140 
 
[13] Humpl T, Furness S, Gruenwald C, Hyslop C, Arsdell GV: The Berlin Heart EXCOR 
pediatrics-the SickKids experience 2004-2008. Artif Organs 34: 1082-1086, 2010. 
 
[14] Rockett SR, Bryant JC, Morrow R, Frazier EA, Fiser WP, et al.: Preliminary single center 
North American experience with the Berlin Heart pediatric EXCOR device. ASAIO J 54: 479-
482, 2008. 
 
[15] Slater JP, Rose EA, Levin HR, Frazier OH, Roberts JK, et al.: Low thromboembolic risk 
without anticoagulation using advanced-design left ventricular assist devices. Ann Thorac Surg 
62: 1321-1328, 1996. 
 
[16] Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, et al.: Long-term use of a 
left ventricular assist device for end-stage heart failure. New Engl J Med 345: 1435-1443, 2001. 
 
[17] Drakos SG, Wever-Pinzon O, Selzman CH, Gilbert EM, Alharethi R, et al.: Magnitude and 
time course of changes induced by continuous-flow left ventricular assist device unloading in 
chronic heart failure. J Am Coll Cardiol 61: 1985-1994, 2013. 
 
[18] Lang SA, O’Neill B, Waterworth P, Bilal H: Can the temporary use of right ventricular 
assist devices bridge patients with acute right ventricular failure after cardiac surgery to 
recovery? Interac Cardiovas Thorac Surg 18: 499-510, 2014. 
 
[19] George CLS, Ameduri RK, Reed RC, Dummer KB, Overman DM, St. Louis JD: Long-term 
use of ventricular assist device as a bridge to recovery in acute fulminant myocarditis. Ann 
Thorac Surg 95: e59-e60, 2013. 
 
[20] McCarthy PM, Nakatani S, Vargo R, Kottke-Marchant K, Harasaki H, et al.: Structural and 
left ventricular histologic changes after implantable LVAD insertion. Ann Thorac Surg 59: 609-
613, 1995. 
[21] Robertis FD, Rogers P, Amrani M, Petrou M, Pepper JR, et al.: Bridge to decision using the 
Levitronix CentriMag short term ventricular assist device. J Heart Lung Transplant 27: 474-478, 
2008. 
 
[22] Carpenter BA, Gonzalez CG, Jessen SL, Moore EJ, Thrapp AN, et al.: Brief review of 
ventricular assist devices and a recommended protocol for pathology evaluations. Cardiovasc 
Pathol 22: 408-415, 2013. 
 
[23] Lund LH, Gabrielsen A, Tiren L, Hallberg A, Karlsson KEL, Eriksson MJ: Derived and 
displayed power consumption, flow, and pulsatility over a range of HeartMate II left ventricular 
assist device settings. ASAIO J 58: 183-190, 2012. 
 
[24] Chorpenning K, Brown MC, Voskoboynikov N, Reyes C, Dierlam AE, Tamez D: 
HeartWare controller logs a diagnostic tool and clinical management aid for the HVAD pump. 
ASAIO J 60: 115-118, 2014. 
 
[25] United States Food and Drug Administration, Center of Devices and Radiological Health 
Division of Industry Communication and Education: Serious adverse events with implantable 
141 
left ventricular assist devices (LVADs): FDA safety communication. 5 Aug 2015. Available at: 
http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm457327.htm?source=govdeliv
ery&utm_medium=email&utm_source=govdelivery. Accessed 5 Aug 2015. 
[26] Levinson MM, Smith RG, Cork RC, Gallo J, Emery RW, et al.: Thromboembolic 
complications of the Jarvik-7 total artificial heart: case report. Artif Organs 10: 236-244, 1986. 
[27] Icenogle TB, Smith RG, Cleavinger M, Vasu MA, Williams RJ, et al.: Thromboembolic 
complications of the Symbion AVAD system. Artif Organs 13: 532-538, 1989. 
[28] Eckman PM, John R: Bleeding and thrombosis in patients with continuous-flow ventricular 
assist devices. Circulation 125: 3038-3047, 2012. 
[29] Goldstein DJ, John R, Salerno C, Silvestry S, Moazami N, et al.: Algorithm for the 
diagnosis and management of suspected pump thrombus. J Heart Lung Transpl 32: 667-670, 
2013. 
[30] Muthiah K, Robson D, Macdonald PS, Keogh AM, Kotlyar E, et al.: Thrombolysis for 
suspected intrapump thrombosis in patients with continuous flow centrifugal left ventricular 
assist device. Artif Organs 37: 313-322, 2013. 
[31] Najjar SS, Slaughter MS, Pagani FD, Starling RC, McGee EC, et al.: An analysis of pump 
thrombus events in patients in the HeartWare ADVANCE bridge to transplant and continued 
access protocol trial. J Heart Lung Transpl 33: 23-34, 2014. 
[32] Pratt AK, Shah NS, Boyce SW: Left ventricular assist device management in the ICU. Crit 
Care Med 42: 158-168, 2014. 
[33] Uriel N, Han J, Morrison KA, Nahumi N, Yuzefpolskaya M, et al.: Device thrombosis in 
HeartMate II continuous-flow left ventricular assist device: a multifactorial phenomenon. J 
Heart Lung Transpl 33: 53-59, 2014. 
[34] Hasin T, Deo S, Maleszewski JJ, Topilsky Y, Edwards BS, et al.: The role of medical 
management for acute intravascular hemolysis in patients supported on axial flow LVAD. 
ASAIO J 60: 9-14, 2014. 
[35] McBride LR, Naunheim KS, Fiore AC, Moroney DA, Swartz MT: Clinical experience with 
111 Thoratec ventricular assist devices. Ann Thorac Surg 67: 1233-1239, 1999. 
[36] Starling RC, Moazami N, Silvestry SC, Ewald G, Rogers JG, et al.: Unexpected abrupt 
increase in left ventricular assist device thrombosis. New Engl J Med 370: 33-40, 2013. 
[37] Fyfe B, Schoen FJ: Pathologic analysis of 34 explanted Symbion ventricular assist devices 
and 10 explanted Jarvik-7 total artificial hearts. Cardiovasc Patholo 2: 187-197, 1993. 
[38] Bashir J, Cheung A, Kaan A, Kearns M, Ibey A, Ignaszewski A: Thrombosis and failure of 
a HeartMate II device in the absence of alarms. J Heart Lung Transpl 30: 1197-1199, 2011. 
 142 
 
[39] Levin HR, Oz MC, Chen JM, Packer M, Rose EA, Burkhoff D: Reversal of chronic 
ventricular dilation in patients with end-stage cardiomyopathy by prolonged mechanical 
unloading. Circulation 91: 2717-2720, 1995. 
 
[40] Ferns J, Dowling R, Bhat G: Evaluation of a patient with left ventricular assist device 
dysfunction. ASAIO J 47: 696-698, 2001. 
 
[41] Ong C, Dokos S, Chan B, Lim E, Al Abed A, et al.: Numerical investigation of the effect of 
cannula placement on thrombosis. Theor Biol Med Model 10: 1-14, 2013. 
 
[42] Laumen M, Kaufmann T, Timms D, Schlanstein P, Jansen S, et al.: Flow analysis of 
ventricular assist device inflow and outflow cannula positioning using a naturally shaped 
ventricle and aortic branch. Artif Organs 34: 798-806, 2010. 
 
[43] Sumikura H, Toda K, Takewa Y, Tsukiya T, Ohnuma K, et al.: Development and 
hydrodynamic evaluation of a novel inflow cannula in a mechanical circulatory support system 
for bridge to decision. Artif Organs 35: 756-764, 2011. 
 
[44] Tsukiya T, Toda K, Sumikura H, Takewa Y, Watanabe F, et al.: Computational fluid 
dynamic analysis of the flow field in the newly developed inflow cannula for a bridge-to-
decision mechanical circulatory support. Artif Organs 14: 381-384, 2011. 
 
[45] Karmonik C, Partovi S, Loebe M, Schmack B, Ghodsizad A, et al.: Influence of LVAD 
cannula outflow tract location on hemodynamics in the ascending aorta: a patient-specific 
computational fluid dynamics approach. ASAIO J 58: 562-567, 2012. 
 
[46] Timms D, Hayne M, McNeil K, Galbraith A: A complete mock circulation loop for the 
evaluation of left, right, and biventricular assist devices. Artif Organs 29: 564-572, 2005. 
 
[47] Pantalos GM, Koenig SC, Gillars JK, Giriharan GA, Ewert DL: Characterization of an adult 
mock circulation for testing cardiac support devices. ASAIO J 50: 37-46, 2004. 
 
[48] Birks EJ, Tansley PD, Yacoub MH, Bowles CT, Hipkin M, et al.: Incidence and clinical 
management of life-threatening left ventricular assist device failure. J Heart Lung Transpl 23: 
964-969, 2004. 
 
[49] Baloa LA, Boston JR, Antaki JF: Elastance-based control of a mock circulatory system. Ann 
Biomed Eng 29: 244-251, 2001. 
 
[50] Ferrari G, Lazzari CD, Kozarski M, Clemente F, Gorczynska K, et al.: A hybrid mock 
circulatory system: testing a prototype under physiologic and pathological conditions. ASAIO J 
48: 487-494, 2002. 
 
[51] Taylor JO, Witmer KP, Neuberger T, Craven BA, Meyer RS, et al.: In vitro quantification 
of time dependent size using magnetic resonance imaging and computational simulations of 
thrombus near surface shear stresses. J Biomech Eng 136: 1-11, 2014. 
 
143 
[52] Navitsky MA, Taylor JO, Smith AB, Slattery MJ, Deutsch S, et al.: Platelet adhesion to 
polyurethane urea under pulsatile flow conditions. Artif Organs 38: 1046-1053, 2014. 
[53] Koenig SC, Pantalos GM, Gillars KJ, Ewert DL, Litwak KN, Etoch SW: Hemodynamic and 
pressure-volume responses to continuous and pulsatile ventricular assist in an adult mock 
circulation. ASAIO J 50: 15-24, 2004. 
[54] Schima H, Baumgartner H, Spitaler F, Kuhn P, Wolner E: A modular mock circulation for 
hydromechanical studies on valves, stenosis, vascular grafts and cardiac assist devices. Int J Artif 
Organs 15: 417-421, 1992. 
[55] Vandenberghe S, Segers B, Meyns B, Verdonck P: Hydrodynamic characterization of 
ventricular assist devices. Int J Artif Organs 24: 470-477, 2001. 
[56] Vermette P, Thibault J, Laroche G: A continuous and pulsatile flow circulation system for 
evaluation of cardiovascular devices. Artif Organs 22: 746-752, 1998. 
[57] Esper SA, Subramaniam K: Heart failure and mechanical circulatory support. Best Pract 
Res Cl Anaesthesiol 26: 91-104, 2012. 
[58] American Heart Association: Classes of heart failure. Available at: 
http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/Classes-of-
Heart-Failure_UCM_306328_Article.jsp#.VvRJmuIrLIU. Accessed 5 Jan 2014. 
[59] DeVries WC, Anderson JL, Joyce LD, Anderson FL, Hammond EH, et al.: Clinical use of 
the total artificial heart. New Engl J Med 310: 273-278, 1984. 
[60] Johnson KE, Prieto M, Joyce LD, Pritzker M, Emery RW: Summary of the clinical use of 
the Symbion total artificial heart: a registry report. J Heart Lung Transpl 11: 103-116, 1992. 
[61] Burton NA, Lefrak EA, Macmanus Q, Hill A, Marino JA, et al.: A reliable bridge to cardiac 
transplantation: the TCI left ventricular assist device. Ann Thorac Surg 55: 1425-1431, 1993. 
[62] United States Food and Drug Administration, Center for Devices and Radiological Health: 
Summary of safety and effectiveness data for Thoratec HeartMate® II left ventricular assist 
system (LVAS). 21 Apr 2008. Available at: 
http://www.accessdata.fda.gov/cdrh_docs/pdf6/P060040b.pdf. Accessed 3 June 2013. 
[63] United States Food and Drug Administration, Center for Devices and Radiological Health: 
Summary of safety and probable benefit for EXCOR® pediatric ventricular assist device 
(EXCOR). 16 Dec 2011. Available at: 
http://www.accessdata.fda.gov/cdrh_docs/pdf10/h100004b.pdf. Accessed 3 June 2013. 
[64] United States Food and Drug Administration, Center for Devices and Radiological Health: 
Summary of safety and effectiveness data for HeartWare® ventricular assist system. 20 Nov 
2012. Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf10/p100047b.pdf. Accessed 3 
June 2013. 
144 
[65] Nativi JN, Drakos SG, Kucheryavaya AY, Edwards LB, Selzman CH, et al.: Changing 
outcomes in patients bridged to heart transplantation with continuous- versus pulsatile-flow 
ventricular assist devices: an analysis of the registry of the International Society for Heart and 
Lung Transplantation. J Heart Lung Transpl 30: 854-861, 2011. 
[66] Kato TS, Chokshi A, Singh P, Khawaja T, Cheema F, et al.: Effects of continuous-flow 
versus pulsatile-flow left ventricular assist devices on myocardial unloading and remodeling. 
Circ Heart Fail 4: 546-553, 2011. 
[67] Potapov EV, Loforte A, Weng Y, Jurmann M, Pasic M, et al.: Experience with over 1000 
implanted ventricular assist devices. J Card Surg 23: 185-194, 2008. 
[68] Garbade J, Bittner HB, Barten MJ, Mohr FW: Current trends in implantable left ventricular 
assist devices. Cardiol Res Pract 2011: 1-9 (Article ID 290561), 2011. 
[69] Slaughter MS., Pagani FD, Rogers JG, Miller LW, Sun B, et al.: Clinical management of 
continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transpl 
29: S1-S39, 2010. 
[70] Travis AR, Giridharan GA, Pantalos GM, Dowling RD, Prabhu SD, et al.: Vascular 
pulsatility in patients with a pulsatile- or continuous-flow ventricular assist device. J Thorac 
Cardiov Sur 133: 517-524. 2007. 
[71] Tuzun E, Rutten M, Dat M, van de Voss F, Kadipasaoglu C, de Mol B: Continuous-flow 
cardiac assistance: effects on aortic valve function in a mock loop. J Surg Res 171: 443-447, 
2011. 
[72] Wang Q, Yambe T, Shiraishi Y, Duan X, Yoshizawa M, et al.: Non-blood contacting 
electro-hydraulic artificial myocardium (EHAM) improves the myocardial tissue perfusion. 
Technol Health Care 13: 229-234, 2005. 
[73] Fragasso T, Ricci Z, Grutter G, Albanese S, Varano C, et al.: Incidence of healthcare-
associated infections in a pediatric population with an extracorporeal ventricular assist device. 
Artif Organs 35: 1110-1114, 2011. 
[74] Felker GM, Rogers JG: Same bridge, new destinations – rethinking paradigms for 
mechanical cardiac support in heart failure. J Am Coll Cardiol 47: 930-932, 2006. 
[75] Stevenson LW, Pagani FD, Yount JB, Dessup M, Miller L, et al.: INTERMACS profiles of 
advanced heart failure: the current picture. J Heart Lung Transpl 28: 535-541, 2009. 
[76] United States Food and Drug Administration, Center for Devices and Radiological Health: 
Guidance for industry and FDA staff: premarket approval application filing review. 3 Nov 2003. 
Available at: 
http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocument
s/ucm089767.pdf Accessed 6 June 2013. 
145 
[77] United States Food and Drug Administration, Center for Devices and Radiological Health: 
Code of Federal Regulation: Title 21, Part 58. Available at: 
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRsearch.cfm?CFRPart=58 Accessed 
6 June 2013. 
[78] Schoen FJ, Anderson JM, Didisheim P, Dobbins JJ, Gristina AG, et al.: Ventricular assist 
device (VAD) pathology analyses: guidelines for clinical studies. J Appl Biomater 1: 49-56, 
1990. 
[79] Gilbert EF, Huntington RW: Diseases of the blood. In: An introduction to pathology. 
Oxford University Press, New York, NY, 1978. 
[80] Taussig MJ: The circulation. In: Processes in pathology. Blackwell Scientific Publications, 
London, England, 1979. 
[81] Kumar V, Abbas AK, Fausto N, Mitchell RN: Hemodynamic disorders, thrombosis, and 
shock. In: Robbins basic pathology, 8th edition. Saunders Elsevier, Philadelphia, PA, 2007. 
[82] Boron WF, Boulpaep EL: The cardiovascular system. In: Medical physiology, 2nd edition. 
Saunders Elsevier, Philadelphia, PA, 2012. 
[83] Butenas S, Mann KG: Blood coagulation. Biochemistry (Moscow) 67: 3-12, 2002. 
[84] Dickson BC: Venous thrombosis: on the history of Virchow’s triad. U Toronto Med J 81: 
166-171, 2004. 
[85] Spanier T, Oz M, Levin H, Weinberg A, Stamatis K, et al.: Activation of coagulation and 
fibrinolytic pathways in patients with left ventricular assist devices. J Thorac Cardiov Sur 112: 
1090-1097, 1996. 
[86] Hochareon P, Manning KB, Fontaine AA, Tarbell JM, Deutsch S: Correlation of in vivo clot 
deposition with the flow characteristics in the 50 cc Penn State artificial heart: a preliminary 
study. ASAIO J 50: 537-542, 2004. 
[87] Milner KR, Snyder AJ, Siedlecki CA: Sub-micron texturing for reducing platelet adhesion 
to polyurethane biomaterials. J Biomed Mater Res 76A: 561-570, 2006. 
[88] Hirsh J, Fletcher AP, Sherry S: Effect of fibrin and fibrinogen proteolysis products on clot 
physical properties. Am J Physiol 209: 415-424, 1965. 
[89] Rosenberg RD: Biochemistry of heparin antithrombin interactions, and the physiologic role 
of this natural anticoagulant mechanism. Am J Med 87: 1-8, 1989. 
[90] Plumb DC: Plumb’s veterinary drug handbook pocket, 7th edition. PharmaVet Press, 
Stockholm, Sweden, 2011. pp. 112-113, 661-662, 1393-139. 
146 
[91] Noon GP, Morley DL, Irwin S, Abdelsayed SV, Benkowski RJ, Lynch BE: Clinical 
experience with the MicroMed DeBakey ventricular assist device. Ann Thorac Surg 71: S133-
S138, 2001. 
[92] Long CC, Marsden AL, Bazilevs Y: Shape optimization of pulsatile ventricular assist 
devices using FSI to minimize thrombotic risk. Comput Mech 54: 921-932, 2014. 
[93] Lopez JA, Chen J: Pathophysiology of venous thrombosis. Thromb Res 123: S30-S34, 
2009. 
[94] Olsen DB, Unger F, Oster H, Lawson J, Kessler T, et al.: Thrombus generation within the 
artificial heart. J Thorac Cardiov Sur 70: 248-255, 1975. 
[95] Dasse KA, Chipman SD, Sherman CN, Levine AH, Frazier OH: Clinical experience with 
textured blood contacting surfaces in ventricular assist devices. T Am Soc Artif Intern Organs 33: 
418-425, 1987. 
[96] McGee E, Chorpenning K, Brown MC, Breznock E, LaRose JA, Tamez D: In vivo 
evaluation of the Heartware MVAD pump. J Heart Lung Transpl 33: 366-371, 2014. 
[97] Anderson JM: Cardiovascular device retrieval and evaluation. Cardiovas Patholo 2: 199S-
208S, 1993. 
[98] Chueh JY, Wakhloo AK, Hendricks GH, Silva CF, Weaver JP, Gounis MJ: Mechanical 
characterization of thromboemboli in acute ischemic stroke and laboratory embolus analogs. Am 
J Neuroradiol 32: 1237-1244, 2011. 
[99] Ryan EA, Mockros LF, Weisel JW, Lorand L: Structural origins of fibrin clot rheology. 
Biophys J 77: 2813-2826, 1999. 
[100] Fraser KH, Taskin ME, Griffith BP, Wu ZJ: The use of computational fluid dynamics in 
the development of ventricular assist devices. Med Eng Phys 33: 263-280, 2011. 
[101] Sakaguchi T, Matsumiya G, Yoshioka D, Miyagawa S, Nishi H, et al.: DuraHeartTM 
magnetically levitated left ventricular assist device: Osaka University experience. Circ J 77: 
1736-1741, 2013. 
[102] Fraser KH, Zhang T, Taskin E, Griffith BP, Wu ZJ: Computational fluid dynamics 
analysis of thrombosis potential in left ventricular assist device drainage cannulae. ASAIO J 56: 
157-163, 2010. 
[103] Radovancevic B, Frazier OH, Duncan JM: Implantation technique for the Heartmate® left 
ventricular assist device. J Cardiac Surg 7: 203-207, 1992. 
[104] Westaby S, Frazier OH, Pigott DW, Saito S, Jarvik RK: Implant technique for the Jarvik 
2000 Heart. Ann Thorac Surg 73: 1337-1340, 2002. 
147 
[105] Gregoric ID, Cohn WE, Frazier OH: Diaphragmatic implantation of the Heartware 
ventricular assist device. J Heart Lung Transpl 30: 467-470, 2011. 
[106] Komoda T, Weng Y, Nojiri C, Hetzer R: Implantation technique for the DuraHeart left 
ventricular assist system. Artif Organs 10: 124-127, 2007. 
[107] Kirklin JK, Naftel DC, Kormos RL, Pagani FD, Myers SL, et al.: Interagency registry for 
mechanically assisted circulatory support (INTERMACS) analysis of pump thrombosis in the 
HeartMate II left ventricular assist device. J Heart Lung Transpl 33: 12-22, 2014. 
[108] Taghavi S, Ward C, Jayaranjan SN, Gaughan J, Wilson LM, Mangi AA: Surgical 
technique influences HeartMate II left ventricular assist device thrombosis. Ann Thorac Surg 96: 
1259-1265, 2013. 
[109] Truong TV, Stanfield R, Chaffin JS, Elkins CC, Kanaly PJ, et al.: Postimplant left 
ventricular assist device fit analysis using three-dimensional reconstruction. ASAIO J 59: 586-
592, 2013. 
[110] Milano CA, Simeone AA, Blue LJ, Rogers JG: Presentation and management of left 
ventricular assist device inflow cannula malposition. J Heart Lung Transpl 30: 838-840, 2011. 
[111] Bolen MA, Popovic ZB, Gonzalez-Stawinski G, Schoenhagen P: Left ventricular assist 
device malposition interrogated by 4-D cine computed tomography. J Cardiovasc Comput 
Tomogr 5:186-188, 2011. 
[112] Paluszkiewicz L, Schulte-Eistrup S, Gummert J, Koertke H: Asymptomatic displacement 
of the inflow cannula of a patient 18 months after implantation of a DuraHeart left ventricular 
assist device. J Am Coll Cardiol 58: 1, 2011. 
[113] Douglas PA, Morrow R, Ioli A, Reichek N: Left ventricular shape, afterload and survival 
in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 13: 311-315, 1989. 
[114] Semelka RC, Tomei E, Wagner S, Mayo J, Caputo G, et al.: Interstudy reproducibility of 
dimensional and functional measurements between cine magnetic resonance studies in the 
morphologically abnormal left ventricle. Am Heart J 119: 1367-1373, 1990. 
[115] Shernan SK: e-Echocardiography, an echocardiography and ultrasound learning resource: 
normal mitral valve measurements. Available at: https://e-
echocardiography.com/page/page.php?UID=1867001. Accessed 5 Jan 2016. 
[116] Wang SH, Lee LP, Lee JS: A linear relation between the compressibility and density of 
blood. J Acoust Soc Am 109: 390-396, 2001. 
[117] Gijsen FJH, van de Vosse FN, Janssen JD: The influence of the non-Newtonian properties 
of blood on the flow in large arteries: steady flow in a carotid bifurcation model. J Biomech 32: 
601-608, 1999. 
148 
[118] John R, Mantz K, Eckman P, Rose A, May-Newman K: Aortic valve pathophysiology 
during left ventricular assist device support. J Heart Lung Transpl 29: 1321-1329, 2010. 
[119] Chandler AB: In vitro thrombotic coagulation of the blood – a method for producing a 
thrombus. Lab Invest 7: 110-114, 1958. 
[120] Topper SR, Navitsky MA, Medivtz RB, Paterson EC, Siedlecki CA, et al.: The use of fluid 
mechanics to predict regions of microscopic thrombus formation in pulsatile VADs. Cardiovasc 
Eng Technol 5: 54-69, 2014. 
[121] Geddes LA, Sadler C: The specific resistance of blood at body temperature. Med Biol Eng 
Comput 11: 336-339, 1973. 
[122] Knisely MH, Bloch EH, Brooks F, Warner L: Microscopic observations of the circulating 
blood of nine healthy normal horses, all of which had unagglutinated circulating blood cells and 
high in vitro erythrocyte sedimentation rates: a contribution to the theory and general 
understanding of the pathologic circulatory physiology of sludged blood. Am J Med Sci 219: 
249-267, 1950. 
[123] Eicker SW, Ainsworth DM: Equine plasma banking: collection by exsanguination. J Am 
Vet Med Assoc 185: 772-774, 1984. 
[124] Roessler FC, Ohlrich M, Marxsen JH, Stellmacher F, Sprenger A, et al.: The platelet-rich 
plasma clot: a standardized in-vitro clot formation protocol for investigations of 
sonothrombolysis under physiological flows. Blood Coagul Fibrinolysis 22: 407-415, 2011. 
[125] Joy DC: Scanning electron microscopy. In: Materials science and technology. Wiley-VCH 
Verlag GmbH & Co KGaA. Weinheim, Germany, 2006. DOI 10.1002/9783527603978.mst0012. 
[126] Weng X, Cloutier G, Pibarot P, Durand LG: Comparison and simulation of different levels 
of erythrocyte aggregation with pig, horse, sheep, calf, and normal human blood. Biorheology 
33: 365-377, 1996. 
[127] Colacino FM, Arabia M, Moscato F, Danieli GA: Modeling, analysis, and validation of a 
pneumatically driven left ventricle for use in mock circulatory systems. Med Eng Phys 29: 829-
839, 2007. 
[128] Tuzun E, Roberts K, Cohn WE, Sargin M, Gemmato C, et al.: In vivo evaluation of the 
HeartWare centrifugal ventricular assist device. Tex Heart Inst J 34: 406-411, 2007. 
[129] Chiu WC, Girdhar G, Xenos M, Alemu Y, Soares JS, et al.: Thromboresistance 
comparison of the HeartMate II ventricular assist device with the device thromboenicity 
emulation-optimized HeartAssist 5 VAD. J Biomech Eng 136: 1-9, 2014. 
[130] Stevens MC, Gregory SD, Nestler F, Thomson B, Choudhary J, et al.: In vitro and in vivo 
characterization of three different modes of pump operation when using a left ventricular assist 
device as a right ventricular assist device. Artif Organs 38: 931-939, 2014. 
149 
[131] Sherwood L: Human physiology: from cells to systems, 8th edition. Brooks/Cole, Cengage 
Lerning, Belmont, CA, 2013. pp. 404-410. 
[132] Malaisrie SC, Pelletier MP, Yun JJ, Sharma K, Timek TA, et al.: Pneumatic paracorporeal 
ventricular assist device in infants and children: initial Stanford experience. J Heart Lung 
Transpl 27: 173-177, 2008. 
[133] Berlin Heart: EXCOR® VAD with stationary driving unit Ikus instructions for use. Jan 
2008. Available online at: 
http://www.berlinheart.de/UserFiles/Downloaddokumente/Medical_Professionals_Distributoren/
Non_US/EXCOR_Parakorporales_Herzunterstuetzungssystem/Gebrauchsanweisungen/EXCOR
_VAD_Ikus_Antrieb/Ikus_Rev_2_1_Software_3_40/Gebrau3.40AMRev80en.pdf. Accessed 10 
Oct 2015. 
150 
APPENDIX I
COAGULATION CASCADE
The figure below displays creation of a stabilized fibrin clot originating from tissue injury, 
negatively charged surfaces, and non-laminar flow. Tissue injury involves injury of endothelial 
cells (EC) and exposure of subendothelial collagen. Injured EC release von Willebrand factor 
(vWf), which activates when bound to subendothelial collagen. Mammalian platelets are 
activated once they bind to activated vWf. Platelets contain secretory vesicles that release 
adenosine diphosphate (ADP), platelet factors, thromboxane A2, vWf, vasoconstrictors, and 
several others once activated within the plasma [1]. The activation of platelets initiates a second 
messenger signaling pathway (IP3/DAG) that causes the release of cytosolic calcium from 
intracellular stores within the endoplasmic reticulum of platelets [2]. Intracellular and 
extracellular calcium play an important role in mediating the release of secretory vesicles [3]. 
ADP and thromboxane A2 released from the vesicles of activated platelets attract additional 
circulating platelets to aggregate and form a platelet plug. Thrombin helps to further activate 
platelets, thereby intensifying aggregation. ADP released from platelets stimulates the healthy 
surrounding endothelium to secrete nitric oxide and prostacyclin, which prevents the clot from 
extending to the normal tissue. 
Injured tissue, in addition to activating platelets, also activates the extrinsic pathway by releasing 
Tissue Factor (TF) [4]. TF binds with clotting factor VII, which is normally present in its 
inactive form in the bloodstream. TF activates factor VII to become factor VIIa, which activates 
clotting factor X in the presence of calcium and additional TF, thereby completing the extrinsic 
clotting cascade and initiating the common pathway.
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APPENDIX II 
CFD MOTION EQUATIONS 
 
Equations for movement of ventricle wall with cannula in anterior apical placement:  
 
(1.1)            !"!" =    (𝑦! − 𝑙𝑖𝑛𝑒) ∗   !"! ∗ sin  (!!! 𝑡) 
(1.2)            !"!" =   0 
Where 𝑙𝑖𝑛𝑒 =   𝑦! − (𝑚𝑥! + 𝑦!"#) 
 𝑥!  𝑎𝑛𝑑  𝑦!  𝑎𝑟𝑒  𝑐𝑜𝑜𝑟𝑑𝑖𝑛𝑎𝑡𝑒𝑠  𝑜𝑓  𝑡ℎ𝑒  𝑣𝑒𝑛𝑡𝑟𝑖𝑐𝑙𝑒  𝑤𝑎𝑙𝑙  𝑎𝑡  𝑒𝑛𝑑  𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑒 
 𝑦!"#  𝑎𝑛𝑑  𝑚  𝑎𝑟𝑒  𝑡ℎ𝑒  𝑦  𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡  𝑎𝑛𝑑  𝑠𝑙𝑜𝑝𝑒  𝑣𝑎𝑙𝑢𝑒𝑠  𝑜𝑓  𝑡ℎ𝑒  𝑙𝑖𝑛𝑒   𝑐𝑟𝑒𝑎𝑡𝑒𝑑  𝑏𝑦  𝑐𝑜𝑛𝑛𝑒𝑐𝑡𝑖𝑛𝑔  𝑡ℎ𝑒  𝑒𝑛𝑑  𝑝𝑜𝑖𝑛𝑡𝑠  𝑜𝑓  𝑡ℎ𝑒  𝑚𝑜𝑣𝑖𝑛𝑔  𝑤𝑎𝑙𝑙 
 𝑇 = 𝑝𝑒𝑟𝑖𝑜𝑑 
 𝑡 = 𝑡𝑖𝑚𝑒 
 𝑎 = 𝑎𝑣𝑒𝑟𝑎𝑔𝑒  𝑦!"#$!   𝑜𝑓  "𝑙𝑖𝑛𝑒" 
 
 
Equations for movement of ventricle wall with cannula in posterior diaphragmatic placement: 
  
(2.1)            !"!" =   !!"#!   ∗   sin !!"! ∗ [cos(2 𝜋 −   𝜃! ) +   𝜃!]                                     𝑓𝑜𝑟                                  𝑦! − 𝑦!   < 0 
 
(2.2)             !"!" =   !!"#!   ∗   sin !!"! ∗ cos(2 𝜋 −   𝜃! )                                                             𝑓𝑜𝑟                                    𝑦! − 𝑦!   ≥ 0 
 
(2.3)            !"!" =   !!"#!   ∗   sin !!"! ∗ [sin(2 𝜋 −   𝜃! ) +   𝜃!]                                     𝑓𝑜𝑟                                    𝑦! − 𝑦!   < 0 
 
(2.4)            !"!" =   !!"#!   ∗   sin !!"! ∗ sin(2 𝜋 −   𝜃! )                                                                 𝑓𝑜𝑟                                    𝑦! − 𝑦!   ≥ 0 
 
Where  𝑎 =   𝑎!"# ∗   sin 𝜋𝑎! −   𝑎!   ∗ (2 𝜋 −   𝜃! +   𝜃!                 𝑓𝑜𝑟                    𝑦! − 𝑦!   < 0 
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𝑎 =   𝑎!"# ∗   sin 𝜋𝑎! −   𝑎!   ∗ (2 𝜋 −   𝜃!                                     𝑓𝑜𝑟                    𝑦! − 𝑦!   ≥ 0 
 𝑟 = 𝑟𝑎𝑑𝑖𝑢𝑠 =    (𝑥! − 𝑥!)! −   (𝑦! − 𝑦!)! 
 𝑇 = 𝑃𝑒𝑟𝑖𝑜𝑑 = 1 
 𝑡 = 𝑡𝑖𝑚𝑒 
 𝜃! = cos!!((𝑥! −   𝑥!)/𝑟) 
 𝑥!  𝑎𝑛𝑑  𝑦! = 𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙  𝑥  𝑎𝑛𝑑  𝑦  𝑐𝑜𝑜𝑟𝑑𝑖𝑛𝑎𝑡𝑒𝑠  𝑜𝑓  𝑡ℎ𝑒  𝑚𝑜𝑣𝑖𝑛𝑔  𝑤𝑎𝑙𝑙𝑠 
 𝑥!   𝑎𝑛𝑑  𝑦! = 𝑥  𝑎𝑛𝑑  𝑦  𝑐𝑜𝑜𝑟𝑑𝑖𝑛𝑎𝑡𝑒𝑠  𝑜𝑓  𝑡ℎ𝑒  𝑐𝑒𝑛𝑡𝑒𝑟  𝑜𝑓  𝑡ℎ𝑒  𝑣𝑒𝑛𝑡𝑟𝑖𝑐𝑙𝑒 
 𝑎!"# = 𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡 
 𝑎! = 𝑚𝑖𝑛  𝜃! 
 𝑎! = 𝑚𝑎𝑥  𝜃! 
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APPENDIX III 
COMPLETE ARTIFICIAL CLOT DATA 
	  
Forty-eight clots were created to determine the best method for producing artificial clots 
(outlined in Section 7 of above work). This appendix contains specific information for each clot 
including date of creation, blood component(s) used, species of blood, concentration of Calcium 
Chloride (CaCl2) used to make the blood clot, and a brief description of the method used to 
create the clot. 
 
Clot Name: Clot 1 
Date Created: 4/22/13 
Blood Component: Whole Blood 
Species: Porcine 
CaCl2 Concentration: 12mg CaCl2 / mL distilled H2O 
Method: Approximately 5mL of porcine blood collected for transfusion was placed into a 50mL 
Erlenmeyer flask. Ten drops of the CaCl2 solution at 3 separate times, each 2 minutes apart. The 
blood began to have a noticeable clot after 6 minutes since the first drops of CaCl2 were added. 
The blood clot was photographed and transferred to a conical vial and stored at room 
temperature overnight.  
Gross Evaluation: The clot is malleable (but shape retentive), bright red, and measured 16mm x 
31mm. Clot is transferred to formalin and sectioned after 44.8 hours (since time of formation). 
 
 
 
Clot Name: Clot 2 
Date Created: 4/22/13 
Blood Component: Whole Blood 
156 
	  
Species: Porcine 
CaCl2 Concentration: 12mg CaCl2 / mL distilled H2O 
Method: 5mL of porcine whole blood and the CaCl2 solution were placed in a petri dish (50mm 
diameter). A second petri dish (38mm diameter) applied a rotational force on the blood while it 
was clotting.	  
RPM: 60 
Gap Thickness: 4mm 
Total Time Rotating: 2.87 hours 
Gross Evaluation: Clot formed on the inferior surface of the rotating petri dish. Stationary dish 
also had a small deposit. Both deposits were collected for histology. 
 
 
 
Clot Name: Clot 3 
Date Created: 4/23/13 
Blood Component: Whole Blood 
Species: Porcine 
CaCl2 Concentration: 12mg CaCl2 / mL distilled H2O 
Method: 5mL of porcine whole blood and the CaCl2 solution were placed in a petri dish (50mm 
diameter). A second petri dish (38mm diameter) applied a rotational force on the blood while it 
was clotting.	  
RPM: 60 
Gap Thickness: 2mm 
Total Time Rotating: 5.05 hours 
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Clot Name: Clot 4 
Date Created: 5/20/13 
Blood Component: Whole Blood 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: Whole blood and CaCl2 solution allowed to clot in a stationary glass test tube. 
 
 
 
Clot Name: Clot 5 
Date Created: 5/20/13 
Blood Component: Plasma 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: Plasma and CaCl2 solution allowed to clot in a stationary glass test tube. 
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Clot Name: Clot 6 
Date Created: 5/20/13 
Blood Component: Plasma 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: Equine plasma and the CaCl2 solution were placed in a petri dish (84mm diameter). A 
second petri dish (38mm diameter) applied a rotational force on the plasma while it was clotting.	  
RPM: 60 
Gap Thickness: 5mm 
Total Time Rotating: 8.58 hours  
 
 
 
Clot Name: Clot 7 
Date Created: 5/20/13 
Blood Component: Plasma 
Species: Equine 
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CaCl2 Concentration: 12mg CaCl2 / mL distilled H2O 
Method: Plasma and CaCl2 solution allowed to clot in a stationary glass test tube. 
 
 
 
Clot Name: Clot 8 
Date Created: 5/20/13 
Blood Component: Whole Blood 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: Whole blood and CaCl2 solution allowed to clot in a stationary glass test tube. 
 
 
 
Clot Name: Clot 9 
Date Created: 5/20/13 
Blood Component: Plasma 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: Plasma and CaCl2 solution allowed to clot in a stationary glass test tube. 
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Clot Name: Clot 10 
Date Created: 5/21/13 
Blood Component: Whole Blood 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: Equine whole blood and the CaCl2 solution were placed in a petri dish (50mm 
diameter) l. A second petri dish (38mm diameter) applied a rotational force on the blood while it 
was clotting.	  
RPM: 60 
Gap Thickness: 7.5mm 
Total Time Rotating: 7.55 hours 
 
 
 
Clot Name: Clot 11 
Date Created: 5/21/13 
Blood Component: Whole Blood 
Species: Equine 
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CaCl2 Concentration: 12mg CaCl2 / mL distilled H2O 
Method: Whole blood and CaCl2 solution allowed to clot in a stationary glass test tube. 
 
 
 
Clot Name: Clot 12 
Date Created: 5/21/13 
Blood Component: Plasma 
Species: Equine 
CaCl2 Concentration: 12mg CaCl2 / mL distilled H2O 
Method: Plasma and CaCl2 solution allowed to clot in a stationary glass test tube. 
 
 
 
Clot Name: Clot 13 
Date Created: 5/22/13 
Blood Component: Whole Blood 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
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Method: Equine whole blood and the CaCl2 solution were placed in a petri dish (55mm 
diameter). A second petri dish (38mm diameter) lined with aluminum foil applied a rotational 
force on the blood while it was clotting.	  
RPM: 60 
Gap Thickness: 4 mm 
Total Time Rotating: 6.35 hours 
 
 
 
Clot Name: Clot 14 
Date Created: 5/23/13 
Blood Component: Whole Blood 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: Equine whole blood and the CaCl2 solution were placed in a petri dish (55mm 
diameter). A second petri dish (38mm diameter) lined with aluminum foil that had been 
scratched with sand paper applied a rotational force on the blood while it was clotting.	  
RPM: 60 
Gap Thickness: 5.5mm 
Total Time Rotating: 9.15 hours 
 
 
163 
	  
 
 
 
Clot Name: Clot 15 
Date Created: 5/28/13 
Blood Component: Whole Blood 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: Equine whole blood and the CaCl2 solution were placed in a petri dish (50mm 
diameter) lined with aluminum foil. A second petri dish (38mm diameter) lined with aluminum 
foil applied a rotational force on the blood while it was clotting.	  
RPM: 60 
Gap Thickness: 5mm 
Total Time Rotating: 6.62 hours 
 
 
 
Clot Name: Clot 16 
Date Created: 5/29/13 
Blood Component: Plasma 
Species: Equine 
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CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: Equine plasma and the CaCl2 solution were placed in a petri dish (50 mm diameter) 
lined with aluminum foil. A second petri dish (38mm diameter) lined with aluminum foil applied 
a rotational force on the plasma while it was clotting.	  
RPM: 60 
Gap Thickness: Unknown 
Total Time Rotating: 6.82 hours 
  
 
 
Clot Name: Clot 17 
Date Created: 6/3/13 
Blood Component: Plasma 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: Equine plasma and the CaCl2 solution were placed in a petri dish (50mm diameter) 
lined with aluminum foil. A second petri dish (38mm diameter) lined with aluminum foil applied 
a rotational force on the plasma while it was clotting.	  
RPM: 60 
Gap Thickness: 4.5mm 
Total Time Rotating: 6.55 hours 
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Clot Name: Clot 18 
Date Created: 6/11/13 
Blood Component: Plasma 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: Plasma and CaCl2 solution allowed to clot in a stationary glass test tube. 
 
 
Clot Name: Clot 19 
Date Created: 6/11/13 
Blood Component: Plasma 
Species: Equine 
CaCl2 Concentration: 48mg CaCl2 / mL distilled H2O 
Method: Equine plasma diluted with distilled water was placed in a plastic jar with two 
openings in the bottom that were connected to a continuous flow pump. The CaCl2 solution as 
added as the diluted plasma was moved by the pump; a rotational force was applied to the 
plasma as it pumped throughout the reservoir by a petri dish lined with aluminum foil that was 
connected to a rotational motor. 
RPM: 60 
Gap Thickness: 9mm 
Total Time Rotating: 5.75 hours 
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Clot Name: Clot 20 – Failed to clot 
 
 
Clot Name: Clot 21 
Date Created: 6/17/13 
Blood Component: Plasma 
Species: Equine 
CaCl2 Concentration: 48mg CaCl2 / mL distilled H2O 
Method: Equine plasma diluted with distilled water was placed in a plastic jar with two 
openings in the bottom that were connected to a continuous flow pump. The CaCl2 solution as 
added as the diluted plasma was moved by the pump; a rotational force was applied to the 
plasma as it pumped throughout the reservoir by a petri dish lined with aluminum foil that was 
connected to a rotational motor. 
RPM: 60 
Gap Thickness: 7mm 
Total Time Rotating: 6.83 hours 
 
 
 
Clot Name: Clot 22 
Date Created: 6/18/13 
Blood Component: Whole Blood 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
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Method: Equine whole blood the CaCl2 solution were placed in a petri dish (84mm diameter) 
lined with aluminum foil. A second petri dish (38mm diameter) also lined with aluminum foil 
applied a rotational force on the blood while it was clotting. 
RPM: 60 
Gap Thickness:  
Total Time Rotating: 5.5 hours 
 
 
 
Clot Name: Clot 23 
Date Created: 6/20/13 
Blood Component: Plasma 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: Equine plasma and the CaCl2 solution were placed in a petri dish (50mm diameter) 
lined with aluminum foil. A second petri dish (38mm diameter) also lined with aluminum foil 
applied a rotational force on the plasma while it was clotting. 
RPM: 60 
Gap Thickness: 8mm 
Total Time Rotating: 5.85 hours 
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Clot Name: Clot 24 
Date Created: 6/24/13 
Blood Component: Whole Blood 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: 5mL of equine whole blood and 12 drops of CaCl2 solution were placed in a petri dish 
(50mm diameter) lined with aluminum foil. A second petri dish (38mm diameter) also lined with 
aluminum foil applied a rotational force on the blood while it was clotting.	  
RPM: 225 
Gap Thickness: 5.56mm 
Total Time Rotating: 5.68 hours 
Gross Evaluation: Rotating surface had a large bubble in the middle, but was otherwise clean 
and free of deposits. Stationary surface had one larger deposit and five smaller deposits collected 
for histology. 
 
 
Clot Name: Clot 25 
Date Created: 6/24/13 
Blood Component: Whole Blood 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: 5mL of equine whole blood and 12 drops of CaCl2 solution were placed in a petri dish 
(50mm diameter) lined with aluminum foil. A second petri dish (38mm diameter) also lined with 
aluminum foil applied a rotational force on the blood while it was clotting. 
RPM: 75 
Gap Thickness: 3.95mm 
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Total Time Rotating: 5.67 hours 
Gross Evaluation: Rotating surface had a large deposit off center and radiating off of that are 
several smaller deposits in a spiral like pattern. The stationary surface had a filmy like substance 
on the aluminum foil that came off in four pieces. There were two deposits that remained when 
the blood was drained. Five deposits from stationary surface and the aluminum foil from the 
rotating surface collected for histology. 
 
 
 
Clot Name: Clot 26 
Date Created: 6/25/13 
Blood Component: Whole Blood 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: 5mL of equine whole blood and 12 drops of CaCl2 solution were placed in a petri dish 
(50mm diameter) lined with aluminum foil. A second petri dish (38mm diameter) also lined with 
aluminum foil applied a rotational force on the blood while it was clotting.	  
RPM: 225 
Gap Thickness: 4mm 
Total Time Rotating: 6 hours 
Gross Evaluation: Rotating surface was clean. Stationary surface had one large and three small 
deposits. All four deposits were collected for histology. 
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Clot Name: Clot 27 
Date Created: 6/25/13 
Blood Component: Whole Blood 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: 5mL of equine whole blood and 12 drops of CaCl2 solution were placed in a petri dish 
(50mm diameter) lined with aluminum foil. A second petri dish (38mm diameter) also lined with 
aluminum foil applied a rotational force on the blood while it was clotting.	  
RPM: 75 
Gap Thickness: 6.05mm 
Total Time Rotating: 6 hours 
Gross Evaluation: Rotating surface had a large deposit in the center with a spiral pattern 
radiating out from it. The stationary surface had two medium sized, and 2 small red-brown to 
black deposits. Top aluminum foil piece and four bottom deposits collected for histology. 
 
 
 
Clot Name: Clot 28 
Date Created: 6/26/13 
Blood Component: Plasma 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: 5mL of equine plasma and 22 drops of CaCl2 solution were placed in a petri dish 
(50mm diameter) lined with aluminum foil. A second petri dish (38mm diameter) also lined with 
aluminum foil applied a rotational force on the plasma while it was clotting.	  
RPM: 75 
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Gap Thickness: 3.96mm 
Total Time Rotating: 6 hours 
Gross Evaluation: Rotating surface has a gel-like deposit firmly adhered to the entire flat 
surface. This circular deposit was removed in one piece and collected for histology. The 
stationary surface had a thin film along the outer rim of dish (donut shaped) that was collected 
for histology. 
 
 
 
Clot Name: Clot 29 
Date Created: 6/26/13 
Blood Component: Plasma 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: 5mL of equine plasma and 22 drops of CaCl2 solution were placed in a petri dish 
(50mm diameter) lined with aluminum foil. A second petri dish (38mm diameter) also lined with 
aluminum foil applied a rotational force on the plasma while it was clotting.	  
RPM: 225 
Gap Thickness: 3.88mm 
Total Time Rotating: 6 hours 
Gross Evaluation: Rotating surface had a gelatinous material along outer rim of aluminum foil 
that measured ~7.9cm x 1-3mm. The stationary surface had a circular shaped deposit, and 
another deposit along the outer rim that measured ~5cm x 2-6mm. All three deposits were 
collected for histology. 
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Clot Name: Clot 30 
Date Created: 6/26/13 
Blood Component: Plasma 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: 5mL of equine plasma and 22 drops of CaCl2 solution were placed in a petri dish 
(50mm diameter) lined with aluminum foil. A second petri dish (38mm diameter) also lined with 
aluminum foil applied a rotational force on the plasma while it was clotting.	  
RPM: 240 
Gap Thickness: 4.14mm 
Total Time Rotating: 6 hours 
Gross Evaluation: Rotating surface had several bubbles grouped together on the outer edge. 
The outer edge had a thin film that came off in four small pieces. Stationary surface had a large 
circular deposit. Five deposits were collected for histology. 
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Clot Name: Clot 31 
Date Created: 6/26/13 
Blood Component: Plasma 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: 5mL of equine plasma and 22 drops of CaCl2 solution were placed in a petri dish 
(50mm diameter) lined with aluminum foil. A second petri dish (38mm diameter) also lined with 
aluminum foil applied a rotational force on the plasma while it was clotting.	  
RPM: 300 
Gap Thickness: 3.98mm 
Total Time Rotating: Approximately 2 hours 
Gross Evaluation: Stationary surface adhered to the rotating surface throughout experiment. 
Plasma splashed around counter in 4-5cm radius. The motor stopped at two hours in. On 6/27/13, 
the rotating surface was clean and free of deposits. Stationary surface had a gelatinous material 
that came off in several small pieces. 
 
 
 
Clot Name: Clot 32 
Date Created: 6/27/13 
Blood Component: Plasma 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: 5mL of equine plasma and 18 drops of CaCl2 solution were placed in a petri dish 
(50mm diameter) lined with aluminum foil. A second petri dish (38mm diameter) also lined with 
aluminum foil applied a rotational force on the plasma while it was clotting. 
RPM: 75 
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Gap Thickness: 5.68mm 
Total Time Rotating: 10.2 hours 
 
 
 
Clot Name: Clot 33 
Date Created: 6/27/13 
Blood Component: Plasma 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: 5mL of equine plasma and 18 drops of CaCl2 solution were placed in a petri dish 
(50mm diameter) lined with aluminum foil. A second petri dish (38mm diameter) also lined with 
aluminum foil applied a rotational force on the plasma while it was clotting.	  
RPM: 225 
Gap Thickness: 6.08mm 
Total Time Rotating: 10.2 hours 
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Clot Name: Clot 34 
Date Created: 6/27/13 
Blood Component: Plasma 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: 5mL of equine plasma and 18 drops of CaCl2 solution were placed in a petri dish 
(50mm diameter) lined with aluminum foil. A second petri dish (38mm diameter) also lined with 
aluminum foil applied a rotational force on the plasma while it was clotting.	  
RPM: 240 
Gap Thickness: 6.16mm 
Total Time Rotating: 10.2 hours 
 
 
 
 
Clot Name: Clot 35 
Date Created: 6/27/13 
Blood Component: Plasma 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: 5mL of equine plasma and 18 drops of CaCl2 solution were placed in a petri dish 
(50mm diameter) lined with aluminum foil. A second petri dish (38mm diameter) also lined with 
aluminum foil applied a rotational force on the plasma while it was clotting.	  
RPM: 300 
Gap Thickness: 6.14mm 
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Total Time Rotating: 10.2 hours 
 
 
Clot Name: Clot 36 
Date Created: 7/1/13 
Blood Component: Whole Blood 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: 7.5mL of equine whole blood and 18 drops of CaCl2 solution were placed in a petri 
dish (50mm diameter) lined with aluminum foil. A second petri dish (38mm diameter) also lined 
with aluminum foil applied a rotational force on the blood while it was clotting.	  
RPM: 75 
Gap Thickness: 4.13mm 
Total Time Rotating: 23 hours 
 
 
 
Clot Name: Clot 37 
Date Created: 7/1/13 
Blood Component: Whole Blood 
Species: Equine 
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CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: 7.5mL of equine whole blood and 18 drops of CaCl2 solution were placed in a petri 
dish (50mm diameter) lined with aluminum foil. A second petri dish (38mm diameter) also lined 
with aluminum foil applied a rotational force on the blood while it was clotting.	  
RPM: 225 
Gap Thickness: 4.13mm 
Total Time Rotating: 23 hours 
 
 
 
Clot Name: Clot 38 
Date Created: 7/1/13 
Blood Component: Whole Blood 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: 7.5mL of equine whole blood and 18 drops of CaCl2 solution were placed in a petri 
dish (50mm diameter) lined with aluminum foil. A second petri dish (38mm diameter) also lined 
with aluminum foil applied a rotational force on the blood while it was clotting.	  
RPM: 240 
Gap Thickness: 3.98mm 
Total Time Rotating: 23 hours 
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Clot Name: Clot 39 
Date Created: 7/1/13 
Blood Component: Whole Blood 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: 7.5mL of equine whole blood and 18 drops of CaCl2 solution were placed in a petri 
dish (50mm diameter) lined with aluminum foil. A second petri dish (38mm diameter) also lined 
with aluminum foil applied a rotational force on the blood while it was clotting.	  
RPM: 300 
Gap Thickness: 4.07 
Total Time Rotating: 23 hours 
 
 
 
Clot Name: Clot 40 
Date Created: 7/7/13 
Blood Component: Plasma 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: 7.5mL equine plasma and 33 drops of CaCl2 solution were placed in a petri dish 
(50mm diameter) lined with aluminum foil. A second petri dish (38mm diameter) also lined with 
aluminum foil applied a rotational force on the plasma while it was clotting.	  
RPM: 75 
Gap Thickness: 3.99mm 
Total Time Rotating: 45.5 hours 
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Gross Evaluation: Gelatinous clot lightly adhered to the rotating dish. Stationary dish contained 
a donut shaped gelatinous material. 
 
 
Clot Name: Clot 41 
Date Created: 7/7/13 
Blood Component: Plasma 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: 7.5mL of equine plasma and 33 drops of CaCl2 solution were placed in a petri dish 
(50mm diameter) lined with aluminum foil. A second petri dish (38mm diameter) also lined with 
aluminum foil applied a rotational force on the plasma while it was clotting.	  
RPM: 225 
Gap Thickness: 3.92mm 
Total Time Rotating: 45.5 hours 
 
 
 
Clot Name: Clot 42 
Date Created: 7/7/13 
Blood Component: Plasma 
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Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: 7.5mL of equine plasma and 33 drops of CaCl2 solution were placed in a petri dish 
(50mm diameter) lined with aluminum foil. A second petri dish (38mm diameter) also lined with 
aluminum foil applied a rotational force on the plasma while it was clotting.	  
RPM: 240 
Gap Thickness: 4.13mm 
Total Time Rotating: 45.5 hours 
Gross Evaluation: Brittle, fragile, greenish-yellow (with gray to black center) discolored 
deposit adhered to the outer rim of the rotating dish and the stationary dish. 
 
 
 
Clot Name: Clot 43 
Date Created: 7/7/13 
Blood Component: Plasma 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: 7.5mL of equine plasma and 33 drops of CaCl2 solution were placed in a petri dish 
(50mm diameter) lined with aluminum foil. A second petri dish (38mm diameter) also lined with 
aluminum foil applied a rotational force on the plasma while it was clotting.	  
RPM: 300 
Gap Thickness: 3.9mm 
Total Time Rotating: 45.5 hours 
Gross Evaluation: Brittle, fragile, greenish-yellow pieces along the outer rim of the rotating 
dish. In the center of the rotating dish, there is an approximately 4mm diameter circular deposit 
firmly adhered to the aluminum foil. 
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Clot Name: Clot 44 
Date Created: 7/10/13 
Blood Component: Plasma 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: 7.5mL of equine plasma and 33 drops of CaCl2 solution were placed in a petri dish 
(50mm diameter) lined with aluminum foil. A second petri dish (38mm diameter) also lined with 
aluminum foil applied a rotational force on the plasma while it was clotting.	  
RPM: 75 
Gap Thickness: 4.08mm 
Total Time Rotating: 24 hours 
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Clot Name: Clot 45 
Date Created: 7/10/13 
Blood Component: Plasma 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: 7.5mL of equine plasma and 33 drops of CaCl2 solution were placed in a petri dish 
(50mm diameter) lined with aluminum foil. A second petri dish (38mm diameter) also lined with 
aluminum foil applied a rotational force on the plasma while it was clotting.	  
RPM: 225 
Gap Thickness: 4.03mm 
Total Time Rotating: 24 hours 
 
 
 
Clot Name: Clot 46 
Date Created: 7/10/13 
Blood Component: Plasma 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: 7.5mL of equine plasma and 33 drops of CaCl2 solution were placed in a petri dish 
(50mm diameter) lined with aluminum foil. A second petri dish (38mm diameter) also lined with 
aluminum foil applied a rotational force on the plasma while it was clotting.	  
RPM: 240 
Gap Thickness: 4mm 
Total Time Rotating: 24 hours  
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Clot Name: Clot 47 
Date Created: 7/10/13 
Blood Component: Plasma 
Species: Equine 
CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: 7.5mL of equine plasma and 33 drops of CaCl2 solution were placed in a petri dish 
(50mm diameter) lined with aluminum foil. A second petri dish (38mm diameter) also lined with 
aluminum foil applied a rotational force on the plasma while it was clotting.	  
RPM: 300 
Gap Thickness: 4.01mm 
Total Time Rotating: 24 hours 
 
 
 
Clot Name: Clot 48 
Date Created: 5/14/14 
Blood Component: Plasma 
Species: Bovine 
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CaCl2 Concentration: 24mg CaCl2 / mL distilled H2O 
Method: Plasma and CaCl2 solution allowed to clot in a stationary glass test tube. 
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APPENDIX IV 
COMPLETE IN VITRO ANALYSIS 
 
Experiments to analyze the interaction of ventricular assist devices and thromboemboli (outlined 
in Section 8 of above work) are detailed below. 
 
Centrifugal Flow Experiments 
Setup for experiments 1-11: 
 
  
	  
V 
VAD 
	  V 
	  V 
Insert Clot 
To Drain 
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Centrifugal Flow Mock-VAD Design Version 1.0 (used in experiments 1-6): 
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List of Experiments: 
1. Experiment 1 (Clot 50) 
a. Experiment Description: 5mL of equine plasma and the CaCl2 solution were 
added to a petri dish (50mm diameter) lined with aluminum foil. A second petri 
dish (38mm diameter) was affixed to a rotational motor capable of 75 RPM. The 
petri dish applied a rotational force to the plasma as it clotted. The clot formed 
in a circular shape under the rotating surface as the motor ran for 6 hours. The 
clot was then sectioned into 4 pieces of equal size. One piece was collected as a 
control and the other was administered to the mock-VAD. The VAD ran for 
approximately 20 seconds. VAD disassembly revealed that the clot was stuck 
inside the VAD near the outflow. 
b. Data Collected: 
i. Cassette 1: Control (one section of clot that was not subjected to the 
VAD) 
ii. Cassette 2: One section of clot that was subjected to the VAD.  
 
2. Experiment 2 (Clot 50) 
a. Experiment Description: Remaining two sections of Clot 50 were stored in the 
refrigerator for 2 days before subjected to the mock-VAD. The VAD ran for 
approximately 3 minutes. Clot appeared to be in the outflow. The VAD was 
turned off, and the clot floated into the loop distal to the outflow. The VAD was 
Whole Clot.                            Clot Sectioned into 4 pieces.       Section of Clot 
collected from VAD	  
188 
	  
turned back on and the clot appeared to break into smaller pieces. When the 
VAD was turned off, deposits were seen in the outflow track and in the central 
section of the impeller. 
b. Data Collected: 
i. Cassette 3: Control 
ii. Cassette 4: Specimens collected from the outflow and impeller. 
 
 
 
 
3. Experiment 3 (Clot 52) 
a. Experiment Description: 5mL of equine plasma and the CaCl2 solution were 
added to a petri dish (50mm diameter) lined with aluminum foil. A second petri 
dish (38mm diameter) was affixed to a rotational motor capable of 225 RPM. 
The petri dish applied a rotational force to the plasma as it clotted. The clot 
formed in a circular shape under the rotating surface as the motor ran for 30 
hours. There were also pieces of clot around the rim of the stationary petri dish. 
The circular clot was sectioned into 4 pieces of equal size. One piece of the 
circular clot and one section of the clot along the rim of the stationary dish were 
collected as controls. A piece from the rim of the stationary dish was 
administered to the flow loop along with a piece from the circular clot. The 
VAD motor was turned on several times. The clot got stuck and then traveled 
through the loop several times. The clot eventually got stuck in the outflow 
track. 
b. Data Collected: 
i. Cassette 1: Control from circular clot 
ii. Cassette 2: Control from rim of stationary dish 
iii. Cassette 3: Specimens from the outflow track 
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4. Experiment 4 (Clot 52) 
a. Experiment Description: The remaining sections of Clot 52 were stored in water 
for less than 24 hours. One section was collected as a control to be dehydrated 
and analyzed with scanning electron microscopy. The remaining sections were 
administered to the VAD. The clot appeared to be stuck in the outflow track. 
Specimens were collected for analysis with scanning electron microscopy. 
b. Data Collected: 
i. Cassette 4: Control 
ii. Cassette 5: Specimen from the outflow track 
 
 
 
5. Experiment 5 (Clot 53) 
a. Experiment Description: Stationary blood clot created from 5mL equine plasma 
and CaCl2 solution in a glass test tube. 
b. Data Collected: 
i. Cassette 1: Control 
ii. Cassette 2: Pieces found floating in liquid in VAD chamber 
iii. Cassette 3: Specimen from the outflow track 
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6. Experiment 6 (Clot 53) 
a. Experiment Description: Remaining sections of Clot 53 were subjected to the 
VAD flow loop after condensing for less than 24 hours. 
b. Data Collected: 
i. Cassette 4: Control 
ii. Cassette 5: Specimen from the outflow track 
iii. Cassette 6: Floating specimens 
 
 
 
  
191 
	  
Centrifugal Flow Mock-VAD Design Version 2.0 (used in remaining centrifugal flow 
experiments): 
                    
 
7. Experiment 7 (Clot 54) 
a. Experiment Description: 5mL of equine plasma and the CaCl2 solution were 
added to a petri dish (50mm diameter) lined with aluminum foil. A second petri 
dish (38mm diameter) was affixed to a rotational motor capable of 75 RPM. The 
petri dish applied a rotational force to the plasma as it clotted. The clot formed 
in a circular shape under the rotating surface as the motor ran for 6.5 hours. Clot 
was sectioned into 4 pieces. One section was put into formalin and saved as a 
control. The second was inserted into the flow loop and disintegrated upon 
contact with the impeller. Fragments were too small to collect for histological 
evaluation. 
b. Data Collected: 
i. Cassette 1: Control 
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8. Experiment 8 (Clot 54) 
a. Experiment Description: Remaining section of Clot 54 after sitting in DI water 
for less than 24 hours. 
i. Cassette 3: Specimen adhered to the lower housing 
ii. Cassette 4: Control 
 
 
 
9. Experiment 9 (Clot 55) 
a. Experiment Description: Stationary blood clot created from 5mL equine plasma 
and CaCl2 solution in a glass test tube. 
b. Data Collected: 
i. Cassette 1: Control 
ii. Cassette 2A: Pieces filtered out of flow loop 
iii. Cassette 2B: Piece adhered to the lower housing 
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10. Experiment 10 (Clot 55) 
a. Experiment Description: Remaining section of Clot 55 administered to the flow 
loop with the motor for the VAD set at a lower power setting (6V instead of 
12V). 
b. Data Collected: 
i. Cassette 3: Specimens collected via filtration 
 
 
 
11. Experiment 11 (Clot 55) 
a. Experiment Description: Final section of Clot 55 administered to the flow loop 
48 hours after clot was created. 
b. Data Collected: 
i. Cassette 4: Specimens collected via filtration 
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Setup for Experiments 12-22: (See Figure 34 in Section 8) 
 
                                         
12. Experiment 12 (Clot 58) 
a. Experiment Description: Stationary blood clot created from 5mL equine plasma 
and CaCl2 solution in a glass test tube. Clot was administered to the flow loop 
16 days after CaCl2 solution was added to the plasma. The fluid in the flow loop 
was water. The clot entered the VAD approximately 8-9 seconds after data 
collection began. After the clot entered the VAD there were loose pieces in the 
tubing and a piece on the impeller. 
b. Data Collected: 
i. Cassette 1: Control 
ii. Cassette 2: Loose pieces collected via filtration 
iii. Cassette 3: Piece on impeller 
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13. Experiment 13 (Clot 58) 
a. Experiment Description: Section 2 from Clot 58 was administered to the VAD 
approximately 17 days after clot creation. The clot entered the VAD 
approximately 3 seconds after data collection began. After the clot interacted 
with the VAD, there were loose pieces in the tubing and a small deposit on the 
inferior surface of the impeller. 
b. Data Collected: 
i. Cassette 4: Loose pieces in tubing 
ii. Cassette 5: Small deposit on inferior surface of impeller 
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14. Experiment 14 (Clot 58) 
a. Experiment Description: The fibrous section of Clot 58 was inserted into the 
flow loop approximately 30 days after clot creation. The clot entered the VAD 
approximately 19 seconds after data collection began. 
b. Data Collected: 
i. Cassette 6: Control 
ii. Cassette 7: Deposit on impeller 
 
 
 
 
15. Experiment 15 (Clot 59) 
a. Experiment Description: Stationary blood clot created from 5mL equine plasma 
and CaCl2 solution in a glass test tube. Clot was sectioned into 3 sections and 
administered to the flow loop on two separate dates approximately 30 days after 
clot creation. The fluid in the loop was water. 
b. Data Collected: 
i. Cassette 1: Control 
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  30 Time	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197 
	  
ii. Cassette 2: Floating pieces 
iii. Cassette 3: Impeller pieces 
 
 
 
 
16. Experiment 16 (Clot 59) 
a. Experiment Description: Section 2 from Clot 59 was inserted into the flow loop. 
The fluid in the loop was water. 
b. Data Collected: 
i. Cassette 4: Control 
ii. Cassette 5: Pieces from VAD 
iii. Cassette 6: Pieces from VAD 
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17. Experiment 17 (Clot 59) 
a. Experiment Description: Section 3 from Clot 59 was inserted into the flow loop 
approximately 30 days after clot creation. Clot went into the VAD at 43 
seconds. The fluid in the loop was water. 
b. Data Collected: 
i. Cassette 7: Floating pieces 
ii. Cassette 8: Pieces from the lower housing 
iii. Cassette 9: Piece from the outflow 
iv. Cassette 10: Pieces from the impeller 
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18. Experiment 18 (Clot 63) 
a. Experiment Description: Stationary blood clot created from 5mL equine plasma 
and CaCl2 solution in a glass test tube. Clot was sectioned into 2 sections and 
administered to the flow loop approximately 30 years after clot creation. The 
fluid within the flow loop was a water/glycerin mixture. The temperature of the 
fluid was set to 38°C to simulate normal temperature of equine specimens. The 
pulsatile pump was set to higher flow rates to simulate normal heart flow. 
b. Data Collected: 
i. Cassette 1: Control 
ii. Cassette 2: Floating pieces in the reservoir 
 
 
 
19. Experiment 19 (Clot 63) 
a. Experiment Description: Section 2 from Clot 63. This section was larger than 
previous samples. The clot went through the VAD after 6.56 seconds of data 
collection. The fluid within the flow loop was a water/glycerin mixture. The 
temperature of the fluid was set to 38°C to simulate normal temperature of 
equine specimens. The pulsatile pump was set to higher flow rates to simulate 
normal heart flow.  
b. Data Collected: 
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i. Cassette 3: Floating pieces 
ii. Cassette 4: Pieces most near VAD (one floating, two in one-way valve) 
 
 
 
20. Experiment 20 (Clot 64) 
a. Experiment Description: Stationary blood clot created from 5mL equine plasma 
and CaCl2 solution in a glass test tube. Clot was sectioned into 2 sections and 
administered to the flow loop. The fluid within the flow loop was a 
water/glycerin mixture. The temperature of the fluid was set to 38°C to simulate 
normal temperature of equine specimens. The pulsatile pump was set to lower 
flow rates to simulate heart failure. The clot went through the VAD at 16.40 
seconds. 
b. Data Collected: 
i. Cassette 1: Floating pieces 
ii. Cassette 2: Floating pieces 
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21. Experiment 21 (Clot 64) 
a. Experiment Description: Section 2 from Clot 64 was inserted into the flow loop. 
The fluid within the flow loop was a water/glycerin mixture. The temperature of 
the fluid was set to 38°C to simulate normal temperature of equine specimens. 
The pulsatile pump was set to lower flow rates to simulate heart failure. The clot 
went through the VAD at 13.01 seconds. 
b. Data Collected: 
i. Cassette 3: Floating pieces 
ii. Cassette 4: Floating pieces 
iii. Cassette 5: Floating pieces  
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22. Experiment 22 (Clot 65) 
a. Experiment Description: Stationary blood clot created from 5mL equine plasma 
and CaCl2 solution in a glass test tube. Clot was administered to the flow loop. 
The clot went through the VAD at 13.9 seconds. The fluid within the loop was a 
water/glycerin mixture. The temperature of the fluid was set to 38°C to simulate 
normal temperature of equine specimens. The pulsatile pump was set to lower 
flow rates to simulate heart failure. 
b. Data Collected: 
i. Cassette 1: Specimen within VAD 
ii. Flow and pressure data: Clot 65 take 2 
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Axial Flow Experiments 
Axial Flow Mock-VAD Design (used in following experiments): 
                                   
 
1. Experiment 1 (Axial Test Clot) 
a. Experiment Description: Stationary blood clot created from 5mL of feline 
packed red blood cells and CaCl2 solution in a glass test tube. Clot was 
administered to the flow loop approximately 30 days after clot creation. The 
fluid within the loop was water at room temperature. The pulsatile pump was set 
to lower flow rates to simulate heart failure. 
b. Data Collected: 
i. Cassette 1: Pieces around stator/bearing/impeller 
ii. Cassette 2: Control 
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2. Experiment 2 (Clot 66) 
a. Experiment Description: Stationary blood clot created from 5mL of gently 
centrifuged bovine plasma and CaCl2 solution in a glass test tube. Clot was 
administered to the flow loop approximately 14 days after clot creation. The 
fluid within the loop was water at room temperature. The pulsatile pump was set 
to higher flow rates to simulate normal heart function. The clot remained in the 
stator after it entered the VAD. 
b. Data Collected: 
i. Cassette 1: Control 
ii. Cassette 2: Clot in stator 
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3. Experiment 3 (Clot 66) 
a. Experiment Description: Stationary blood clot created from 5mL of gently 
centrifuged bovine plasma and CaCl2 solution in a glass test tube. Clot was 
administered to the flow loop approximately 14 days after clot creation. The 
fluid within the loop was water at room temperature. The pulsatile pump was set 
to higher flow rates to simulate normal heart function. The clot remained in the 
stator after it entered the VAD. 
b. Data Collected: 
i. Cassette 3: Clot in stator 
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4. Experiment 4 (Clot 67) 
a. Experiment Description: Stationary blood clot created from 5mL of bovine 
plasma and CaCl2 solution in a glass test tube. Clot was administered to the flow 
loop approximately 31 days after clot creation. The fluid within the loop was 
water at room temperature. The pulsatile pump was set to lower flow rates to 
simulate heart failure. The clot went into the VAD quickly after data collection 
began. 
b. Data Collected: 
i. Cassette 1: Control 
ii. Cassette 2: Stator/impeller interface material 
 
 
 
 
5. Experiment 5 (Clot 67) 
a. Experiment Description: Stationary blood clot created from 5mL of bovine 
plasma and CaCl2 solution in a glass test tube. Clot was administered to the flow 
loop approximately 35 days after clot creation. The fluid within the loop was 
water at room temperature. The pulsatile pump was set to higher flow rates to 
simulate normal heart function. The clot broke into several pieces before 
entering the VAD. 
b. Data Collected: 
i. Cassette 3: Impeller piece 
ii. Cassette 4: Stator piece 
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6. Experiment 6 (Clot 67) 
a. Experiment Description: Stationary blood clot created from 5mL of bovine 
plasma and CaCl2 solution in a glass test tube. Clot was administered to the flow 
loop approximately 35 days after clot creation. The fluid within the loop was 
water at room temperature. The pulsatile pump was set to higher flow rates to 
simulate normal heart function. The clot broke into several pieces before 
entering the VAD. 
b. Data Collected: 
i. Cassette 5: Stator piece 
 
 
 
  
209 
	  
7. Experiment 7 (Clot 68) 
a. Experiment Description: Stationary blood clot created from 5mL of gently 
centrifuged bovine plasma and CaCl2 solution in a glass test tube. Clot was 
administered to the flow loop approximately 15 days after clot creation. The 
fluid within the loop was water at room temperature. The pulsatile pump was set 
to lower flow rates to simulate heart failure. The clot broke into several pieces 
that entered the VAD at different times. After clot entered the VAD, there were 
several floating pieces noticed in the chamber, several pieces collected from the 
stator arms, and one piece from the stator/bearing ball interface. 
b. Data Collected: 
i. Cassette 1: Multiple small pieces from lower reservoir 
ii. Cassette 2: 2 pieces of silicone sealant with sections of clot 
iii. Cassette 3: ~6 small pieces from top reservoir and 2 larger pieces from 
stator arms 
iv. Cassette 4: 1 small piece from stator/bearing ball interface 
 
 
 
8. Experiment 8 (Clot 68) 
a. Experiment Description: Stationary blood clot created from 5mL of gently 
centrifuged bovine plasma and CaCl2 solution in a glass test tube. Clot was 
administered to the flow loop approximately 28 days after clot creation. The 
fluid within the loop was water at room temperature. The pulsatile pump was set 
210 
	  
to higher flow rates to simulate normal heart function. After the VAD and 
pulsatile pump were turned off, a piece of the clot was noted in floating in the 
chamber and two small pieces were noted on the stator. 
b. Data Collected: 
i. Cassette 5: Control 
ii. Cassette 6: 2 small pieces on stator 
iii. Cassette 7: Large piece in unit (floating) 
 
 
 
 
 
9. Experiment 9 (Clot 70) 
a. Experiment Description: Stationary blood clot created from 5mL of bovine 
plasma and CaCl2 solution in a glass test tube. Clot was administered to the flow 
loop approximately 56 days after clot creation. The fluid within the loop was a 
water/glycerin mixture at room temperature. After the VAD and pulsatile pump 
were turned off, several pieces of the clot were noted floating in the chamber 
and small pieces were noted on the stator and impeller. 
b. Data Collected: 
i. Cassette 1: Control 
ii. Cassette 2: 11 small pieces, 1 large piece 
iii. Cassette 3: 7 small pieces, 2 medium pieces, 1 large piece 
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iv. Cassette 4: 1 from bottom of impeller, 2 from stator 
 
 
 
10. Experiment 10 (Clot 70) 
a. Experiment Description: Stationary blood clot created from 5mL of bovine 
plasma and CaCl2 solution in a glass test tube. Clot was administered to the flow 
loop approximately 70 days after clot creation. The fluid within the loop was a 
water/glycerin mixture at room temperature. The pulsatile pump was set to 
lower flow rates to simulate heart failure. After the VAD and pulsatile pump 
were turned off, one small piece was filtered from the flow loop. 
b. Data Collected: 
i. Cassette 5: Control 
ii. Cassette 6: 1 small filtered piece 
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11. Experiment 11 (Clot 72) 
a. Experiment Description: Stationary blood clot created from 5mL of bovine 
plasma and CaCl2 solution in a glass test tube. Clot was administered to the flow 
loop approximately 56 days after clot creation. The fluid within the loop was a 
water/glycerin mixture at 43°C. The pulsatile pump was set to higher flow rates 
to simulate normal heart function. After the VAD and pulsatile pump were 
turned off, the clot remained on one of the impeller blades. 
b. Data Collected: 
i. Cassette 1: Control 
ii. Cassette 2: Clot from chamber 
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12. Experiment 12 (Clot 72) 
a. Experiment Description: Stationary blood clot created from 5mL of bovine 
plasma and CaCl2 solution in a glass test tube. Clot was administered to the flow 
loop approximately 56 days after clot creation. The fluid within the loop was a 
water/glycerin mixture at 38°C. The pulsatile pump was set to higher flow rates 
to simulate normal heart function. After the VAD and pulsatile pump were 
turned off, the clot remained on one of the stator struts. 
b. Data Collected: 
i. Cassette 3: Clot 
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13. Experiment 13 (Clot 73) 
a. Experiment Description: Stationary blood clot created from 5mL of gently 
centrifuged bovine plasma and CaCl2 solution in a glass test tube. Clot was 
administered to the flow loop approximately 63 days after clot creation. The 
fluid within the loop was a water/glycerin mixture at 43°C. The pulsatile pump 
was set to lower flow rates to simulate heart failure. After the VAD and pulsatile 
pump were turned off, the clot remained within the VAD casing. 
b. Data Collected: 
i. Cassette 1: Control 
ii. Cassette 2: Clot 
 
 
 
 
14. Experiment 14 (Clot 73) 
a. Experiment Description: Stationary blood clot created from 5mL of gently 
centrifuged bovine plasma and CaCl2 solution in a glass test tube. Clot was 
administered to the flow loop approximately 63 days after clot creation. The 
fluid within the loop was a water/glycerin mixture at 38°C. The pulsatile pump 
was set to lower flow rates to simulate heart failure. After the VAD and pulsatile 
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pump were turned off, the clot had broken into several pieces floating within the 
fluid and lightly adhered to the casing wall and stator struts. 
b. Data Collected: 
i. Cassette 3: Floating pieces 
ii. Cassette 4: 1 small piece from wall, 2 cylindrical pieces from stator 
 
 
 
